Filed pursuant to General Instruction II.L of Form
F-10;
File No. 333-254096
PROSPECTUS SUPPLEMENT
TO THE SHORT FORM BASE SHELF PROSPECTUS DATED
MARCH 29, 2021
|
|
|
New Issue |
|
November 25, 2022 |

AURORA CANNABIS INC.
6,600,000 Common Shares
This Prospectus Supplement relates to: (i) up to 6,600,000
common shares (the “Warrant Shares”) of Aurora Cannabis Inc.
(“we”, “our”, “Aurora” or the
“Company”), issuable from time to time upon the exercise of
6,600,000 common share purchase warrants (the “Warrants”)
issued by the Company pursuant to the Unit Offering (defined
below); and (ii) such indeterminate number of additional
Warrant Shares that may be issuable by reason of the anti-dilution
provisions contained in the Warrant Indenture (as defined herein)
(the “Offering”). See “Plan of Distribution”.
The Company previously filed a prospectus supplement (the
“Original Warrant Share Prospectus Supplement”) dated
January 25, 2021 to its base shelf prospectus dated
October 28, 2020 (the “Original Base Prospectus”) with
the securities commission or similar regulatory authority in each
of the provinces of Canada, except Québec, and, in connection
therewith, filed a prospectus supplement dated January 25,
2021 to its registration statement on Form F-10 with the United States Securities
and Exchange Commission (the “SEC”) relating to the Warrant
Shares.
In accordance with Canadian shelf prospectus rules under National
Instrument 44-102 Shelf
Distributions (“NI 44-102”), the Original Base
Prospectus will cease to be effective as of November 28, 2022.
This Prospectus Supplement replaces the Original Warrant Share
Prospectus Supplement in order to maintain the registration of the
offering of the Warrant Shares under the United States Securities
Act of 1933, as amended (the “U.S. Securities Act”), beyond
the expiry date of the Original Base Prospectus.
The Warrants were qualified for distribution by a prospectus
supplement dated January 22, 2021 to the Original Base
Prospectus filed with the securities commission or similar
regulatory authority in each of the provinces of Canada, except
Québec, and, in connection therewith, a prospectus supplement dated
January 22, 2021 to its registration statement on Form
F-10 with the SEC relating
to the offering (the “Unit Offering”) by the Company to the
public in Canada and the United States of units (“Units”),
each Unit consisting of one common share of the Company (a
“Common Share”) and one-half of one Warrant.
Each Warrant entitles the holder thereof to purchase one Warrant
Share at an exercise price of U.S.$12.60 per Warrant Share at any
time until 5:00 p.m. (Toronto time) on January 26, 2024 (the
“Expiry Date”), being the date that is 36 months from the
closing of the Unit Offering, subject to adjustment in accordance
with the terms of the Warrant Indenture. The exercise price of the
Warrants was determined by negotiation between the Company and a
syndicate of underwriters for the Unit Offering (the
“Underwriters”).
S-i
The Common Shares are listed on the Toronto Stock Exchange (the
“TSX”) and on the Nasdaq Global Select Market (the
“Nasdaq”) under the symbol “ACB” and on the Frankfurt
Stock Exchange (the “FSE”) under the symbol “21P”.
The TSX has approved the listing of the Warrant Shares issuable on
exercise of the Warrants on the TSX.
This Prospectus Supplement is filed pursuant to (i) the Base
Prospectus filed in all of the provinces of Canada except Québec,
and (ii) a base shelf prospectus filed as part of a
registration statement on Form F-10 under the U.S. Securities Act,
which became effective on March 30, 2021 upon filing with the
SEC (the “Registration Statement”).
This Prospectus Supplement should be read in conjunction with, and
may not be delivered or utilized without, the Base Prospectus.
No Underwriter has been involved in the preparation of, or has
performed any review of, this Prospectus Supplement or the
accompanying Base Prospectus.
An investment in the Warrant Shares involves significant risks.
You should carefully read the “Risk Factors” section of
this Prospectus Supplement beginning on page S-15, the “Risk Factors” section in the
Base Prospectus beginning on page 35 and in the documents
incorporated by reference herein and therein.
You should rely only on the information contained in or
incorporated by reference into this Prospectus Supplement. The
Company has not authorized anyone to provide you with different
information. The Company is not making an offer of these securities
in any jurisdiction where the offer is not permitted. You should
not assume that the information contained in or incorporated by
reference in this Prospectus Supplement is accurate as of any date
other than the date on the front of this Prospectus Supplement or
the date of such documents incorporated by reference herein, as
applicable.
This Offering is made by a Canadian issuer that is permitted,
under a multijurisdictional disclosure system (the “MJDS”) adopted
by the United States and Canada, to prepare this Prospectus
Supplement in accordance with Canadian disclosure requirements.
Prospective investors should be aware that such requirements are
different from those of the United States. Financial statements
included or incorporated by reference herein have been prepared in
accordance with International Financial Reporting Standards
(“IFRS”) as issued by the International Accounting Standards Board
(“IASB”) and may not be comparable to financial statements of
United States companies. Our financial statements are audited in
accordance with the standards of the Public Company Accounting
Oversight Board (United States).
Prospective investors should be aware that the exercise of the
Warrants and acquisition of the Warrant Shares described herein may
have tax consequences both in the United States and in Canada. Such
consequences for investors who are resident in, or citizens of, the
United States may not be described fully herein. You should read
the tax discussion in this Prospectus Supplement and the
accompanying Base Prospectus fully and consult with your own tax
advisers. See “Certain Canadian Federal Income Tax Considerations”,
“Material U.S. Federal Income Tax Considerations” and “Risk
Factors”.
The enforcement by investors of civil liabilities under United
States federal securities laws may be affected adversely by the
fact that we are incorporated under the laws of British Columbia,
Canada, that the majority of our officers and directors are not
residents of the United States, that the majority of the experts
named in the Registration Statement are not residents of the United
States and that a substantial portion of the assets of these
persons are located outside the United States.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SEC OR ANY STATE OR CANADIAN SECURITIES COMMISSION NOR HAS ANY SUCH
SECURITIES REGULATORY AUTHORITY PASSED UPON THE ACCURACY OR
ADEQUACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE.
S-ii
All references in this Prospectus Supplement and the Base
Prospectus to “dollars” or “C$” are to Canadian dollars and all
references to “U.S.$” are to United States dollars.
Miguel Martin, the Chief Executive Officer and a director of the
Company, and Margaret Shan Atkins and Lance Friedmann, directors of
the Company, reside outside of Canada. Each of Miguel Martin,
Margaret Shan Atkins and Lance Friedmann has appointed the Company,
at its head office located at 500 – 10355 Jasper Avenue, Edmonton,
Alberta, Canada, T5J 1Y6 as their agent for service of process in
Canada. Purchasers are advised that it may not be possible for
investors to enforce judgments obtained in Canada against any such
person, even though they have each appointed an agent for service
of process.
The corporate head office of the Company is located at 500 – 10355
Jasper Avenue, Edmonton, Alberta, Canada, T5J 1Y6. The registered
office of the Company is located at Suite 1700, 666 Burrard Street,
Vancouver, British Columbia, V6C 2X8.
S-iii
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
S-iv
TABLE OF CONTENTS
BASE SHELF PROSPECTUS
S-v
IMPORTANT NOTICE
This document is in two parts. The first part is this Prospectus
Supplement, which describes the specific terms of the securities
being offered and also adds to and updates information contained in
the Base Prospectus and the documents that are incorporated by
reference into this Prospectus Supplement and the Base Prospectus.
The second part is the Base Prospectus which provides more general
information. This Prospectus Supplement is deemed to be
incorporated by reference into the Base Prospectus solely for the
purposes of the Offering. Other documents are also incorporated or
deemed to be incorporated by reference into this Prospectus
Supplement and into the Base Prospectus. See “Documents
Incorporated by Reference”.
The Company filed the Base Prospectus with the securities
commissions in all Canadian provinces other than Québec (the
“Canadian Qualifying Jurisdictions”) in order to qualify the
offering of the securities described in the Base Prospectus in
accordance with NI 44-102.
The Alberta Securities Commission issued a receipt dated
March 30, 2021 in respect of the final Base Prospectus as the
principal regulatory authority under Multilateral Instrument
11-102 Passport System, and
each of the other commissions in the Canadian Qualifying
Jurisdictions is deemed to have issued a receipt under National
Policy 11-202 Process for
Prospectus Review in Multiple Jurisdictions.
The Base Prospectus also forms part of the Registration Statement
that we filed with the SEC under the U.S. Securities Act utilizing
the MJDS. The Registration Statement became effective upon filing
under the U.S. Securities Act on March 30, 2021. The
Registration Statement incorporates the Base Prospectus with
certain modifications and deletions permitted by Form F-10. This Prospectus Supplement is
being filed by the Company with the SEC in accordance with the
instructions to Form F-10.
You should rely only on the information contained in or
incorporated by reference in this Prospectus Supplement and the
Base Prospectus. If the description of the Warrant Shares varies
between this Prospectus Supplement and the Base Prospectus, you
should rely on the information in this Prospectus Supplement. To
the extent that any statement made in this Prospectus Supplement
differs from those in the Base Prospectus, the statements made in
the Base Prospectus and the information incorporated by reference
therein are deemed modified or superseded by the statements made in
this Prospectus Supplement and the information incorporated by
reference herein. The Company has not authorized any other person
to provide investors with additional or different information. If
anyone provides you with any additional, different or inconsistent
information, you should not rely on it.
You should not assume that the information contained in or
incorporated by reference in this Prospectus Supplement or the Base
Prospectus is accurate as of any date other than the date of the
document in which such information appears. Our business, financial
condition, results of operations and prospects may have changed
since those dates. Information in this Prospectus Supplement
updates and modifies the information in the Base Prospectus and
information incorporated by reference herein and therein.
The Company is not making any offer of the Warrant Shares in any
jurisdiction where the offer is not permitted by law.
DOCUMENTS INCORPORATED BY
REFERENCE
The following documents (“documents incorporated by reference” or
“documents incorporated herein by reference”) filed by the Company
with the securities regulatory authorities in the jurisdictions in
Canada in which the Company is a reporting issuer and filed with,
or furnished to, the SEC, are specifically incorporated by
reference into, and form an integral part of, this Prospectus
Supplement:
|
• |
|
the
annual information form of the Company for the year ended
June 30, 2022, dated and filed on SEDAR on September 20,
2022 (our “2022 AIF”);
|
|
• |
|
the
audited consolidated financial statements of the Company, and
the notes thereto for the years ended June 30, 2022 and 2021,
together with the reports of independent registered public
accounting firm thereon, filed on SEDAR on September 20,
2022;
|
S-1
|
• |
|
the
management’s discussion and analysis of financial condition and
results of operations for the year ended June 30, 2022, filed
on SEDAR on September 20, 2022 (our “2022 Annual
MD&A”);
|
|
• |
|
the
management’s discussion and analysis of financial condition and
results of operations for the three months ended September 30,
2022, filed on SEDAR on November 10, 2022 (our “Interim
MD&A”);
|
|
• |
|
the
material change report regarding the Company’s acquisition of a
controlling interest in Bevo Agtech Inc., dated and filed on SEDAR
on August 25, 2022; and
|
|
• |
|
the
management information circular of the Company dated
September 30, 2022, distributed in connection with the
Company’s annual general and special meeting of shareholders held
on November 14, 2022, filed on SEDAR on October 3,
2022.
|
Any document of the type referred to in section 11.1 of Form
44-101F1 of National
Instrument 44-101 –
Short Form Prospectus Distributions filed by us with the
securities commissions or similar regulatory authorities in the
jurisdictions in Canada in which the Company is a reporting issuer
after the date of this Prospectus Supplement and prior to the
termination of the Offering shall be deemed to be incorporated by
reference into this Prospectus Supplement.
When new documents of the type referred to in the paragraph above
are filed by the Company with the commissions or similar regulatory
authorities in the jurisdictions in Canada in which the Company is
a reporting issuer during the currency of this Prospectus
Supplement, such documents will be deemed to be incorporated by
reference in this Prospectus Supplement and the previous documents
of the type referred to in the paragraph above will no longer be
deemed to be incorporated by reference in this Prospectus
Supplement.
To the extent that any document or information incorporated by
reference into this Prospectus Supplement is included in any report
on Form 6-K,
Form 40-F,
Form 20-F,
Form 10-K,
Form 10-Q or
Form 8-K (or any
respective successor form) that is filed with or furnished to the
SEC after the date of this Prospectus Supplement, such document or
information shall be deemed to be incorporated by reference as an
exhibit to the Registration Statement of which this Prospectus
Supplement forms a part. In addition, the Company may incorporate
by reference into this Prospectus Supplement, or the Registration
Statement, other information from documents that the Company files
with or furnishes to the SEC pursuant to Section 13(a) or
15(d) of the United States Securities Exchange Act of
1934, as amended (the “U.S. Exchange Act”), if and to
the extent expressly provided therein.
Any statement contained in this Prospectus Supplement, the Base
Prospectus or in a document incorporated or deemed to be
incorporated by reference herein or therein, will be deemed to be
modified or superseded, for the purposes of this Prospectus
Supplement, to the extent that a statement contained in this
Prospectus Supplement or in any other subsequently filed document
that is also incorporated or is deemed to be incorporated by
reference in this Prospectus Supplement modifies or supersedes such
statement. The modifying or superseding statement need not state
that it has modified or superseded a prior statement or include any
other information set forth in the document that it modifies or
supersedes. The making of a modifying or superseding statement will
not be deemed an admission for any purpose that the modified or
superseded statement, when made, constituted a misrepresentation,
an untrue statement of a material fact or an omission to state a
material fact that is required to be stated or that is necessary to
make a statement not misleading in light of the circumstances in
which it was made. Any statement so modified or superseded will not
be deemed, except as so modified or superseded, to constitute a
part of this Prospectus Supplement.
Information contained on the Company’s website,
www.auroramj.com, is not part of this Prospectus Supplement
or the Base Prospectus and is not incorporated herein by reference
and may not be relied upon by you in connection with an investment
in the Warrant Shares.
S-2
Copies of the documents incorporated herein by reference may be
obtained from us upon request without charge from Aurora Cannabis
Inc., 500 – 10355 Jasper Avenue, Edmonton, Alberta, Canada, T5J 1Y6
(Telephone: 1-855-279-4652) Attn:
Corporate Secretary. These documents are also available
electronically from the website of Canadian Securities
Administrators at www.sedar.com (“SEDAR”) and from the EDGAR
filing website of the United States Securities and Exchange
Commission at www.sec.gov (“EDGAR”). The Company’s filings
through SEDAR and EDGAR are not incorporated by reference in the
Prospectus except as specifically set out herein.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This Prospectus Supplement, the accompanying Base Prospectus and
the documents incorporated by reference herein and therein, contain
forward-looking statements and forward-looking information
(collectively, “forward-looking statements”) which may not be based
on historical fact. These forward-looking statements are made as of
the date of this Prospectus Supplement, the accompanying Base
Prospectus or the applicable document incorporated by reference
herein or therein, and the Company does not intend, and does not
assume any obligation, to update these forward-looking statements,
except as required under applicable securities legislation.
Forward-looking statements relate to future events or future
performance and reflect Company management’s expectations or
beliefs regarding future events. In certain cases, forward-looking
statements can be identified by the use of words such as “plans”,
“expects” or “does not expect”, “is expected”, “budget”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or
“does not anticipate”, or “believes”, or variations of such words
and phrases or statements that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur” or “be
achieved” or the negative of these terms or comparable terminology.
In this document, certain forward-looking statements are identified
by words including “may”, “future”, “expected”, “intends” and
“estimates”. By their very nature forward-looking statements
involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
the Company to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. The Company provides no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements. Forward-looking
statements in this Prospectus Supplement and the documents
incorporated by reference include, but are not limited to,
statements with respect to:
|
• |
|
pro forma measures including revenue, cash flow, adjusted gross
margin before fair value adjustments, expected SG&A
run-rates and grams
produced;
|
|
• |
|
the Company’s ability to fund operating activities and cash
commitments for investments for investing and financing activities
for the foreseeable future;
|
|
• |
|
the Company’s expectation of achieving positive cash flow from
operating activities in future periods;
|
|
• |
|
expectations regarding production capacity, costs and yields;
|
|
• |
|
statements made under the heading “Our Strategy” in the documents
incorporated by reference, where applicable;
|
|
• |
|
statements made with respect to the anticipated disposition of
legal claims;
|
|
• |
|
the Company’s ability to execute on its business transformation
plan and path to Adjusted EBITDA profitability including, but not
limited to, anticipated cost savings and planned cost
efficiencies;
|
|
• |
|
growth opportunities including the expansion into additional
international markets;
|
|
• |
|
expectations related to increased legalization of consumer markets,
including the United States;
|
|
• |
|
the recovery of the Company’s domestic consumer segment;
|
|
• |
|
the acquisition of Thrive, including the anticipated impact on the
consumer business and the Company’s path to Adjusted EBITDA
profitability;
|
|
• |
|
competitive advantages and strengths in medical, scientific
leadership, multi-jurisdictional regulatory expertise, compliance,
testing and product quality;
|
|
• |
|
product portfolio and innovation, and associated revenue
growth;
|
|
• |
|
licensing of genetic innovations to other Licensed Producers and
associated revenue growth;
|
|
• |
|
expectations regarding biosynthetic production and associated
intellectual property;
|
|
• |
|
the use of proceeds generated from the ATM Program;
|
|
• |
|
future strategic plans;
|
|
• |
|
the impact of the COVID-19 pandemic on the Company’s business
operations, capital resources and/or financial results; and
|
|
• |
|
other risks detailed from time to time in the documents
incorporated herein by reference, and those risks which are
discussed under the heading “Risk Factors” in this
Prospectus Supplement and the Base Prospectus.
|
S-3
The above and other aspects of the Company’s anticipated future
operations are forward-looking in nature and, as a result, are
subject to certain risks and uncertainties. Such forward-looking
statements are estimates reflecting the Company’s best judgment
based upon current information and involve a number of risks and
uncertainties, and there can be no assurance that other factors
will not affect the accuracy of such forward-looking statements.
These risks include, but are not limited to: the Company has a
limited operating history and there is no assurance the Company
will be able to achieve or maintain profitability; the Company
operates in a highly regulated business and any failure or
significant delay in obtaining applicable regulatory approvals
could adversely affect its ability to conduct its business; the
Company’s Canadian licenses are reliant on its established sites;
the failure to maintain its licenses and remain in compliance with
regulations could adversely affect the Company’s ability to conduct
business; a change in the laws, regulations, and guidelines that
impact the business may cause adverse effects on the Company’s
operations; the Company competes for market share with a number of
competitors and expects even more competitors to enter our market,
and many of the Company’s current and future competitors may have
longer operating histories, more financial resources, and lower
costs than the Company; management’s estimates of consumer demand
in Canada and in jurisdictions where the Company exports are
accurate; expectations of future results and expenses; management’s
estimation that the Company will be able to maintain current
SG&A expenditure levels and the SG&A will grow only in
proportion to revenue growth, the yield from cannabis growing
operations, product demand, changes in prices of required
commodities; the selling prices and the cost of cannabis production
may vary based on a number of factors outside of the Company’s
control; the Company may not be able to realize our growth targets
or successfully manage our growth; the continuance of our
contractual relations with provincial and territorial governments
upon which much of the Company’s business depends cannot be
guaranteed; the Company’s continued growth and ongoing operations
may require additional financing, which may not be available on
acceptable terms or at all; any default under the Company’s
existing debt that is not waived by the applicable lenders could
materially adversely impact the Company’s results of operations and
financial results and may have a material adverse effect on the
trading price of the Company’s Common Shares; the Company is
subject to credit risk; the Company may not be able to successfully
develop new products or find a market for their sale; the Company
may not have supply continuity given the Company’s asset
rationalization initiative; as the cannabis market continues to
mature, the Company’s products may become obsolete, less
competitive, or less marketable; restrictions on branding and
advertising may negatively impact the Company’s ability to attract
and retain customers; the cannabis business may be subject to
unfavorable publicity or consumer perception, which may adversely
affect the market for cannabis products generally and the Company’s
products specifically; third parties with whom the Company does
business may perceive themselves as being exposed to reputational
risk by virtue of their relationship with the Company and may
ultimately elect to discontinue their relationships with the
Company; there may be unknown health impacts associated with the
use of cannabis and cannabis derivative products; the Company may
enter into strategic alliances or expand the scope of currently
existing relationships with third parties and there are risks
associated with such activities; the Company’s success will depend
on attracting and retaining key personnel; the Company is dependent
on its senior management; future expansion efforts may not be
successful; the Company has expanded and intends to further expand
our business and operations into jurisdictions outside of Canada,
and there are risks associated with doing so; the Company may have
challenges in accessing banks and/or financial institutions in
jurisdictions where cannabis is not yet federally regulated, which
may adversely affect the Company’s growth plans; the business may
be affected by political and economic instability and a period of
sustained inflation across the markets in which it operates;
failure to comply with the Corruption of Foreign Public Officials
Act (Canada) and the Foreign Corrupt Practices Act (United States),
as well as the anti-bribery laws of the other nations in which the
Company conducts business, could subject the Company to penalties
and other adverse consequences; the Company’s employees,
independent contractors and consultants may engage in fraudulent or
other illegal activities; the Company may be subject to uninsured
or uninsurable risk; the Company may be subject to product
liability claims; the Company’s cannabis products may be subject to
recalls for a variety of reasons; the Company is and may become
party to litigation, mediation, and/or arbitration from time to
time; the transportation of the Company’s products is subject to
security risks and disruptions; the Company’s business is subject
to the risks inherent in agricultural operations; the Company has
in the past, and may in the future, record significant write-downs
of its assets; the Company’s operations are subject to various
environmental and employee health and safety regulations,
compliance with which may affect the Company’s cost of operations;
the Company may not be able to protect our intellectual property;
the Company may experience breaches of security at our facilities
or in respect of electronic documents and data storage and may face
risks related to breaches of applicable privacy laws; the Company
may be subject to
S-4
risks related to our information technology systems, including
cyber-attacks; the Company may not be able to successfully identify
and execute future acquisitions or dispositions, or to successfully
manage the impacts of such transactions on its operations; as a
holding company, Aurora Cannabis Inc. is dependent on its operating
subsidiaries to pay dividends and other obligations; management
will have substantial discretion concerning the use of proceeds
from future share sales and financing transactions; there is no
assurance the Company will continue to meet the listing standards
of the Nasdaq and the TSX; the financial reporting obligations of
being a public company and maintaining a dual listing on the TSX
and on Nasdaq requires significant company resources and management
attention; the Company does not anticipate paying any dividends to
the holders of Common Shares in the foreseeable future; the
Company’s business has and may continue to be subject to
disruptions as a result of the COVID-19 pandemic; Reliva, LLC’s
(“Reliva”) operations in the United States may be impacted
by regulatory action and approvals from the Food and Drug
Administration; and other risks detailed from time to time in our
annual information forms, annual financial statements, MD&A,
interim financial statements and material change reports filed with
and furnished to securities regulators, and those risks which are
discussed under the heading “Risk Factors”.
Readers are cautioned that the foregoing list of risk factors is
not exhaustive, and it is recommended that prospective investors
consult the more complete discussion of risks and uncertainties
facing the Company included in this Prospectus Supplement and the
accompanying Base Prospectus under the heading “Risk
Factors”, as well as those set out in our 2022 AIF under the
heading “Risk Factors” and in our 2022 Annual MD&A and Interim
MD&A, each of which documents are incorporated by reference
into this Prospectus Supplement. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information.
Should one or more of these risks or uncertainties materialize, or
should underlying factors or assumptions prove incorrect, actual
results may vary materially from those described in forward looking
statements. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of the cannabis industry which the Company
believes to be reasonable.
Although the Company believes that the expectations conveyed by the
forward-looking statements are reasonable based on the information
available to the Company on the date hereof, no assurance can be
given as to future results, approvals or achievements.
Forward-looking statements contained in this Prospectus Supplement,
the accompanying Base Prospectus and in the documents incorporated
by reference herein and therein are expressly qualified by this
cautionary statement. The Company disclaims any duty to update any
of the forward-looking statements after the date of this Prospectus
Supplement except as otherwise required by applicable law.
NOTE TO UNITED STATES
READERS REGARDING DIFFERENCES
BETWEEN UNITED STATES AND CANADIAN FINANCIAL
REPORTING PRACTICES
We prepare our financial statements in accordance with IFRS, as
issued by the IASB, which differs from U.S. generally accepted
accounting principles (“U.S. GAAP”). Accordingly, our
financial statements and other financial information included or
incorporated by reference in this Prospectus Supplement and the
accompanying Base Prospectus may not be comparable to financial
statements of United States companies prepared in accordance with
U.S. GAAP.
NON-IFRS MEASURES
The information presented in this Prospectus Supplement and the
accompanying Base Prospectus, including certain documents
incorporated by reference herein and therein, may include
non-IFRS measures that are
used by us as indicators of financial performance. These financial
measures do not have standardized meanings prescribed under IFRS
and our computation may differ from similarly-named computations as
reported by other entities and, accordingly, may not be comparable.
These financial measures should not be considered as an alternative
to, or more meaningful than, measures of financial performance as
determined in accordance with IFRS as an indicator of performance.
The Company believes these measures may be useful supplemental
information to assist investors in assessing our operational
performance and our ability to generate cash through operations.
The non-IFRS measures also
provide investors with insight into our decision making as we use
these non-IFRS measures to
make financial, strategic and operating decisions.
S-5
Because non-IFRS measures
do not have a standardized meaning and may differ from
similarly-named computations as reported by other entities,
securities regulations require that non-IFRS measures be clearly defined
and qualified, reconciled with their nearest IFRS measure and given
no more prominence than the closest IFRS measure. If non-IFRS measures are included in
documents incorporated by reference herein, information regarding
these non-IFRS measures are
presented in the sections dealing with these financial measures in
such documents.
Non-IFRS measures are not
audited. These non-IFRS
measures have important limitations as analytical tools and
investors are cautioned not to consider them in isolation or place
undue reliance on ratios or percentages calculated using these
non-IFRS measures.
CURRENCY PRESENTATION AND
EXCHANGE RATE INFORMATION
Unless stated otherwise or as the context otherwise requires, all
references to dollar amounts in this Prospectus Supplement are
references to Canadian dollars. References to “C$” are to Canadian
dollars and references to “U.S. dollars” or “U.S.$” are to United
States dollars.
Except as otherwise noted in our 2022 AIF and the Company’s
financial statements and related management’s discussion and
analysis of financial condition and results of operations of the
Company that are incorporated by reference into this Prospectus
Supplement, the financial information contained in such documents
is expressed in Canadian dollars.
The high, low, average and closing daily exchange rates for the
United States dollar in terms of Canadian dollars for each of the
financial periods of the Company ended September 30, 2022,
June 30, 2022 and June 30, 2021, as quoted by the Bank of
Canada, were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30, 2022
|
|
|
Year ended
June 30, 2022 |
|
|
Year ended
June 30, 2021 |
|
|
|
(expressed in Canadian dollars)
|
|
High
|
|
|
1.3726 |
|
|
|
1.3039 |
|
|
|
1.3682 |
|
Low
|
|
|
1.2753 |
|
|
|
1.2329 |
|
|
|
1.2040 |
|
Average
|
|
|
1.3056 |
|
|
|
1.2659 |
|
|
|
1.2882 |
|
Closing
|
|
|
1.3707 |
|
|
|
1.2886 |
|
|
|
1.2394 |
|
On November 24, 2022, the daily exchange rate for the United
States dollar in terms of Canadian dollars, as quoted by the Bank
of Canada, was U.S.$1.00 = C$1.3338.
OUR BUSINESS
This summary does not contain all the information about the
Company that may be important to you. You should read the more
detailed information, public filings and financial statements and
related notes that are incorporated by reference into and are
considered to be a part of this Prospectus Supplement and the
accompanying Base Prospectus.
S-6
Aurora is a Canadian-headquartered cannabis company serving both
the medical and consumer markets. Aurora is a pioneer in global
cannabis, dedicated to helping people improve their lives. The
Company’s adult-use brand portfolio includes Aurora Drift, San
Rafael ‘71, Daily Special, Whistler, Being and Greybeard, as
well as CBD brands, Reliva and KG7. Medical cannabis brands include
MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co.
Aurora also has a controlling interest in Bevo Farms, North
America’s leading supplier of propagated agricultural plants.
Driven by science and innovation, and with a focus on high-quality
cannabis products, Aurora’s brands continue to break through as
industry leaders in the medical, performance, wellness and adult
recreational markets wherever they are launched.
USE OF PROCEEDS
We will receive all proceeds of the full issue price of U.S.$12.60
per Warrant Share upon issuance of the Warrant Shares upon any
exercise of the Warrants from time to time. Assuming that all of
the Warrants are exercised prior to 5:00 p.m. (Toronto time) on the
Expiry Date for cash and that no adjustment based on anti-dilution
provisions contained in the Warrant Indenture has taken place, the
proceeds to the Company will be U.S.$83,160,000. There is no
assurance as to how many Warrants will be exercised, if any.
Accordingly, there is no assurance as to how many Warrant Shares
will be issued pursuant to this Prospectus Supplement, if any, or
the proceeds of such offering.
It is currently anticipated that the Company will use any proceeds
from the Offering for general corporate purposes.
Although we intend to use the proceeds from the Offering as set
forth above, the actual allocation of the net proceeds may vary
depending on future developments, at the discretion of our board of
directors and management. See “Risk Factors – The Company has
discretion with respect to the use of proceeds from
this Offering”.
S-7
During the fiscal year ended June 30, 2022 and the first
quarter ended September 30, 2022, the Company had negative
cash flow from operating activities. Although the Company
anticipates it will be able to generate positive cash flow from
operating activities in the future, the Company cannot guarantee it
will have positive cash flow from operating activities in any
future period. To the extent that the Company has negative
operating cash flow in any future period, current working capital
and certain of the proceeds from the Offering may be used to fund
such negative cash flow from operating activities. See “Risk
Factors – Negative Cash Flow from Operations”.
CONSOLIDATED
CAPITALIZATION
As of September 30, 2022, the Company had 300,437,433 Common
Shares issued and outstanding. Except as described below, there
have been no material changes in our share and debt capital, on a
consolidated basis, since September 30, 2022, being the date
of the Interim Financial Statements incorporated by reference in
this Prospectus, other than:
|
• |
|
the issuance of a total of 186,497 Common Shares related to
Aurora’s RSU share based compensation program; and
|
|
• |
|
the issuance of an aggregate of 24,958,371 Common Shares pursuant
to the Company’s at-the-market offering program
(the “ATM Program”) for gross proceeds of approximately
U.S.$31,216,903,
|
each as described further below under “Prior Sales”.
The following table shows the effect of the Warrants and Warrant
Shares (assuming all Warrants are exercised prior to the Expiry
Date) on the issued share capital of the Company. This table should
be read in conjunction with the consolidated financial statements
of the Company and the related notes and management’s discussion
and analysis of financial condition and results of operations in
respect of those statements that are incorporated by reference in
the Prospectus.
|
|
|
|
|
|
|
|
|
Description(1)
|
|
As at September 30, 2022,
before giving effect
to the exercise of the
Warrants |
|
|
As at September 30, 2022,
after giving effect
to the exercise of
the Warrants(2) |
|
Common Shares
|
|
|
300,437,433
|
|
|
|
307,037,433
|
|
Share Capital (in thousands of $)
|
|
C$ |
6,764,621 |
|
|
C$ |
6,878,500 |
|
Warrants
|
|
|
89,124,788 |
|
|
|
82,524,788 |
|
(1) |
This table does not give effect to issuances of Common
Shares that occurred after September 30, 2022.
|
(2) |
Assuming a currency exchange rate equivalent to the
daily exchange rate for the United States dollar in terms of
Canadian dollars on September 30, 2022, as quoted by the Bank
of Canada, being U.S.$1.00 = C$1.3707.
|
S-8
PRIOR SALES
The following table sets out details of all Common Shares issued by
the Company since the year ended June 30, 2022. For details of
all Common Shares issued during the year ended June 30, 2022,
see the Company’s 2022 AIF.
|
|
|
|
|
|
|
|
|
|
|
Date of Issuance
|
|
Reason for Issuance
|
|
Number of
Securities
Issued |
|
|
Issue/Exercise Price
per Security |
|
July 4, 2022
|
|
PSU Release |
|
|
54 |
|
|
C$ |
8.22 |
|
July 4, 2022
|
|
RSU Release |
|
|
250 |
|
|
C$ |
8.22 |
|
July 7, 2022
|
|
Shares issued for business
combinations & asset acquisitions |
|
|
2,614,995 |
|
|
C$ |
3.70 |
|
July 26, 2022
|
|
RSU Release |
|
|
334 |
|
|
C$ |
12.61 |
|
July 26, 2022
|
|
RSU Release |
|
|
820 |
|
|
C$ |
8.22 |
|
July 26, 2022
|
|
RSU Release |
|
|
328 |
|
|
C$ |
10.09 |
|
July 26, 2022
|
|
RSU Release |
|
|
489 |
|
|
C$ |
8.22 |
|
July 26, 2022
|
|
RSU Release |
|
|
251 |
|
|
C$ |
12.61 |
|
July 26, 2022
|
|
RSU Release |
|
|
606 |
|
|
C$ |
8.22 |
|
July 26, 2022
|
|
RSU Release |
|
|
368 |
|
|
C$ |
8.22 |
|
August 31, 2022
|
|
RSU Release |
|
|
1,061 |
|
|
C$ |
8.22 |
|
August 22, 2022
|
|
RSU Release |
|
|
247 |
|
|
C$ |
10.09 |
|
August 22, 2022
|
|
RSU Release |
|
|
343 |
|
|
C$ |
12.61 |
|
August 22, 2022
|
|
PSU Release |
|
|
167 |
|
|
C$ |
8.22 |
|
August 22, 2022
|
|
RSU Release |
|
|
363 |
|
|
C$ |
8.22 |
|
August 22, 2022
|
|
RSU Release |
|
|
417 |
|
|
C$ |
113.16 |
|
September 7, 2022
|
|
RSU Release |
|
|
652 |
|
|
C$ |
94.92 |
|
September 7, 2022
|
|
RSU Release |
|
|
12,622 |
|
|
C$ |
10.09 |
|
September 7, 2022
|
|
RSU Release |
|
|
5,755 |
|
|
C$ |
17.84 |
|
September 7, 2022
|
|
RSU Release |
|
|
22,582 |
|
|
C$ |
8.22 |
|
September 7, 2022
|
|
RSU Release |
|
|
53 |
|
|
C$ |
33.48 |
|
September 7, 2022
|
|
RSU Release |
|
|
1,140 |
|
|
C$ |
17.84 |
|
September 7, 2022
|
|
RSU Release |
|
|
1,298 |
|
|
C$ |
8.22 |
|
October 3, 2022
|
|
ATM Program |
|
|
835,824 |
|
|
U.S.$ |
1.27 |
|
October 3, 2022
|
|
RSU Release |
|
|
1,052 |
|
|
C$ |
2.08 |
|
October 3, 2022
|
|
RSU Release |
|
|
7,454 |
|
|
C$ |
7.91 |
|
October 3, 2022
|
|
RSU Release |
|
|
2,917 |
|
|
C$ |
8.22 |
|
October 3, 2022
|
|
RSU Release |
|
|
41,364 |
|
|
C$ |
10.09 |
|
October 3, 2022
|
|
RSU Release |
|
|
594 |
|
|
C$ |
12.61 |
|
October 3, 2022
|
|
RSU Release |
|
|
1,023 |
|
|
C$ |
17.84 |
|
October 3, 2022
|
|
ATM Program |
|
|
525,000 |
|
|
U.S.$ |
1.24 |
|
October 4, 2022
|
|
ATM Program |
|
|
3,500,000 |
|
|
U.S.$ |
1.27 |
|
October 6, 2022
|
|
ATM Program |
|
|
11,000,883 |
|
|
U.S.$ |
1.31 |
|
October 7, 2022
|
|
ATM Program |
|
|
951,900 |
|
|
U.S.$ |
1.22 |
|
October 12, 2022
|
|
ATM Program |
|
|
278,736 |
|
|
U.S.$ |
1.07 |
|
October 13, 2022
|
|
ATM Program |
|
|
1,000,000 |
|
|
U.S.$ |
1.10 |
|
October 14, 2022
|
|
ATM Program |
|
|
166,094 |
|
|
U.S.$ |
1.11 |
|
October 17, 2022
|
|
ATM Program |
|
|
2,548,929 |
|
|
U.S.$ |
1.12 |
|
S-9
|
|
|
|
|
|
|
|
|
|
|
Date of Issuance
|
|
Reason for Issuance
|
|
Number of
Securities
Issued |
|
|
Issue/Exercise Price
per Security |
|
October 18, 2022
|
|
ATM Program |
|
|
1,155,047 |
|
|
U.S.$ |
1.13 |
|
October 19, 2022
|
|
ATM Program |
|
|
197,481 |
|
|
U.S.$ |
1.11 |
|
October 20, 2022
|
|
ATM Program |
|
|
596,498 |
|
|
U.S.$ |
1.11 |
|
October 21, 2022
|
|
ATM Program |
|
|
952,261 |
|
|
U.S.$ |
1.10 |
|
October 4, 2022
|
|
RSU Release |
|
|
61,766 |
|
|
C$ |
8.22 |
|
October 27, 2022
|
|
RSU Release |
|
|
1,574 |
|
|
C$ |
12.61 |
|
October 27, 2022
|
|
RSU Release |
|
|
2,253 |
|
|
C$ |
8.22 |
|
October 27, 2022
|
|
RSU Release |
|
|
157 |
|
|
C$ |
10.09 |
|
October 27, 2022
|
|
RSU Release |
|
|
36,128 |
|
|
C$ |
10.09 |
|
October 27, 2022
|
|
RSU Release |
|
|
29,032 |
|
|
C$ |
8.22 |
|
November 3, 2022
|
|
RSU Release |
|
|
136 |
|
|
C$ |
7.91 |
|
November 3, 2022
|
|
RSU Release |
|
|
1,047 |
|
|
C$ |
8.22 |
|
November 17, 2022
|
|
ATM Program |
|
|
1,004,058 |
|
|
U.S.$ |
1.43 |
|
November 18, 2022
|
|
ATM Program |
|
|
131,538 |
|
|
U.S.$ |
1.37 |
|
November 21, 2022
|
|
ATM Program |
|
|
114,122 |
|
|
U.S.$ |
1.35 |
|
The following table sets out details of all securities convertible
or exercisable into Common Shares that were issued or granted by
the Company following the year ended June 30, 2022. For
details of all securities convertible or exercisable into Common
Shares that were issued or granted during the year ended
June 30, 2022, see the Company’s 2022 AIF.
|
|
|
|
|
|
|
|
|
|
|
Date of Issuance
|
|
Type of Security
Issued |
|
Number of Common Shares
Issuable Upon Exercise or
Conversion |
|
|
Exercise or Conversion Price
Per Common Share |
|
September 23, 2022
|
|
Options |
|
|
3,168,334 |
|
|
C$ |
1.87 |
|
September 23, 2022
|
|
PSU |
|
|
1,725,010 |
|
|
|
N/A |
|
September 30, 2022
|
|
Options |
|
|
216,664 |
|
|
C$ |
1.67 |
|
September 30, 2022
|
|
DSU |
|
|
62,872 |
|
|
|
N/A |
|
September 30, 2022
|
|
DSU |
|
|
52,395 |
|
|
|
N/A |
|
November 15, 2022
|
|
PSU |
|
|
9,736 |
|
|
|
N/A |
|
November 15, 2022
|
|
RSU |
|
|
22,716 |
|
|
|
N/A |
|
TRADING PRICE AND
VOLUME
Our Common Shares are listed on the TSX and Nasdaq under the
trading symbol “ACB”. The following tables set forth the reported
high and low closing prices and the aggregate trading volume of our
Common Shares on the TSX and the Nasdaq for each of the months (or,
if applicable, partial months) indicated during the 12-month period prior to the date of
this Prospectus Supplement.
S-10
|
|
|
|
|
|
|
|
|
|
|
|
|
Month |
|
TSX Price Range |
|
|
Total Volume |
|
|
High (C$) |
|
|
Low (C$) |
|
November 2021
|
|
|
10.87 |
|
|
|
7.82 |
|
|
|
37,218,206 |
|
December 2021
|
|
|
8.52 |
|
|
|
6.82 |
|
|
|
27,760,176 |
|
January 2022
|
|
|
7.61 |
|
|
|
4.74 |
|
|
|
34,879,925 |
|
February 2022
|
|
|
6.22 |
|
|
|
4.46 |
|
|
|
33,793,195 |
|
March 2022
|
|
|
5.70 |
|
|
|
3.70 |
|
|
|
46,742,887 |
|
April 2022
|
|
|
5.27 |
|
|
|
3.58 |
|
|
|
31,228,245 |
|
May 2022
|
|
|
4.09 |
|
|
|
2.13 |
|
|
|
58.935,771 |
|
June 2022
|
|
|
2.03 |
|
|
|
1.58 |
|
|
|
60,410,007 |
|
July 2022
|
|
|
2.12 |
|
|
|
1.63 |
|
|
|
35,831,695 |
|
August 2022
|
|
|
2.43 |
|
|
|
1.84 |
|
|
|
52,673,201 |
|
September 2022
|
|
|
2.11 |
|
|
|
1.59 |
|
|
|
62,684,576 |
|
October 2022
|
|
|
1.96 |
|
|
|
1.43 |
|
|
|
58,502,905 |
|
November 1—24, 2022
|
|
|
2.05 |
|
|
|
1.65 |
|
|
|
55,394,107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Month
|
|
Nasdaq Price Range |
|
|
Total Volume |
|
|
High (U.S.$) |
|
|
Low (U.S.$) |
|
November 2021
|
|
|
8.69 |
|
|
|
6.10 |
|
|
|
144,607,688 |
|
December 2021
|
|
|
6.74 |
|
|
|
5.39 |
|
|
|
102,100,806 |
|
January 2022
|
|
|
6.0499 |
|
|
|
3.71 |
|
|
|
135,122,353 |
|
February 2022
|
|
|
4.90 |
|
|
|
3.47 |
|
|
|
107,807,976 |
|
March 2022
|
|
|
4.56 |
|
|
|
2.89 |
|
|
|
207,854,075 |
|
April 2022
|
|
|
4.215 |
|
|
|
2.79 |
|
|
|
123,460,666 |
|
May 2022
|
|
|
3.19 |
|
|
|
1.66 |
|
|
|
266,659,678 |
|
June 2022
|
|
|
1.62 |
|
|
|
1.23 |
|
|
|
235,834,334 |
|
July 2022
|
|
|
1.65 |
|
|
|
1.26 |
|
|
|
177,785,725 |
|
August 2022
|
|
|
1.89 |
|
|
|
1.37 |
|
|
|
262,879,542 |
|
September 2022
|
|
|
1.61 |
|
|
|
1.16 |
|
|
|
177,050,937 |
|
October 2022
|
|
|
1.43 |
|
|
|
1.04 |
|
|
|
309,461,793 |
|
November 1—24, 2022
|
|
|
1.54 |
|
|
|
1.21 |
|
|
|
231,709,939 |
|
DESCRIPTION OF SECURITIES
BEING DISTRIBUTED
Common Shares
The Company is authorized to issue an unlimited number of Common
Shares without par value. For a description of the terms and
provisions of the Common Shares, see “Description of Securities
Being Distributed – Common Shares” in the Base Prospectus. As
of September 30, 2022, there were 300,437,433 Common Shares
outstanding. If all of the Warrants are exercised, there will be
307,037,433 Common Shares outstanding.
S-11
PLAN OF
DISTRIBUTION
This Prospectus Supplement relates to: (i) up to 6,600,000
Warrant Shares issuable from time to time on exercise of 6,600,000
Warrants issued by the Company pursuant to the Unit Offering; and
(ii) such indeterminate number of additional Warrant Shares
that may be issuable by reason of the anti-dilution provisions
contained in the indenture governing the Warrants (the “Warrant
Indenture”) entered into between the Company and Computershare
Trust Company of Canada, as warrant agent (the “Warrant
Agent”).
Each Warrant entitles the holder to purchase one Warrant Share from
the treasury of the Company at the price of U.S.$12.60 per Warrant
Share at any time until 5:00 p.m. (Toronto time) on the Expiry
Date, subject to adjustment and in accordance with the terms and
conditions set out in the Warrant Indenture, after which the
Warrants will become null and void.
The following summary of certain provisions of the Warrant
Indenture does not purport to be complete and is qualified in its
entirety by reference to the detailed provisions of the Warrant
Indenture. Reference is made to the Warrant Indenture for the full
text of the attributes of the Warrants, which is filed on SEDAR
under the issuer profile of the Company at www.sedar.com and with
the SEC at www.sec.gov. A register of holders of Warrants is
maintained at the principal offices of the Warrant Agent in
Vancouver, British Columbia. The holders of Warrants do not, as
such, have any voting right or other right attached to the Warrant
Shares until and unless the Warrants are duly exercised as provided
for in the Warrant Indenture.
The Warrant Indenture provides that the number of Warrant Shares
which may be acquired by a holder of Warrants upon the exercise
thereof will be subject to anti-dilution provisions governed by the
Warrant Indenture, including provisions for the appropriate
adjustment of the class, number and price of the securities
issuable under the Warrant Indenture upon the occurrence of certain
events, including:
|
(a) |
the issuance of Common Shares or securities
exchangeable for or convertible into Common Shares to all or
substantially all of the holders of Common Shares by way of a stock
dividend or other distribution (other than a distribution of Common
Shares upon the exercise of any outstanding warrants, options or
other convertible securities);
|
|
(b) |
the subdivision, redivision or change of the Common
Shares into a greater number of shares;
|
|
(c) |
the consolidation, reduction or combination of the
Common Shares into a lesser number of shares;
|
|
(d) |
the issuance to all or substantially all of the
holders of Common Shares of rights, options or warrants under which
such holders are entitled, during a period expiring not more than
45 days after the record date for such issuance, to subscribe for
or purchase Common Shares, or securities exchangeable for or
convertible into Common Shares, at a price per Common Share to the
holder (or at an exchange or conversion price per share) of less
than 95% of the “current market price” (as defined in the Warrant
Indenture) of Common Shares on such record date; and
|
|
(e) |
the issuance or distribution to all or substantially
all of the holders of Common Shares of (i) securities,
including rights, options or warrants to acquire shares of any
class or securities exchangeable or convertible into any such
shares or property or assets or (ii) any property or assets,
including evidences of indebtedness.
|
The Warrant Indenture also includes provisions for the appropriate
adjustment of the class, number and price of the securities
issuable under the Warrant Indenture upon the occurrence of the
following additional events:
|
(a) |
the reclassification of the Common Shares or exchange
or change of the Common Shares into other shares;
|
S-12
|
(b) |
the amalgamation, arrangement or merger with or into
any other corporation or other entity (other than an amalgamation,
arrangement or merger which does not result in any reclassification
of the Company’s outstanding Common Shares or an exchange or change
of the Common Shares into other shares); and
|
|
(c) |
the transfer of the Company’s undertakings or assets
as an entirety or substantially as an entirety to another
corporation or other entity.
|
The Warrant Indenture provides that: (i) no adjustment to the
exercise price for the Warrants will be required to be made unless
such adjustment would result in a change of at least 1% in the
exercise price for the Warrants; and (ii) no adjustment to the
number of Warrant Shares issuable upon exercise of the Warrants
will be required to be made unless such adjustment would result in
a change of at least one one-hundredth of a Warrant Share.
The Company has covenanted in the Warrant Indenture, during the
period in which the Warrants are exercisable, to give notice to
holders of Warrants of certain stated events, including events that
would result in an adjustment to the exercise price for the
Warrants or the number of Warrant Shares issuable upon exercise of
the Warrants, a prescribed number of days prior to the record date
or effective date, as the case may be, of such event.
The Warrant Indenture provides that, from time to time, the Warrant
Agent and the Company, without the consent of the holders of
Warrants, is able to amend or supplement the Warrant Indenture for
certain purposes, including rectifying any ambiguities, defective
provisions, clerical omissions or mistakes, or other errors
contained in the Warrant Indenture or in any deed or indenture
supplemental or ancillary to the Warrant Indenture, provided that,
in the opinion of the Warrant Agent, relying on legal counsel, the
rights of the holders of Warrants, as a group, are not prejudiced
thereby. Subject to the voting rights set forth in the Warrant
Indenture, the rights of holders of the Warrants may, in certain
circumstances, be modified by way of an extraordinary resolution
passed by the affirmative vote of the holders of not less than
662⁄3% of the aggregate number of all the
then outstanding Warrants at a meeting duly called and held in
accordance with the terms of the Warrant Indenture at which there
are present in person or by proxy at least two holders representing
at least 20% of the aggregate number of all the then outstanding
Warrants.
The Warrant Indenture also provides that in the event of an
extraordinary transaction, as described in the Warrant Indenture
and generally including any merger, arrangement or amalgamation of
the Company with or into another entity, sale of all or
substantially all of the Company’s assets, tender offer or exchange
offer, or reclassification of the Common Shares, the holders of the
Warrants will generally be entitled to receive upon exercise of the
Warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the
Warrants immediately prior to such extraordinary transaction.
The Warrant Indenture includes certain beneficial ownership
limitations under which Warrants are not exercisable to the extent
that, after giving effect to the issuance of the Warrant Shares
issuable upon such exercise of the Warrants, the holder, together
with its affiliates and other persons acting as a group with the
holder or any of its affiliates, would beneficially own in excess
of 4.99% of the number of Common Shares outstanding immediately
after giving effect to such issuance. Such beneficial ownership
limitation may be increased or decreased by the holder upon notice
to the Company, to a maximum of 9.99%. Except as provided in the
Warrant Indenture, beneficial ownership will be calculated in
accordance with Section 13(d) of the U.S. Exchange Act and the
rules and regulations promulgated thereunder. To the extent the
beneficial ownership limitations apply, the determination of
whether a Warrant is exercisable and of which portion of a Warrant
is exercisable shall be in the sole discretion and at the sole
responsibility of the holder, and the submission of an exercise
notice in respect of any Warrants shall be deemed to be the
holder’s determination of whether the Warrants are exercisable, and
neither the Warrant Agent nor the Company will have any obligation
to verify or confirm the accuracy of such determination.
The Company will use commercially reasonable best efforts to
maintain a registration statement effective until the earlier of
the Expiry Date or such time as no Warrants remain outstanding
(provided, however, that nothing shall prevent the Company’s
amalgamation, arrangement, merger or sale, including any take-over
bid, and any associated delisting or deregistration or ceasing to
be a reporting issuer, provided that, so long as the Warrants
are
S-13
still outstanding and represent a right to acquire securities of
the acquiring company, the acquiring company shall assume the
Company’s obligations under the Warrant Indenture), which could
require the additional filing of a new registration statement
and/or base shelf prospectus and prospectus supplement if the
current Prospectus is no longer usable. If, at any time prior to
the Expiry Date, the Company determines that no registration
statement filed with the SEC is effective, or that its use is
suspended, no holder of Warrants will be permitted to exercise
Warrants unless an exemption from the registration requirements of
the U.S. Securities Act and applicable state securities laws is
available, and the holders of Warrants will receive a notice of
this determination, together with written confirmation that the
Warrants may, until the earlier of (x) a registration
statement becoming effective or ceasing to be suspended and any
prospectus supplement necessary in relation thereto having been
filed and (y) the Expiry Date, if the Current Market Price (as
defined in the Warrant Indenture) of the Common Shares exceeds the
exercise price for the Warrants, also be exercised by means of a
“cashless exercise” in which the holder of Warrants will be
entitled to receive a certificate for a number of Warrant Shares
determined on the basis of the excess of the current market price
over the exercise price for the Warrants.
The principal transfer office of the Warrant Agent in Vancouver,
British Columbia is the location at which Warrants may be
surrendered for exercise or transfer.
The Company previously filed the Original Warrant Share Prospectus
Supplement to the Original Base Prospectus on January 25, 2021
with the securities commission or similar regulatory authority in
each of the provinces of Canada, except Québec, and, in connection
therewith, filed a prospectus supplement dated January 25,
2021 to its registration statement on Form F-10 with the SEC relating to the
Warrant Shares.
In accordance with Canadian shelf prospectus rules under NI
44-102, the Original Base
Prospectus will cease to be effective as of November 28, 2022.
This Prospectus Supplement replaces the Original Warrant Share
Prospectus Supplement in order to maintain the registration of the
offering of the Warrant Shares under the U.S. Securities Act,
beyond the expiry date of the Original Base Prospectus.
The Warrants were qualified for distribution by a prospectus
supplement dated January 22, 2021 to the Original Base
Prospectus filed with the securities commission or similar
regulatory authority in each of the provinces of Canada, except
Québec, and, in connection therewith, a prospectus supplement dated
January 22, 2021 to its registration statement on Form
F-10 with the SEC relating
to the Unit Offering, pursuant to which the Company qualified the
distribution by the Company of 13,200,000 Units at a price of
U.S.$10.45 per Unit pursuant to the terms of the underwriting
agreement entered into between the Company and the Underwriters on
January 22, 2021 (the “Underwriting Agreement”). The
Unit Offering was completed on January 26, 2021. The exercise
price of the Warrants was determined by negotiation between the
Company and the Underwriters.
This Prospectus Supplement registers the offering of the securities
to which it relates under the U.S. Securities Act in accordance
with the MJDS. This Prospectus Supplement does not qualify in
any of the provinces or territories of Canada the distribution of
the Warrant Shares to which it relates.
The Warrant Shares to which this Prospectus Supplement relates will
be sold directly by the Company to holders of Warrants upon any
exercise of such Warrants. No underwriters, dealers or agents will
be involved in these sales.
The Common Shares are listed on the TSX and on the Nasdaq under the
symbol “ACB” and on the FSE under the symbol “21P”.
The TSX has approved the listing of the Warrant Shares issuable on
exercise of the Warrants on the TSX.
There is no assurance as to how many of the Warrants will be
exercised, and accordingly, there is no assurance as to how many
Warrant Shares will be issued pursuant to this Prospectus
Supplement, if any. No party has any obligation to purchase any
Warrant Shares qualified by this Prospectus Supplement.
No fractional Common Shares will be issuable upon the exercise of
any Warrants, and no cash or other consideration will be paid in
lieu of fractional Common Shares.
S-14
RISK FACTORS
An investment in the Warrant Shares is highly speculative and
subject to a number of known and unknown risks. Only those persons
who can bear the risk of loss of their investment should purchase
the Warrant Shares. Investors should consider carefully the risk
factors set out herein and contained in and incorporated by
reference in the Base Prospectus. Discussions of certain risks
affecting us in connection with our business are set out under the
heading “Risk Factors” in the accompanying Base Prospectus as well
as in the documents incorporated by reference therein and herein,
including, specifically, under the heading “Risk Factors” in the
2022 AIF. Any of the matters highlighted in these risk factors
could have a material adverse effect on our business, results of
operations and financial conditions, causing an investor to lose
all, or part of, its, his or her investment.
The Company has discretion with respect to the use of
proceeds from this Offering.
Management will have broad discretion with respect to the use of
the proceeds from this Offering, if any, and investors will be
relying on the judgment of management regarding the application of
these proceeds. At the date of this Prospectus Supplement, the
Company intends to use the proceeds from this Offering as described
under the heading “Use of Proceeds”. However, the Company’s
needs may change as its business and the industry the Company
addresses evolve. As a result, the proceeds to be received in this
Offering may be used in a manner significantly different from the
Company’s current expectations. The failure by management to apply
these funds effectively could have a material adverse effect on the
Company’s business.
Negative Cash Flow from Operations
The Company had negative operating cash flows for the fiscal year
ended June 30, 2022 and the first quarter ended
September 30, 2022. Although the Company anticipates it will
be able to generate positive cash flow from operating activities in
the future, the Company cannot guarantee it will have positive cash
flow from operating activities in any future period. To the extent
that the Company has negative operating cash flow in any future
period, certain of the proceeds from the Offering may be used to
fund such negative cash flow from operating activities. See “Use
of Proceeds”.
Future sales or issuances of Common Shares could decrease the
value of any existing Common Shares or Warrants, dilute voting
power of holders of Common Shares and reduce the Company’s earnings
per share.
Future issuances of equity securities by the Company could decrease
the value of any existing Common Shares and Warrants, dilute voting
power of holders of Common Shares, reduce the Company’s earnings
per share and make future sales of the Company’s equity securities
more difficult. With any additional sale or issuance of equity
securities, holders of Common Shares will suffer dilution of their
voting power and may experience dilution in the Company’s earnings
per share. Sales of Common Shares by shareholders might also make
it more difficult for the Company to sell equity securities at a
time and price that it deems appropriate.
The Company may issue additional equity securities (including
through the sale of securities convertible into, or exchangeable
for, Common Shares) under the Company’s current equity incentive
plans. In addition, the Company may issue Common Shares to finance
its operations or future acquisitions. The Company cannot predict
the size of future sales and issuances of debt or equity securities
or the effect, if any, that future sales and issuances of equity
securities will have on the market price of the Common Shares and
Warrants.
Sales or issuances of a substantial number of equity securities, or
the perception that such sales could occur, may adversely affect
prevailing market prices for the Common Shares and the
Warrants.
S-15
The Common Share price has experienced volatility and may be
subject to fluctuation in the future based on market conditions,
which could also affect the market price of the
Warrants.
The market prices for the securities of cannabis companies,
including the Company, have historically been, and may in the
future be, subject to large fluctuations. The market has from time
to time experienced significant price and volume fluctuations that
are unrelated to the operating performance of any particular
company. In addition, because of the nature of the Company’s
business, certain factors such as announcements and the public’s
reaction, the Company’s operating performance and the performance
of competitors and other similar companies, government regulations,
changes in earnings estimates or recommendations by research
analysts who track the Company’s securities or securities of other
companies in the cannabis industry, general market conditions,
announcements relating to litigation, the arrival or departure of
key personnel and the factors listed under the heading
“Cautionary Note Regarding Forward-Looking Statements” can
have an adverse impact on the market price of the Common Shares and
Warrants.
Any negative change in the public’s perception of the Company’s
prospects could cause the price of the Company’s securities,
including the price of the Common Shares and Warrants, to decrease
dramatically. Furthermore, any negative change in the public’s
perception of the prospects of cannabis companies in general could
depress the price of the Company’s securities, including the price
of the Common Shares and Warrants, regardless of the Company’s
results. Following declines in the market price of a corporation’s
securities, securities class-action litigation could be instituted.
Litigation of this type, if instituted, could result in substantial
costs and a diversion of management’s attention and resources.
No public market for Warrants
There is currently no market through which the Warrants may be sold
and holders may not be able to resell the Warrants. There can be no
assurance that a secondary market for trading in the Warrants will
develop or that any secondary market which does develop will
continue and if it does develop, that it will be active. This may
affect the pricing of the Warrants in the secondary market and the
transparency and availability of tracing prices. Without an active
market, the liquidity of the Warrants will be limited and you may
be unable to sell the Warrants at the prices desired or at all. The
Warrants have an exercise price of U.S.$12.60 per Warrant Share
(subject to adjustment in certain circumstances) and can be
exercised at any time prior to the Expiry Date. In the event the
market price of the Common Shares does not exceed the exercise
price of the Warrants during the period when the Warrants are
exercisable, the Warrants may not have any value. Holders of the
Warrants have no rights as shareholders of the Company until they
exercise the Warrants in accordance with their terms. Upon exercise
of the Warrants, holders of the Warrant Shares deliverable on the
exercise of such Warrants will be entitled to exercise the rights
of a shareholder in respect of such Warrant Shares only in respect
of matters for which the record date occurs after the exercise
date. See “Description of Securities Being Distributed –
Warrants” in the Base Prospectus.
Return on Investment Risk
There is no guarantee that an investment in Warrant Shares will
earn any positive return in the short or long term. An investment
in the Warrant Shares involves a high degree of risk and should be
undertaken only by investors whose financial resources are
sufficient to enable them to assume such risks, who have no need
for immediate liquidity in their investment and who have the
financial capacity to absorb a loss of some or all of their
investment.
We may be a passive foreign investment company, or “PFIC”,
which could result in adverse U.S. federal income tax consequences
to U.S. investors.
The Company does not believe that it was a PFIC for the year ended
June 30, 2021, but has not yet made a formal determination in
respect to its PFIC status for each of the years ended
June 30, 2021 or 2022. If we are a PFIC for any taxable year
(or portion thereof) that is included in the holding period of a
U.S. Holder (as defined in the section of this Prospectus
Supplement captioned “Material U.S. Federal Income Tax
Considerations”) of our Common Shares or Warrants, the U.S.
Holder may be subject to certain adverse U.S. federal income tax
consequences and may be subject to additional reporting
requirements. The Company intends to make a formal determination
concerning its PFIC status with respect to each of its
June 30, 2021 and June 30, 2022 tax years, and also
promptly following the close of the current tax year, to
communicate that determination to investors and will endeavor to
provide information required by investors for a “qualified electing
fund” or “QEF” if the Company determines that it is a PFIC. See
“Material U.S. Federal Income Tax Considerations – Passive
Foreign Investment Company Considerations”.
S-16
CERTAIN CANADIAN FEDERAL
INCOME TAX CONSIDERATIONS
General
The following is a general summary, as of the date hereof, of the
principal Canadian federal income tax considerations under the Tax
Act generally applicable to a holder who acquires, as beneficial
owner, Warrant Shares upon exercise of the Warrants, and who, for
purposes of the Tax Act and at all relevant times, (i) holds
Warrant Shares and Warrants as capital property, (ii) deals at
arm’s length with the Company and the Underwriters, and
(iii) is not affiliated with the Company or the Underwriters.
A holder who meets all of the foregoing requirements is referred to
as a “Holder” herein, and this summary only addresses such
Holders. Generally, the Warrant Shares and Warrants will be
considered to be capital property to a Holder unless they are held
or acquired in the course of carrying on a business or as part of
an adventure or concern in the nature of trade.
This summary is not applicable to (i) a Holder that is a
“financial institution”, as defined in the Tax Act for purposes of
the mark-to-market rules in the Tax
Act, (ii) a Holder that is a “specified financial
institution”, as defined in the Tax Act, (iii) a Holder an
interest in which is a “tax shelter investment” as defined in the
Tax Act, (iv) a Holder that makes or has made a functional
currency reporting election for purposes of the Tax Act, or
(v) a Holder that has entered into or will enter into a
“derivative forward agreement”, a “synthetic disposition
arrangement” or a “dividend rental arrangement”, each as defined in
the Tax Act, with respect to the Warrants or Warrant Shares. In
addition, this summary does not address the deductibility of
interest by a Holder who has borrowed money or otherwise incurred
debt in connection with the acquisition of Warrant Shares or
Warrants. All such Holders should consult their own tax
advisors.
Additional considerations, not discussed herein, may be applicable
to a Holder that is a corporation resident in Canada and is, or
becomes, or does not deal at arm’s length with a corporation
resident in Canada that is, or becomes, controlled by a
non-resident person, or a
group of non-resident
persons not dealing with each other at arm’s length, for purposes
of the “foreign affiliate dumping” rules in section 212.3 of the
Tax Act. Such Holders should consult their own tax advisors with
respect to the consequences of acquiring the Warrant Shares.
This summary is based on the provisions of the Tax Act in force as
of the date hereof, all specific proposals to amend the Tax Act
that have been publicly and officially announced by or on behalf of
the Minister of Finance (Canada) prior to the date hereof (the
“Proposed Amendments”) and our understanding of the current
administrative policies and assessing practices of the Canada
Revenue Agency (the “CRA”) published in writing prior to the
date hereof. This summary assumes the Proposed Amendments will be
enacted in the form proposed. However, no assurance can be given
that the Proposed Amendments will be enacted in their current form,
or at all. This summary is not exhaustive of all possible Canadian
federal income tax considerations and, except for the Proposed
Amendments, does not take into account or anticipate any changes in
the law or any changes in the CRA’s administrative and assessing
policies or practices, whether by legislative, governmental or
judicial action or decision, nor does it take into account or
anticipate any other federal or any provincial, territorial or
foreign tax considerations, which may differ significantly from
those discussed herein. Any particular Holder should consult their
own tax advisors with respect to provincial, territorial or foreign
tax considerations. This summary is not intended to be, nor
should it be construed to be, legal or tax advice to any particular
Holder, and no representations with respect to the income tax
consequences to any Holder are made. Consequently, Holders should
consult their own tax advisors with respect to the tax consequences
applicable to them, having regard to their own particular
circumstances. The discussion below is qualified
accordingly.
Currency Conversion
Holders are required to compute their income and gains for Canadian
tax purposes in Canadian dollars. Therefore, for purposes of the
Tax Act, all amounts relating to the acquisition, holding or
disposition of the Warrant Shares must be converted into Canadian
dollars based on the exchange rate quoted by the Bank of Canada for
the date such amounts arise or such other rate of exchange as is
acceptable to the CRA.
S-17
Exercise of Warrants
No gain or loss will be realized by a Holder on the exercise of a
Warrant to acquire a Warrant Share. When a Warrant is exercised,
the Holder’s cost of the Warrant Share acquired thereby will be
equal to the aggregate of the Holder’s adjusted cost base of such
Warrant and the exercise price paid for the Warrant Share. The
Holder’s adjusted cost base of the Warrant Share so acquired will
be determined by averaging the cost of the Warrant Share with the
adjusted cost base to the Holder of all Common Shares of the
Company held as capital property immediately before the acquisition
of the Warrant Share.
Taxation of Resident Holders
The following portion of this summary applies to Holders (as
defined above) who, for the purposes of the Tax Act, are or are
deemed to be resident in Canada at all relevant times (herein,
“Resident Holders”) and this portion of the summary only
addresses such Resident Holders. Certain Resident Holders whose
Warrant Shares might not otherwise constitute capital property may
make, in certain circumstances, an irrevocable election permitted
by subsection 39(4) of the Tax Act to deem such shares, and every
other “Canadian security” (as defined in the Tax Act) held by such
persons, in the taxation year of the election and each subsequent
taxation year, to be capital property. Resident Holders should
consult their own tax advisors with respect to whether the election
is available and advisable in their particular circumstances.
Taxation of Dividends
A Resident Holder will be required to include in computing income
for a taxation year any dividends received, or deemed to be
received, in the year by the Resident Holder on the Warrant Shares.
In the case of a Resident Holder that is an individual (other than
certain trusts), such dividends will be subject to the gross-up and dividend tax credit rules
normally applicable under the Tax Act to taxable dividends received
from taxable Canadian corporations, including the enhanced
gross-up and dividend tax
credit provisions where the Company designates the dividend as an
“eligible dividend” in accordance with the provisions of the Tax
Act. There may be restrictions on the ability of the Company to
designate any dividend as an “eligible dividend”, and the Company
has made no commitments in this regard.
A dividend received or deemed to be received by a Resident Holder
that is a corporation must be included in computing its income for
a taxation year but will generally be deductible in computing the
corporation’s taxable income, subject to all of the rules and
restrictions under the Tax Act in that regard. In certain
circumstances subsection 55(2) of the Tax Act will treat a taxable
dividend received or deemed to be received by a Resident Holder
that is a corporation as proceeds of disposition or a capital gain.
A corporation that is a “private corporation” (as defined in the
Tax Act) or any other corporation controlled (whether because of a
beneficial interest in one or more trusts or otherwise) by or for
the benefit of an individual (other than a trust) or a related
group of individuals (other than trusts), generally will be liable
to pay an additional tax (refundable under certain circumstances)
under Part IV of the Tax Act on dividends received or deemed to be
received on the Warrant Shares in a year to the extent such
dividends are deductible in computing taxable income for the
year.
Disposition of Warrant Shares
A Resident Holder who disposes or is deemed to dispose of a Warrant
Share generally will realize a capital gain (or capital loss) equal
to the amount, if any, by which the proceeds of disposition, net of
any reasonable costs of disposition, are greater (or are less) than
the adjusted cost base to the Resident Holder of such Warrant
Shares immediately before the disposition or deemed disposition.
The taxation of capital gains and losses is generally described
below under the heading “Capital Gains and Capital
Losses”.
S-18
Capital Gains and Capital Losses
Generally, a Resident Holder is required to include in computing
income for a taxation year one-half of the amount of any capital
gain (a “taxable capital gain”) realized by the Resident
Holder in such taxation year. Subject to and in accordance with the
rules contained in the Tax Act, a Resident Holder is required to
deduct one-half of the
amount of any capital loss (an “allowable capital loss”)
realized in a particular taxation year against taxable capital
gains realized by the Resident Holder in the year. Allowable
capital losses in excess of taxable capital gains for the taxation
year of disposition may, in general terms, be carried back and
deducted in any of the three preceding taxation years, or in any
subsequent year, against net taxable capital gains realized in such
years, to the extent and under the circumstances described in the
Tax Act.
The amount of any capital loss realized by a Resident Holder that
is a corporation on the disposition or deemed disposition of a
Warrant Share may be reduced by the amount of any dividends
received or deemed to have been received by such Resident Holder on
such shares, to the extent and under the circumstances described in
the Tax Act. Similar rules apply where a corporation is a member of
a partnership or a beneficiary of a trust that owns Warrant Shares,
directly or indirectly. Corporations to whom these rules may be
relevant should consult their own tax advisors.
Refundable Tax
A Resident Holder that is throughout the relevant taxation year a
“Canadian-controlled private corporation” (as defined in the Tax
Act) may be liable to pay an additional tax (refundable in certain
circumstances) on certain “aggregate investment income”, including
taxable capital gains and dividends received or deemed to be
received on a Unit Share or Warrant Share to the extent that such
dividends are not deductible in computing the Resident Holder’s
taxable income for the taxation year. Proposed Amendments announced
by the Minister of Finance (Canada) on April 7, 2022 are
intended to extend this additional tax and refund mechanism in
respect of aggregate investment income to “substantive CCPCs” as
defined in the Proposed Amendments announced on April 7, 2022.
The complete legislation for such Proposed Amendments has yet to be
released. Resident Holders should consult their own tax advisors
with regard to this additional tax and refund mechanism.
Alternative Minimum Tax
Capital gains realized and dividends received or deemed to be
received by a Resident Holder that is an individual or a trust,
other than certain specified trusts, may give rise to alternative
minimum tax under the Tax Act. Resident Holders should consult
their own tax advisors in this regard.
Taxation of Non-Resident
Holders
The following portion of this summary is generally applicable to
Holders (as defined above) who, for the purposes of the Tax Act and
at all relevant times: (i) are not resident or deemed to be
resident in Canada, and (ii) do not use or hold, and are not
deemed to use or hold Warrants or Warrant Shares in carrying on a
business in Canada. Holders who meet all of the foregoing
requirements are referred to herein as “Non-Resident Holders”, and this
portion of the summary only addresses such Non-Resident Holders. Special rules,
which are not discussed in this summary, may apply to a
Non-Resident Holder that is
an insurer carrying on business in Canada and elsewhere or an
“authorized foreign bank” (as defined in the Tax Act). Such
Non-Resident Holders should
consult their own tax advisors.
Receipt of Dividends
Dividends paid or credited or deemed to be paid or credited to a
Non-Resident Holder by the
Company are generally subject to Canadian withholding tax at the
rate of 25% of the gross amount of the dividend unless reduced by
the terms of an applicable tax treaty between Canada and the
Non-Resident Holder’s
jurisdiction of residence. Non-Resident Holders should consult
their own tax advisors in this regard. For example, under the
Canada-United States Tax Convention (1980) (the “Treaty”) as
amended, the rate of withholding tax on dividends paid or credited
or deemed to be paid or credited to a Non-Resident Holder who is resident in
the United States for purposes of the Treaty, fully entitled to
benefits under the Treaty and is the beneficial owner of the
dividend (a “U.S. Resident Holder”) is generally limited to
15% of the gross amount of the dividend (or 5% in the case of a
U.S. Resident Holder that is a company beneficially owning at least
10% of the Company’s voting shares). Non-Resident Holders should consult
their own tax advisors regarding the application of any applicable
tax treaty to dividends based on their particular
circumstances.
S-19
Disposition of Warrant Shares
A Non-Resident Holder
generally will not be subject to tax under the Tax Act in respect
of a capital gain realized on the disposition or deemed disposition
of a Warrant Share unless such Warrant Share constitutes “taxable
Canadian property” (as defined in the Tax Act) to the Non-Resident Holder at the time of
disposition and the gain is not exempt from tax pursuant to the
terms of an applicable tax treaty between Canada and the
Non-Resident Holder’s
jurisdiction of residence.
Provided the Warrant Shares are listed on a “designated stock
exchange”, as defined in the Tax Act (which currently includes the
TSX and the Nasdaq) at the time of disposition, the Warrant Shares
will generally not constitute taxable Canadian property of a
Non-Resident Holder at that
time, unless at any time during the 60-month period immediately preceding
the disposition the following two conditions are satisfied
concurrently: (i) (a) the Non-Resident Holder; (b) persons
with whom the Non-Resident
Holder did not deal at arm’s length; (c) partnerships in which
the Non-Resident Holder or
a person described in (b) holds a membership interest directly
or indirectly through one or more partnerships; or (d) any
combination of the persons and partnerships described in
(a) through (c), owned 25% or more of the issued shares of any
class or series of shares of the Company; AND (ii) more than
50% of the fair market value of the Warrant Shares was derived
directly or indirectly from one or any combination of: real or
immovable property situated in Canada, “Canadian resource
properties”, “timber resource properties” (each as defined in the
Tax Act), and options in respect of, or interests in or for civil
law rights in, such properties. Notwithstanding the foregoing,
Warrant Shares may also be deemed to be taxable Canadian property
to a Non-Resident Holder
under certain other provisions of the Tax Act.
Non-Resident Holders who
may hold Warrant Shares as taxable Canadian property should consult
their own tax advisors.
THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE
ANALYSIS OF ALL CANADIAN TAX CONSIDERATIONS APPLICABLE TO HOLDERS
WITH RESPECT TO THE OWNERSHIP, EXERCISE OR DISPOSITION OF THE
WARRANT SHARES. ALL HOLDERS (INCLUDING NON-RESIDENT HOLDERS) SHOULD CONSULT
THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO
THEM IN THEIR PARTICULAR CIRCUMSTANCES.
MATERIAL U.S. FEDERAL
INCOME TAX CONSIDERATIONS
The following is a discussion of material U.S. federal income tax
consequences of the acquisition, ownership, exercise, and
disposition of the Warrant Shares that are applicable to a U.S.
Holder, as defined below, that acquires the Warrant Shares pursuant
to this Prospectus Supplement. This discussion is not a complete
analysis or listing of all of the possible tax consequences of such
transactions and does not address all tax considerations that might
be relevant to particular holders in light of their personal
circumstances or to persons that are subject to special tax rules.
In particular, the information set forth below deals only with U.S.
Holders that will hold Warrant Shares as capital assets for U.S.
federal income tax purposes (generally, property held for
investment) and that do not own 10 percent or more of the
total combined voting power of all classes of Company stock
entitled to vote or 10 percent or more of the total value of
shares of all classes of Company stock. In addition, this
discussion of the U.S. federal income tax consequences does not
address the tax treatment of special classes of U.S. Holders, such
as: financial institutions; regulated investment companies; real
estate investment trusts; tax-exempt entities; insurance
companies; persons holding Warrants and the Warrant Shares as part
of a hedging, integrated or conversion transaction, constructive
sale or “straddle”; persons who acquired Warrants or Warrant Shares
through the exercise or cancellation of employee stock options or
otherwise as compensation for their services; U.S. expatriates;
persons subject to the alternative minimum tax; persons that
generally mark their securities to market for U.S. federal income
tax purposes; dealers or traders in securities or currencies; or
holders whose functional currency is not the U.S. dollar.
S-20
This discussion does not address estate and gift tax, any U.S.
federal tax other than income tax, or tax consequences under any
state, local or foreign laws.
For purposes of this section, a “U.S. Holder” is a beneficial owner
of the Warrants and Warrant Shares that is: (1) an individual
citizen of the United States or a resident alien of the United
States as determined for U.S. federal income tax purposes;
(2) a corporation (or other entity treated as a corporation
for U.S. federal income tax purposes) created or organized under
the laws of the United States, any state thereof or the District of
Columbia; (3) an estate the income of which is subject to U.S.
federal income taxation regardless of its source; or (4) a
trust (A) if a court within the United States is able to
exercise primary supervision over its administration and one or
more U.S. persons have authority to control all substantial
decisions of the trust or (B) that has a valid election in
effect under applicable U.S. Treasury regulations to be treated as
a U.S. person.
If a partnership or other pass-through entity is a beneficial owner
of the Warrant and Warrant Shares, the tax treatment of a partner
or other owner will generally depend upon the status of the partner
(or other owner) and the activities of the entity. A U.S. Holder
that is a partner (or other owner) of a pass-through entity that
acquires Warrants or Warrant Shares is urged to consult its own tax
advisor regarding the tax consequences of acquiring, owning and
disposing of Warrants or Warrant Shares.
The following discussion is based upon the U.S. Internal Revenue
Code of 1986, as amended (the “Code”), existing and proposed
U.S. Treasury regulations, U.S. judicial decisions and
administrative pronouncements, all as in effect as of the date
hereof. All of the preceding authorities are subject to change,
possibly with retroactive effect, so as to result in U.S. federal
income tax consequences different from those discussed below. The
Company has not requested, and will not request, a ruling from the
IRS with respect to any of the U.S. federal income tax consequences
described below, and as a result there can be no assurance that the
IRS will not disagree with or challenge any of the conclusions
described herein.
As discussed below, the Company does not believe that it was a PFIC
for the year ended June 30, 2021, but has not yet made a formal
determination as to whether it was a PFIC for either of the years
ended June 30, 2021 or June 30, 2022. This discussion
assumes that the Company is not a PFIC, as discussed below under
“Passive Foreign Investment Company Considerations”.
The following discussion is for general information only and is
not intended to be, nor should it be construed to be, legal or tax
advice to any holder or prospective holder of Warrants or Warrant
Shares and no opinion or representation with respect to the U.S.
federal income tax consequences to any such holder or prospective
holder is made. Prospective purchasers are urged to consult their
own tax advisors as to the particular consequences to them under
U.S. federal, state and local, and applicable foreign, tax laws of
the acquisition, ownership and disposition of Warrants or Warrant
Shares.
Exercise, Disposition or Expiration of Warrants
Exercise of Warrants
A U.S. Holder generally should not recognize gain or loss on the
exercise of a Warrant and related receipt of a Warrant Share. A
U.S. Holder’s initial tax basis in the Warrant Share received on
the exercise of a Warrant should be equal to the sum of
(a) such U.S. Holder’s tax basis in such Warrant plus
(b) the exercise price paid by such U.S. Holder on the
exercise of such Warrant. Subject to the discussion under “Passive
Foreign Investment Company Considerations” below, a U.S. Holder’s
holding period for the Warrant Share received on the exercise of a
Warrant should generally begin on the date following the date of
exercise of the Warrant, and should not include any period for
which the U.S. Holder held the Warrant. The U.S. federal income tax
treatment of a cashless exercise of a Warrant is uncertain. Each
U.S. Holder should consult its own tax advisor regarding the proper
treatment of any cashless exercise of a Warrant and the tax basis
in, and the holding period for, the Warrant Share received on such
exercise.
S-21
Ownership and Disposition of Warrant Shares
The following discussion is subject in its entirety to the rules
described below under the heading “Passive Foreign Investment
Company Considerations”.
Distributions
Subject to the PFIC rules discussed below, the gross amount of any
distribution made by the Company (without reduction for any
Canadian income tax withheld from such distribution) will generally
be subject to U.S. federal income tax as dividend income to the
extent paid out of the Company’s current or accumulated earnings
and profits, as determined under U.S. federal income tax
principles. Such amount will be includable in gross income by a
U.S. Holder as ordinary income on the date that the U.S. Holder
actually or constructively receives the distribution in accordance
with its regular method of accounting for U.S. federal income tax
purposes. The amount of any distribution made by the Company in
property other than cash will be the fair market value of such
property on the date of the distribution. Dividends paid by the
Company will not be eligible for the dividends received deduction
allowed to corporations.
Subject to applicable exceptions with respect to short-term and
hedged positions, certain dividends received by non-corporate U.S. Holders from a
“qualified foreign corporation” may be eligible for reduced rates
of taxation. A qualified foreign corporation includes a foreign
corporation that is eligible for the benefits of a comprehensive
income tax treaty with the United States that the U.S. Treasury
Department determines to be satisfactory for these purposes and
that includes an exchange of information provision. The U.S.
Treasury Department has determined that the income tax treaty
between the United States and Canada meets these requirements, and
the Company believes that it is eligible for the benefits of this
treaty. A foreign corporation is also treated as a qualified
foreign corporation with respect to dividends paid by that
corporation on ordinary shares that are readily tradable on an
established securities market in the United States. U.S. Treasury
guidance indicates that the Company’s securities will be readily
tradable on an established securities market in the United States;
however, there can be no assurance that the Warrant Shares will be
considered readily tradable on an established securities market in
the United States in future years. Dividends received by U.S.
investors from a foreign corporation that was a PFIC in either the
taxable year of the distribution or the preceding taxable year will
not constitute dividends eligible for the reduced rates of taxation
described above. Instead, such dividends would be subject to tax at
ordinary income rates and to additional rules described below under
“Passive Foreign Investment Company Considerations”.
To the extent that a distribution exceeds the amount of the
Company’s current and accumulated earnings and profits, as
determined under U.S. federal income tax principles, it will be
treated first as a tax-free
return of capital, causing a reduction in the U.S. Holder’s
adjusted tax basis in the Warrant Shares held by such U.S. Holder
(thereby increasing the amount of gain, or decreasing the amount of
loss, to be recognized by such U.S. Holder upon a subsequent
disposition of the Warrant Shares), with any amount that exceeds
the adjusted tax basis being treated as a capital gain recognized
on a sale, exchange or other taxable disposition (as discussed
below). However, the Company does not intend to maintain
calculations of its earnings and profits in accordance with U.S.
federal income tax principles, and a U.S. Holder should therefore
assume that any distribution by the Company with respect to the
Warrant Shares will be treated as dividends for U.S. federal income
tax purposes.
In general, any Canadian withholding tax imposed on dividend
payments in respect of the Warrant Shares will be treated as a
foreign income tax eligible for credit against a U.S. Holder’s U.S.
federal income tax liability (or, at a U.S. Holder’s election, may,
in certain circumstances, be deducted in computing taxable income).
Dividends paid on the Warrant Shares will be treated as
foreign-source income, and generally will be treated as “passive
category income” for U.S. foreign tax credit purposes. The Code
applies various complex limitations on the amount of foreign taxes
that may be claimed as a credit by U.S. taxpayers. Accordingly,
U.S. Holders are urged to consult their own tax advisors regarding
the availability of the foreign tax credit under their particular
circumstances.
S-22
Sale, Exchange or Other Taxable Disposition of Warrant
Shares
A U.S. Holder generally will recognize gain or loss upon the sale,
exchange or other taxable disposition of Warrant Shares in an
amount equal to the difference between (i) the amount realized
upon the sale, exchange or other taxable disposition and
(ii) such U.S. Holder’s adjusted tax basis in the Warrant
Shares. Generally, subject to the application of the PFIC rules
discussed below, such gain or loss will be capital gain or loss and
will be long-term capital gain or loss if, on the date of the sale,
exchange or other taxable disposition, the U.S. Holder has held the
Warrant Shares for more than one year. For individual U.S. Holders,
long-term capital gains are subject to taxation at favorable rates.
The deductibility of capital losses is subject to limitations under
the Code. Gain or loss, if any, realized upon a sale, exchange or
other taxable disposition of the Warrant Shares will be treated as
having a United States source for U.S. foreign tax credit
limitation purposes. Consequently, a U.S. Holder may not be able to
use any foreign tax credits arising from any Canadian tax imposed
on the sale, exchange or other taxable disposition of the Warrant
Shares unless such credit can be applied (subject to applicable
limitations) against tax due on other income treated as derived
from foreign sources or unless an applicable treaty provides
otherwise.
Passive Foreign Investment Company Considerations
Special, generally unfavorable, U.S. federal income tax rules apply
to U.S. persons owning stock of a PFIC. A foreign corporation will
be considered a PFIC for any taxable year in which, after taking
into account the income and assets of the corporation and certain
subsidiaries pursuant to applicable “look through” rules, either
(1) at least 75 percent of its gross income is “passive”
income (the “income test”) or (2) at least 50 percent of
the average value of its assets is attributable to assets that
produce passive income or are held for the production of passive
income (the “asset test”). For purposes of determining whether a
foreign corporation will be considered a PFIC, such foreign
corporation will be treated as holding its proportionate share of
the assets and receiving directly its proportionate share of the
income of any other corporation in which it owns, directly or
indirectly, more than 25 percent (by value) of the stock. PFIC
status is fundamentally factual in nature. It generally cannot be
determined until the close of the taxable year in question and is
determined annually.
The Company has not made a formal determination as to whether it
was a PFIC for either of the years ended June 30, 2021 or
June 30, 2022. The determination of PFIC status for any year
is very fact specific, being based on the types of income the
Company earns and the types and value of the Company’s assets from
time to time, all of which are subject to change, as well as, in
part, the application of complex U.S. federal income tax rules,
which are subject to differing interpretations. As a result, there
can be no assurance in this regard, and the IRS may challenge the
Company’s classification. Accordingly, it is possible that the
Company may be classified as a PFIC in a past year, in its current
taxable year, or in future years. If the Company is classified as a
PFIC in any year during which a U.S. Holder holds the Warrant
Shares, the Company generally will continue to be treated as a PFIC
as to such U.S. Holder in all succeeding years, regardless of
whether the Company continues to meet the income or asset test
discussed above. The Company intends to make a formal determination
concerning its PFIC status for each of its June 30, 2021 and
June 30, 2022 tax years, and also promptly following the close
of the current tax year, to communicate that determination to
investors and endeavor to provide information required by investors
for a QEF election (described below) if the Company determines that
it is a PFIC.
If the Company were classified as a PFIC for any taxable year
during which a U.S. Holder holds the Warrants or Warrant Shares,
such U.S. Holder would be subject to increased tax liability
(generally including an interest charge) upon the sale, exchange or
other disposition of the Warrants or Warrant Shares or upon the
receipt of certain distributions treated as “excess distributions”,
regardless of whether such income was actually distributed. An
excess distribution generally would be the portion of any
distributions to a U.S. Holder with respect to the Warrants or
Warrant Shares during a single taxable year that are in total
greater than 125% of the average annual distributions received by
such U.S. Holder with respect to the Warrants or Warrant Shares
during the three preceding taxable years or, if shorter, during
such U.S. Holder’s holding period for such Warrants or Warrant
Shares. Generally, a U.S. Holder would be required to allocate any
excess distribution or gain from the sale or other disposition of
the Warrants or Warrant Shares rateably over its holding period for
such Warrants or Warrant Shares. Such amounts would be taxed as
ordinary income at the highest applicable rate in effect for each
taxable year of the holding period, and amounts allocated to prior
taxable years would be subject to an interest charge at a rate
applicable to underpayments of tax. As described below under
“Information Reporting and Backup Withholding”, if the
Company were classified as a PFIC, such U.S. Holders would
generally be required to file IRS Form 8261.
S-23
If the Company were classified as a PFIC, certain elections could
be available to mitigate the consequences described above. If the
Warrant Shares are regularly traded on a registered national
securities exchange or certain other exchanges or markets, then
such Warrant Shares will constitute “marketable stock” for purposes
of the PFIC rules. The Company expects that the Warrant Shares will
constitute “marketable stock” for purposes of the PFIC rules. U.S.
Holders that make a “mark-to-market election” with
respect to such marketable stock would not be subject to the
foregoing PFIC rules. After making such an election, a U.S. Holder
generally would include as ordinary income each year during which
the election is in effect and during which the Company is a PFIC
the excess, if any, of the fair market value of the Warrant Shares
at the end of the taxable year over the U.S. Holder’s adjusted tax
basis in such Warrant Shares. These amounts of ordinary income
would not be eligible for the favourable tax rates applicable to
qualified dividend income or long-term capital gains. A U.S. Holder
with a mark-to-market election in
effect also would be allowed to take an ordinary loss in respect of
the excess, if any, of its adjusted tax basis in the Warrant Shares
over their fair market value at the end of the taxable year (but
only to the extent of the net amount of income that was previously
included as a result of the mark-to-market election). A U.S.
Holder’s tax basis in the Warrant Shares would be adjusted to
reflect any income or loss amounts resulting from a mark-to-market election. If
made, a mark-to-market election would be
effective for the taxable year for which the election was made and
for all subsequent taxable years unless the Warrant Shares ceased
to qualify as “marketable stock” for purposes of the PFIC rules or
the IRS consented to the revocation of the election. In the event
that the Company is classified as a PFIC, U.S. Holders are urged to
consult their own tax advisor regarding the availability of the
mark-to-market election, and
whether the election would be advisable in their particular
circumstances.
The PFIC tax rules outlined above also would not apply, and
different rules would apply, to a U.S. Holder that elected to treat
the Company as a “qualified electing fund” or “QEF”. An election
with respect to Warrant Shares to treat the Company as a QEF will
not be available, however, if the Company does not provide the
information necessary to make such an election. A QEF election may
not be made with respect to the Warrants. U.S. Holders are urged to
consult their own tax advisor regarding the manner and consequences
of making a QEF election.
As discussed above in “Distributions”, notwithstanding any election
made with respect to the Warrants or Warrant Shares, if the Company
is a PFIC in either the taxable year of the distribution or the
preceding taxable year, dividends received with respect to the
Warrants or Warrant Shares will not qualify for reduced rates of
taxation.
Receipt of Foreign Currency
The gross amount of any payment in a currency other than U.S.
dollars will be included by each U.S. Holder in income in a U.S.
dollar amount calculated by reference to the exchange rate in
effect on the day such U.S. Holder actually or constructively
receives the payment in accordance with its regular method of
accounting for U.S. federal income tax purposes regardless of
whether the payment is in fact converted into U.S. dollars at that
time. If the foreign currency is converted into U.S. dollars on the
date of the payment, the U.S. Holder should not be required to
recognize any foreign currency gain or loss with respect to the
receipt of foreign currency. If, instead, the foreign currency is
converted at a later date, any currency gains or losses resulting
from the conversion of the foreign currency will be treated as U.S.
source ordinary income or loss for U.S. foreign tax credit
purposes. U.S. Holders are urged to consult their own U.S. tax
advisors regarding the U.S. federal income tax consequences of
receiving, owning, and disposing of foreign currency.
Additional Tax on Passive Income
U.S. Holders that are individuals, estates or trusts are required
to pay an additional 3.8% tax on the lesser of (1) the U.S.
Holder’s “net investment income” for the relevant taxable year and
(2) the excess of the U.S. Holder’s modified adjusted gross
income for the taxable year over a certain threshold. A U.S.
Holder’s “net investment income” generally includes, among other
things, dividends and net gains from disposition of property (other
than
S-24
property held in the ordinary course of the conduct of a trade or
business). Accordingly, dividends on and capital gain from the
sale, exchange or other taxable disposition of the Warrants or
Warrant Shares may be subject to this additional tax. U.S. Holders
are urged to consult their own tax advisors regarding the
additional tax on passive income.
Information Reporting and Backup Withholding
In general, dividends paid to a U.S. Holder in respect of the
Warrants or Warrant Shares and the proceeds received by a U.S.
Holder from the sale, exchange or other disposition of the Warrants
or Warrant Shares within the United States or through certain
U.S.-related financial intermediaries will be subject to U.S.
information reporting rules, unless a U.S. Holder is a Company or
other exempt recipient and properly establishes such exemption.
Backup withholding may apply to such payments if a U.S. Holder does
not establish an exemption from backup withholding and fails to
provide a correct taxpayer identification number and make any other
required certifications.
Backup withholding is not an additional tax. Any amounts withheld
under the backup withholding rules will be allowed as a refund or
credit against U.S. federal income tax liability, provided that the
required information is timely furnished to the IRS.
In addition, U.S. Holders should be aware of reporting requirements
with respect to the holding of certain foreign financial assets,
including stock of foreign issuers which is not held in an account
maintained by certain financial institutions, if the aggregate
value of all of such assets exceeds U.S.$50,000. U.S. Holders must
attach a complete IRS Form 8938, Statement of Specified Foreign
Financial Assets, with their return for each year in which they
hold our Warrants or Warrant Shares. U.S. Holders should also be
aware that if the Company were a PFIC, they would generally be
required to file IRS Form 8261, Information Return by a Shareholder
of a Passive Foreign Investments Company or Qualified Electing
Fund, during any taxable year in which such U.S. Holder recognizes
gain or receives an excess distribution or with respect to which
the U.S. Holder has made certain elections. U.S. Holders are urged
to consult their own tax advisors regarding the application of the
information reporting rules to the Warrants, the Warrant Shares and
their particular situations.
EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX
ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN
WARRANT SHARES IN LIGHT OF THE INVESTOR’S OWN
CIRCUMSTANCES.
AGENT FOR SERVICE OF
PROCESS
Miguel Martin, the Chief Executive Officer and a director of the
Company, and Margaret Shan Atkins and Lance Friedmann, directors of
the Company, reside outside of Canada. Each of Miguel Martin,
Margaret Atkins and Lance Friedmann has appointed the Company, at
its head office located at 500 – 10355 Jasper Avenue, Edmonton,
Alberta, Canada T5J 1Y6 as their agent for service of process in
Canada. Purchasers are advised that it may not be possible for
investors to enforce judgments obtained in Canada against any such
person, even though they have each appointed an agent for service
of process.
Investors are advised that it may not be possible for investors to
enforce judgments obtained in Canada against any person who resides
outside of Canada or a company that is incorporated, continued or
otherwise organized under the laws of a foreign jurisdiction, even
if the party has appointed an agent for service of process.
LEGAL MATTERS
Certain legal matters relating to the Offering under this
Prospectus Supplement will be passed upon on behalf of the Company
by Stikeman Elliott LLP, as to matters of Canadian law, and Paul,
Weiss, Rifkind, Wharton & Garrison LLP, as to matters of
United States law.
As of the date of this Prospectus Supplement, the partners and
associates of Stikeman Elliott LLP, as a group, beneficially,
directly or indirectly, own less than 1% of any class of securities
of the Company.
S-25
AUDITORS
KPMG, LLP are the auditors of the Company and have confirmed with
respect to the Company that they are independent of the Company
within the meaning of the relevant rules and related
interpretations prescribed by the relevant professional bodies in
Canada and any applicable legislation or regulations and also that
they are independent accountants with respect to the Company under
all relevant U.S. professional and regulatory standards.
TRANSFER AGENT AND
REGISTRAR
The transfer agent and registrar for the Common Shares of the
Company is Computershare Trust Company of Canada at its principal
office in Vancouver, British Columbia and Toronto, Ontario, and the
United States co-transfer
agent for the Common Shares is Computershare Trust Company, N.A.,
at its office in Canton, Massachusetts.
ADDITIONAL
INFORMATION
The Company has filed the Registration Statement with the SEC. This
Prospectus Supplement and the accompanying Base Prospectus, which
constitute part of the Registration Statement, together do not
contain all of the information set forth in the Registration
Statement or the accompanying exhibits and schedules, as certain
items that are not included in the Prospectus are included in the
Registration Statement in accordance with the rules and regulations
of the SEC. For further information with respect to us and the
securities offered in the Prospectus, see the Registration
Statement and the accompanying exhibits and schedules. Statements
contained in the Prospectus Supplement and Base Prospectus
regarding the contents of any contract, agreement or any other
document are summaries of the material terms of these contracts,
agreements or other documents. With respect to each of these
contracts, agreements or other documents filed as an exhibit to the
Registration Statement, reference is made to such exhibit for a
more complete description of the matter involved. Such contracts,
agreements, or other documents are or will also be filed by the
Company on SEDAR at www.sedar.com in accordance with
applicable Canadian securities laws.
We are subject to the informational reporting requirements of the
U.S. Exchange Act as the Common Shares are registered under
Section 12(b) of the U.S. Exchange Act. Accordingly, we are
required to publicly file reports and other information with the
SEC. Under the MJDS, the Company is permitted to prepare such
reports and other information in accordance with Canadian
disclosure requirements, which are different from United States
disclosure requirements.
As a foreign private issuer, we are exempt from the rules under the
U.S. Exchange Act prescribing the furnishing and content of proxy
statements in connection with meetings of its shareholders. In
addition, the officers, directors and principal shareholders of the
Company are exempt from the reporting and short-swing profit
recovery rules contained in Section 16 of the U.S. Exchange
Act.
The Company files annual reports on Form 40-F with the SEC under the MJDS, which
annual reports include:
|
• |
|
the annual information form;
|
|
• |
|
management’s annual discussion and analysis of financial condition
and results of operations;
|
|
• |
|
consolidated audited financial statements, which are prepared in
accordance with IFRS, as issued by the IASB; and
|
|
• |
|
other information specified by the Form 40-F.
|
S-26
As a foreign private issuer, the Company is required to furnish the
following types of information to the SEC under cover of Form
6-K:
|
• |
|
material information that the Company otherwise makes publicly
available in reports that the Company files with securities
regulatory authorities in Canada;
|
|
• |
|
material information that the Company files with, and which is made
public by, the TSX and Nasdaq; and
|
|
• |
|
material information that the Company distributes to its
shareholders in Canada.
|
Investors may read and download the documents the Company has filed
with the SEC on EDGAR. Investors may read and download any public
document that the Company has filed with the securities commissions
or similar regulatory authorities in Canada at www.sedar.com.
ENFORCEABILITY OF CIVIL
LIABILITIES BY U.S. INVESTORS
The Company is a corporation existing under the Business
Corporations Act (British Columbia). Other than Martin Miguel,
Margaret Shan Atkins and Lance Friedmann, all of our directors and
officers, and all of the experts named in this Prospectus
Supplement or the accompanying Base Prospectus, are residents of
Canada or otherwise reside outside the United States, and all or a
substantial portion of their assets, and a majority of the
Company’s assets, are located outside the United States. The
Company has appointed an agent for service of process in the United
States, but it may be difficult for holders of Warrant Shares who
reside in the United States to effect service within the United
States upon those directors, officers and experts who are not
residents of the United States. It may also be difficult for
holders of the Securities who reside in the United States to
realize upon judgments of courts of the United States predicated
upon the Company’s civil liability and the civil liability of its
directors, officers and experts under the United States federal
securities laws.
The Company has been advised by its Canadian counsel, Stikeman
Elliott LLP, that there is doubt as to the enforceability in Canada
by a court in original actions, or in actions to enforce judgments
of United States courts, of civil liabilities predicated upon
United States federal securities laws.
The Company filed with the SEC, concurrently with our Registration
Statement, an appointment of agent for service of process on Form
F-X. Under the Form
F-X, the Company appointed
Puglisi & Associates as our agent for service of process
in the United States in connection with any investigation or
administrative proceeding conducted by the SEC, and any civil suit
or action brought against or involving the Company in a United
States court arising out of, related to, or concerning the Warrant
Shares under this Prospectus Supplement and the accompanying Base
Prospectus.
DOCUMENTS FILED AS PART OF
THE REGISTRATION STATEMENT
In addition to the documents referred to in the Base Prospectus,
the following documents have been or will (through post-effective
amendment or incorporation by reference) be filed with the SEC as
part of the Registration Statement:
|
(i) |
the documents referred to under the heading “Documents
Incorporated by Reference” in this Prospectus Supplement and in the
Base Prospectus;
|
|
(ii) |
the Underwriting Agreement among the Company and the
Underwriters;
|
|
(iii) |
the Warrant Indenture between the Company and the
Warrant Agent; and
|
|
(iv) |
the consent of Stikeman Elliott LLP, the Company’s
Canadian counsel.
|
S-27
Information contained herein is subject to
completion or amendment. A registration statement relating to these
securities has been filed with the U.S. Securities and Exchange
Commission. These securities may not be sold nor may offers to buy
be accepted prior to the time the registration statement becomes
effective. This prospectus shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of
these securities in any U.S. state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such U.S.
state.
SHORT FORM BASE SHELF PROSPECTUS
|
|
|
New Issue and/or Secondary Offering |
|
March 29, 2021 |

AURORA CANNABIS INC.
U.S.$1,000,000,000
Common Shares
Warrants
Options
Subscription Receipts
Debt Securities
Units
This short form base shelf prospectus (the “Prospectus”)
relates to the offering for sale of common shares (the “Common
Shares”), warrants (the “Warrants”), options (the
“Options”), subscription receipts (the “Subscription
Receipts”), debt securities (the “Debt Securities”), or
any combination of such securities (the “Units”) (all of the
foregoing, collectively, the “Securities”) by Aurora
Cannabis Inc. (the “Company” or “Aurora”) from time
to time, during the 25-month period that the Prospectus,
including any amendments hereto, remains effective, in one or more
series or issuances, with a total offering price of the Securities
in the aggregate, of up to U.S.$1,000,000,000 The Securities may be
offered in amounts and at prices to be determined based on market
conditions at the time of the sale and set forth in an accompanying
prospectus supplement (a “Prospectus Supplement”). In
addition, Securities may be offered and issued in consideration for
the acquisition of other businesses, assets or securities by the
Company or a subsidiary of the Company. The consideration for any
such acquisition may consist of any of the Securities separately, a
combination of Securities or any combination of, among other
things, Securities, cash and assumption of liabilities. One or more
securityholders of the Company may also offer and sell Securities
under this Prospectus. See “The Selling Securityholders”.
This offering is made by a Canadian issuer that is permitted,
under a multijurisdictional disclosure system adopted by the United
States and Canada, to prepare this Prospectus in accordance with
Canadian disclosure requirements. Prospective investors should be
aware that such requirements are different from those of the United
States. Financial statements included or incorporated by reference
herein have been prepared in accordance with International
Financial Reporting Standards (“IFRS”) as issued by the
International Accounting Standards Board (“IASB”) and may not be
comparable to financial statements of United States companies. Our
financial statements are audited in accordance with the standards
of the Public Company Accounting Oversight Board (United
States).
The enforcement by investors of civil liabilities under the
United States federal securities laws may be affected adversely by
the fact that the Company is incorporated under the laws of British
Columbia, Canada, that the majority of its officers and directors
are residents of Canada, that all of the experts named in the
registration statement are not residents of the United States, and
that a substantial portion of the assets of the Company and said
persons are located outside the United States.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR HAS THE SEC
PASSED UPON THE ACCURACY OR THE ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.
Investing in Securities of the Company involves a high degree of
risk. You should carefully review the risks outlined in this
Prospectus (together with any Prospectus Supplement) and in the
documents incorporated by reference in this Prospectus and any
Prospectus Supplement and consider such risks in connection with an
investment in such Securities. See “Risk Factors”.
Prospective investors should be aware that the acquisition of
the Securities described herein may have tax consequences both in
the United States and in Canada. Such consequences for investors
who are resident in, or citizens of, the United States may not be
described fully herein. Prospective investors should read the tax
discussion contained in the applicable Prospectus Supplement with
respect to a particular offering of Securities.
The specific terms of the Securities with respect to a particular
offering will be set out in one or more Prospectus Supplements and
may include, where applicable: (i) in the case of Common
Shares, the number of Common Shares offered, the offering price and
any other specific terms; (ii) in the case of Warrants or
Options, the number of Warrants or Options offered, the offering
price, the designation, number and terms of the Common Shares
issuable upon exercise of the Warrants or Options, any procedures
that will result in the adjustment of these numbers, the exercise
price, dates and periods of exercise, the currency in which the
Warrants or Options are issued and any other specific terms;
(iii) in the case of Subscription Receipts, the number of
Subscription Receipts offered, the offering price, the procedures
for the exchange of the Subscription Receipts for Common Shares or
Warrants, as the case may be, and any other specific terms;
(iv) in the case of Debt Securities, the specific designation,
aggregate principal amount, the currency or the currency unit for
which the Debt Securities may be purchased, the maturity, interest
provisions, authorized denominations, offering price, covenants,
events of default, any terms for redemption, any exchange or
conversion terms, whether the debt is senior, senior subordinated
or subordinated, whether the debt is secured or unsecured and any
other terms specific to the Debt Securities being offered; and
(v) in the case of Units, the designation, number and terms of
the Common Shares, Warrants, Options, Subscription Receipts or Debt
Securities comprising the Units. Where required by statute,
regulation or policy, and where Securities are offered in
currencies other than Canadian dollars, appropriate disclosure of
foreign exchange rates applicable to the Securities will be
included in the Prospectus Supplement describing the
Securities.
In addition, the Debt Securities that may be offered may be
guaranteed by certain direct and indirect subsidiaries of Aurora
with respect to the payment of the principal, premium, if any, and
interest on the Debt Securities. The Company expects that any
guarantee provided in respect of senior Debt Securities would
constitute a senior and unsecured obligation of the applicable
guarantor. For a more detailed description of the Debt Securities
that may be offered, see “Description of Securities – Debt
Securities - Guarantees”, below.
All information permitted under applicable securities legislation
to be omitted from the Prospectus will be contained in one or more
Prospectus Supplements that will be delivered to purchasers
together with the Prospectus. Each Prospectus Supplement will be
incorporated by reference into the Prospectus for the purposes of
applicable securities legislation as of the date of the Prospectus
Supplement and only for the purposes of the distribution of the
Securities to which the Prospectus Supplement pertains. Investors
should read the Prospectus and any applicable Prospectus Supplement
carefully before investing in the Securities.
This Prospectus constitutes a public offering of the Securities
only in those jurisdictions where they may be lawfully offered for
sale and only by persons permitted to sell the Securities in such
jurisdictions. We may offer and sell Securities to, or through,
underwriters, dealers or selling securityholders, directly to one
or more other purchasers, or through agents pursuant to exemptions
from registration or qualification under applicable securities
laws. A Prospectus Supplement relating to each issue of Securities
will set forth the names of any underwriters, dealers, agents or
selling securityholders involved in the offering and sale of the
Securities and will
set forth the terms of the offering of the Securities, the method
of distribution of the Securities, including, to the extent
applicable, the proceeds to us and any fees, discounts, concessions
or other compensation payable to the underwriters, dealers or
agents, and any other material terms of the plan of distribution.
This Prospectus may qualify an at-the-market distribution
through a stock market or stock exchange outside of Canada. In
connection with any offering of the Securities, other than an
“at-the-market distribution” (as
defined under National Instrument 44-102—Shelf
Distributions (“NI 44-102”) of the Canadian Securities
Administrators) unless otherwise specified in a Prospectus
Supplement, the underwriters or agents may over-allot or effect
transactions which stabilize or maintain the market price of the
Securities offered at a higher level than that which might exist in
the open market. Such transaction, if commenced, may be interrupted
or discontinued at any time. See “Plan of Distribution”.
No underwriter or dealer involved in an at-the-market distribution under
this Prospectus, no affiliate of such an underwriter or dealer and
no person or company acting jointly or in concert with such an
underwriter or dealer will over-allot securities in connection with
such distribution or effect any other transactions that are
intended to stabilise or maintain the market price of the
Securities sold in the at-the-market
distribution.
No underwriter has been involved in the preparation of the
Prospectus or performed any review of the contents of the
Prospectus.
The Company’s outstanding Common Shares are listed for trading on
the Toronto Stock Exchange (the “TSX”) and on the New York
Stock Exchange (“NYSE”) under the trading symbol “ACB” and
on the Frankfurt Stock Exchange (“FSE”) under the symbol
“21P”. The closing price of the Company’s Common Shares on the TSX,
NYSE and FSE on March 26, 2021 was $11.48 per Common Share,
U.S.$9.11 per Common Share and €7.65 per Common Share,
respectively. Unless otherwise disclosed in any applicable
Prospectus Supplement, the Debt Securities, the Warrants, the
Options, the Subscription Receipts and the Units will not be listed
on any securities exchange. Unless the Securities are disclosed to
be listed, there will be no market through which these Securities
may be sold and purchasers may not be able to resell these
Securities purchased under this Prospectus. This may affect the
pricing of such Securities in the secondary market, the
transparency and availability of trading prices, the liquidity of
such Securities, and the extent of issuer regulation.
We have filed an undertaking with the Alberta Securities Commission
(the “ASC”) that we will not distribute in the local
jurisdiction under this Prospectus specified derivatives or
asset-backed securities that, at the time of distribution, are
novel without pre-clearing with the ASC the disclosure to be
contained in the Prospectus Supplement pertaining to the
distribution of such securities.
Miguel Martin, the Chief Executive Officer and a director of the
Company, and Margaret Shan Atkins and Lance Friedmann, directors of
the Company, reside outside of Canada. Each of Miguel Martin,
Margaret Atkins and Lance Friedmann has appointed the Company, at
its head office located at 4818 31 Street East, Edmonton
International Airport, Alberta, Canada, T9E 0V6 as their agent for
service of process in Canada. Purchasers are advised that it may
not be possible for investors to enforce judgments obtained in
Canada against any such person, even though they have each
appointed an agent for service of process.
The corporate head office of the Company is located at 4818 31
Street East, Edmonton International Airport, Alberta, Canada, T9E
0V6. The registered office of the Company is located at Suite 1500,
1055 West Georgia Street, Vancouver, British Columbia,
V6E 4N7.
TABLE OF CONTENTS
GENERAL MATTERS
In this Prospectus, “Aurora”, “we”, “us” and “our” refers,
collectively, to Aurora Cannabis Inc. and our wholly owned
subsidiaries.
ABOUT THIS PROSPECTUS
We are a British Columbia company that is a “reporting issuer”
under Canadian securities laws in each of the provinces of Canada.
In addition, our Common Shares are registered under
Section 12(b) of the United States Securities Exchange Act
of 1934, as amended (the “Exchange Act”). Our Common
Shares are traded in Canada on the TSX and in the United States on
the NYSE under the symbol “ACB”.
This Prospectus is a base shelf prospectus that:
|
• |
|
we have filed with the securities commissions in each of the
provinces of Canada, except Québec (the “Canadian Qualifying
Jurisdictions”) in order to qualify the offering of the
Securities described in this Prospectus in accordance with NI
44-102; and
|
|
• |
|
forms part of a registration statement on Form F-10 (the “Registration
Statement”) that we filed with the Securities and Exchange
Commission (“SEC”) under the Securities Act of 1933,
as amended (the “U.S. Securities Act”) under the
multijurisdictional disclosure system adopted by Canada and the
United States (the “MJDS”).
|
Under this Prospectus, we may sell any combination of the
Securities described in this Prospectus in one or more offerings up
to a total aggregate initial offering price of U.S.$1,000,000,000.
This Prospectus provides you with a general description of the
Securities that we may offer. Each time we sell Securities under
this Prospectus we will provide a Prospectus Supplement that will
contain specific information about the terms of that specific
offering. The specific terms of the Securities in respect of which
this Prospectus is being delivered will be set forth in the
Prospectus Supplement.
You should rely only on the information contained in or
incorporated by reference into this Prospectus and in any
applicable Prospectus Supplement. The Company has not authorized
anyone to provide you with different information. The Company is
not making any offer of these Securities in any jurisdiction where
the offer is not permitted.
2
DOCUMENTS INCORPORATED BY
REFERENCE
We incorporate by reference into this Prospectus documents that
we have filed with securities commissions or similar authorities in
Canada, which have also been filed with, or furnished to, the
SEC. You may obtain copies of the documents incorporated herein
by reference without charge from Aurora Cannabis Inc., 4818 31
Street East, Edmonton International Airport, Alberta, Canada, T9E
0V6 (Telephone: 1-855-279-4652)
Attn: Corporate Secretary. These documents are also available
electronically from the website of Canadian Securities
Administrators at www.sedar.com (“SEDAR”) and from the EDGAR
filing website of the United States Securities and Exchange
Commission at www.sec.gov (“EDGAR”). The Company’s filings
through SEDAR and EDGAR are not incorporated by reference in the
Prospectus except as specifically set out herein.
The following documents (“documents incorporated by
reference” or “documents incorporated herein by
reference”) have been filed by us with various securities
commissions or similar authorities in the provinces of Canada in
which we are a reporting issuer, are specifically incorporated
herein by reference and form an integral part of this
Prospectus:
|
• |
|
the annual information form of the Company for the year ended
June 30, 2020, dated and filed on SEDAR on September 24,
2020 (our “2020 AIF”);
|
|
• |
|
the audited consolidated financial statements of the Company, and
the notes thereto for the years ended June 30, 2020 and 2019,
together with the reports of our independent registered public
accounting firm thereon, filed on SEDAR September 24,
2020;
|
|
• |
|
the management’s discussion and analysis of financial condition and
results of operations for the year ended June 30, 2020, filed
on SEDAR on September 24, 2020 (our “2020 Annual
MD&A”);
|
|
• |
|
the unaudited condensed interim consolidated financial statements
of the Company, and the notes thereto for the three and six months
ended December 31, 2020 and 2019, filed on SEDAR on
February 11, 2021 (our “Interim Financial
Statements”);
|
|
• |
|
the management’s discussion and analysis of financial condition and
results of operations for the three and six months ended
December 31, 2020, filed on SEDAR on February 11, 2021
(our “Interim MD&A”);
|
|
• |
|
the management information circular of the Company dated
September 28, 2020, distributed in connection with the
Company’s annual and special meeting of shareholders held on
November 12, 2020, filed on SEDAR on September 29,
2020;
|
|
• |
|
the material change report regarding (i) the appointment of
Miguel Martin as Chief Executive Officer effective
September 8, 2020; (ii) amendments to the Company’s credit
facility with a syndicate of banks; and (iii) the termination
of the partnership with UFC in consideration of a
U.S.$30 million termination fee, dated and filed on SEDAR on
September 11, 2020;
|
|
• |
|
the material change report regarding (i) the announcement of a
proposed overnight marketed public offering of units of the Company
for total gross proceeds of approximately U.S.$125 million
(the “November 2020 Public Offering”); (ii) the announcement
of the pricing and upsizing of the November 2020 Public Offering;
and (iii) the announcement of the exercise by the underwriters
of their over-allotment option in full and the closing of the
November 2020 Public Offering, dated and filed on SEDAR on
November 18, 2020;
|
|
• |
|
the material change report regarding the Company entering into a
second amended and restated credit facility (the “Second Amended
Credit Agreement”) with a Canadian chartered bank and certain
lenders, dated and filed on SEDAR on December 24, 2020;
|
|
• |
|
the amended material change report amending the material change
report dated and filed on SEDAR on December 24, 2020 regarding
the Second Amended Credit Agreement, dated and filed on SEDAR on
January 21, 2021; and
|
3
|
• |
|
the material change report regarding the announcement of the
closing of the bought deal public offering of units of the Company
for total gross proceeds of approximately U.S.$138 million
(the “January 2021 Public Offering”), dated and filed on
SEDAR on January 29, 2021.
|
Any document of the type referred to in section 11.1 of Form
44-101F1 of National
Instrument 44-101 –
Short Form Prospectus Distributions filed by the Company
with the securities commissions or similar regulatory authorities
in Canada after the date of this Prospectus and all Prospectus
Supplements disclosing additional or updated information filed
pursuant to the requirements of applicable securities legislation
in Canada and during the period that this Prospectus is effective
shall be deemed to be incorporated by reference in this
Prospectus.
To the extent that any document or information incorporated by
reference into the Prospectus is included in any report on Form
6-K, Form 40-F, Form 20-F, Form 10-K, Form 10-Q or Form 8-K (or any respective successor form)
that is filed with or furnished to the SEC after the date of the
Prospectus, such document or information shall be deemed to be
incorporated by reference as an exhibit to the Registration
Statement of which the Prospectus forms a part. In addition, we may
incorporate by reference into the Prospectus, or the Registration
Statement of which it forms a part, other information from
documents that we file with or furnish to the SEC pursuant to
Section 13(a) or 15(d) of the Exchange Act, if and to the
extent expressly provided therein.
Any statement contained in this Prospectus or in a document
incorporated or deemed to be incorporated by reference herein will
be deemed to be modified or superseded to the extent that a
statement contained herein, in any Prospectus Supplement or in any
other subsequently filed document that is also incorporated or is
deemed to be incorporated by reference herein modifies or
supersedes such statement. The modifying or superseding statement
need not state that it has modified or superseded a prior statement
or include any other information set forth in the document that it
modifies or supersedes. The making of a modifying or superseding
statement will not be deemed an admission for any purpose that the
modified or superseded statement, when made, constituted a
misrepresentation, an untrue statement of a material fact or an
omission to state a material fact that is required to be stated or
that is necessary to make a statement not misleading in light of
the circumstances in which it was made. Any statement so modified
or superseded will not be deemed, except as so modified or
superseded, to constitute a part of the Prospectus.
Upon a new annual information form and related annual financial
statements being filed by us with, and where required, accepted by,
the applicable securities regulatory authority during the currency
of this Prospectus, the previous annual information form, the
previous annual financial statements and all interim financial
statements, material change reports and information circulars and
all Prospectus Supplements filed prior to the commencement of our
financial year in which a new annual information form is filed
shall be deemed no longer to be incorporated into this Prospectus
for purposes of future offers and sales of Securities hereunder.
Upon condensed consolidated interim financial statements and the
accompanying management’s discussion and analysis of financial
condition and results of operations being filed by us with the
applicable Canadian securities commissions or similar regulatory
authorities during the period that this Prospectus is effective,
all condensed consolidated interim financial statements and the
accompanying management’s discussion and analysis of financial
condition and results of operations filed prior to such new
condensed consolidated interim financial statements and
management’s discussion and analysis of financial condition and
results of operations shall be deemed to no longer be incorporated
into this Prospectus for purposes of future offers and sales of
Securities under this Prospectus. In addition, upon a new
management information circular for an annual meeting of
shareholders being filed by us with the applicable Canadian
securities commissions or similar regulatory authorities during the
period that this Prospectus is effective, the previous management
information circular filed in respect of the prior annual meeting
of shareholders shall no longer be deemed to be incorporated into
this Prospectus for purposes of future offers and sales of
Securities under this Prospectus.
Any template version of any “marketing materials” (as such term is
defined in National Instrument 41-101 – General Prospectus
Requirements) filed after the date of a Prospectus Supplement
and before the termination of the distribution of the Securities
offered pursuant to such Prospectus Supplement (together with this
Prospectus) is deemed to be incorporated by reference in such
Prospectus Supplement.
4
FORWARD LOOKING
STATEMENTS
The Prospectus, including the documents incorporated by reference,
contain forward-looking statements and forward-looking information
(collectively, “forward-looking statements”) which may not
be based on historical fact. These forward-looking statements are
made as of the date of this Prospectus or the applicable document
incorporated by reference herein. Forward-looking statements relate
to future events or future performance and reflect Company
management’s expectations or beliefs regarding future events. In
certain cases, forward-looking statements can be identified by the
use of words such as “plans”, “expects” or “does not expect”, “is
expected”, “budget”, “scheduled”, “estimates”, “forecasts”,
“intends”, “anticipates” or “does not anticipate”, or “believes”,
or variations of such words and phrases or statements that certain
actions, events or results “may”, “could”, “would”, “might” or
“will be taken”, “occur” or “be achieved” or the negative of these
terms or comparable terminology. In this document, certain
forward-looking statements are identified by words including “may”,
“future”, “expected”, “intends” and “estimates”. Although the
Company believes that the expectations reflected in these
forward-looking statements are reasonable, by their very nature
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. The Company
provides no assurance that forward-looking statements will prove to
be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements. Forward-looking statements in this Prospectus and the
documents incorporated by reference include, but are not limited
to, statements with respect to:
|
• |
|
the Company’s expectation of achieving positive cash flow from
operating activities in future periods;
|
|
• |
|
pro forma measures including revenue, expected SG&A
run-rates, and grams
produced;
|
|
• |
|
strategic investments and capital expenditures, and related
benefits;
|
|
• |
|
adequacy and availability of credit facilities;
|
|
• |
|
the Company’s business transformation plan and the anticipated
benefits thereof;
|
|
• |
|
future strategic plans;
|
|
• |
|
anticipated growth in the global consumer use cannabis market and
the global hemp-derived CBD market and the Company’s expectations
with respect to maintaining and increasing its market share
thereof;
|
|
• |
|
expectations regarding production capacity, costs and yields;
|
|
• |
|
product sales expectations and corresponding forecasted increases
in revenues and earnings before income taxes, depreciation and
amortization; and
|
|
• |
|
the impact of the novel coronavirus pandemic (“COVID-19”) on the Company’s
business, operations, capital resources and/ or financial
results.
|
The above and other aspects of the Company’s anticipated future
operations are forward-looking in nature and, as a result, are
subject to certain risks and uncertainties. Such forward-looking
statements are estimates reflecting the Company’s best judgment
based upon current information and involve a number of risks and
uncertainties, and there can be no assurance that other factors
will not affect the accuracy of such forward-looking statements.
These risks include, but are not limited to: the Company has a
limited operating history and there is no assurance the Company
will be able to achieve or maintain profitability; the Company
operates in a highly regulated business and any failure or
significant delay in obtaining applicable regulatory approvals
could adversely affect its ability to conduct its business; the
Company’s Canadian licenses are reliant on its established sites;
the failure to maintain its licenses and remain in compliance with
regulations could adversely affect Company’s ability to conduct
business; a change in the laws, regulations, and guidelines that
impact the business may cause adverse effects on the Company’s
operations; the Company competes for market share with a number of
competitors and
5
expects even more competitors to enter our market, and many of the
Company’s current and future competitors may have longer operating
histories, more financial resources, and lower costs than the
Company; that management’s estimates of consumer demand in Canada
and in jurisdictions where the Company exports are accurate,
expectations of future results and expenses, management’s
estimation that the Company will be able to maintain current
SG&A expenditure levels and the SG&A will grow only in
proportion to revenue growth, the yield from cannabis growing
operations, product demand, changes in prices of required
commodities; the selling prices and the cost of cannabis production
may vary based on a number of factors outside of the Company’s
control; the Company may not be able to realize our growth targets;
the continuance of our contractual relations with provincial and
territorial governments upon which much of the Company’s business
depends cannot be guaranteed; the Company’s continued growth and
ongoing operations may require additional financing, which may not
be available on acceptable terms or at all; any default under the
Company’s existing debt that is not waived by the applicable
lenders could materially adversely impact the Company’s results of
operations and financial results and may have a material adverse
effect on the trading price of the Company’s common shares; the
Company may not be able to successfully develop new products or
find a market for their sale; the Company may not have supply
continuity given the Company’s asset rationalization initiative; as
the cannabis market continues to mature, the Company’s products may
become obsolete, less competitive, or less marketable; restrictions
on branding and advertising may negatively impact the Company’s
ability to attract and retain customers; the cannabis business may
be subject to unfavorable publicity or consumer perception, which
may adversely affect the market for cannabis products generally and
the Company’s products specifically; third parties with whom the
Company does business may perceive themselves as being exposed to
reputational risk by virtue of their relationship with the Company
and may ultimately elect to discontinue their relationships with
the Company; there may be unknown health impacts associated with
the use of cannabis and cannabis derivative products; the Company
may enter into strategic alliances or expand the scope of currently
existing relationships with third parties and there are risks
associated with such activities; the Company’s success will depend
on attracting and retaining key personnel; future expansion efforts
may not be successful; the Company has expanded and intends to
further expand our business and operations into jurisdictions
outside of Canada, and there are risks associated with doing so;
the Company may have challenges in accessing banks and/or financial
institutions in jurisdictions where cannabis is not yet federally
regulated, which may adversely affect the Company’s growth plans;
the business may be affected by political and economic instability;
failure to comply with the Corruption of Foreign Public Officials
Act (Canada) and the Foreign Corrupt Practices Act (United States),
as well as the anti-bribery laws of the other nations in which the
Company conducts business, could subject the Company to penalties
and other adverse consequences; the may be subject to uninsured or
uninsurable risk; the Company may be subject to product liability
claims; the Company’s cannabis products may be subject to recalls
for a variety of reasons; the Company may become party to
litigation, mediation, and/or arbitration from time to time; the
transportation of the Company’s products is subject to security
risks and disruptions; the Company’s business is subject to the
risks inherent in agricultural operations; the Company’s operations
are subject to various environmental and employee health and safety
regulations, compliance with which may affect the Company’s cost of
operations; the Company may not be able to protect our intellectual
property; the Company may experience breaches of security at our
facilities or in respect of electronic documents and data storage
and may face risks related to breaches of applicable privacy laws;
the Company may be subject to risks related to our information
technology systems, including cyber-attacks; the Company may not be
able to successfully identify and execute future acquisitions or
dispositions, or to successfully manage the impacts of such
transactions on its operations; as a holding company, Aurora
Cannabis Inc. is dependent on its operating subsidiaries to pay
dividends and other obligations; management will have substantial
discretion concerning the use of proceeds from future share sales
and financing transactions; there is no assurance the Company will
continue to meet the listing standards of the NYSE and the TSX; the
Company’s business may be subject to disruptions as a result of the
COVID-19 pandemic; Reliva’s
operations in the United States may be impacted by regulatory
action and approvals from the Food and Drug Administration; and
other risks detailed from time to
6
time in our annual information forms, annual financial statements,
MD&A, interim financial statements and material change reports
filed with and furnished to securities regulators, and those risks
which are discussed under the heading “Risk Factors”.
Readers are cautioned that the foregoing list of risk factors is
not exhaustive, and it is recommended that prospective investors
consult the more complete discussion of risks and uncertainties
facing the Company included in this Prospectus under the heading
“Risk Factors”, as well as those set out in our 2020 AIF under the
heading “Risk Factors” and in our 2020 Annual MD&A and Interim
MD&A, each of which documents are incorporated by reference
into this Prospectus. Readers are urged to consider the risks,
uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information.
Should one or more of these risks or uncertainties materialize, or
should underlying factors or assumptions prove incorrect, actual
results may vary materially from those described in forward looking
statements. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of the cannabis industry which the Company
believes to be reasonable.
Although the Company believes that the expectations conveyed by the
forward-looking statements are reasonable based on the information
available to the Company on the date hereof, no assurance can be
given as to future results, approvals or achievements.
Forward-looking statements contained in this Prospectus and in the
documents incorporated by reference herein are expressly qualified
by this cautionary statement. The Company disclaims any duty to
update any of the forward-looking statements after the date of this
Prospectus except as otherwise required by applicable law.
7
NOTE TO UNITED STATES READERS
REGARDING DIFFERENCES BETWEEN UNITED STATES AND CANADIAN FINANCIAL
REPORTING PRACTICES
We prepare our financial statements in accordance with
International Financial Reporting Standards (“IFRS”), as
issued by the International Accounting Standards Board (the
“IASB”), which differs from U.S. generally accepted
accounting principles (“U.S. GAAP”). Accordingly, our
financial statements and other financial information included or
incorporated by reference in this Prospectus may not be comparable
to financial statements of United States companies prepared in
accordance with U.S. GAAP.
NON-IFRS MEASURES
The information presented in this Prospectus, including certain
documents incorporated by reference herein, may include
non-IFRS measures that are
used by us as indicators of financial performance. These financial
measures do not have standardized meanings prescribed under IFRS
and our computation may differ from similarly-named computations as
reported by other entities and, accordingly, may not be comparable.
These financial measures should not be considered as an alternative
to, or more meaningful than, measures of financial performance as
determined in accordance with IFRS as an indicator of performance.
We believe these measures may be useful supplemental information to
assist investors in assessing our operational performance and our
ability to generate cash through operations. The non-IFRS measures also provide
investors with insight into our decision making as we use these
non-IFRS measures to make
financial, strategic and operating decisions.
Because non-IFRS measures
do not have a standardized meaning and may differ from
similarly-named computations as reported by other entities,
securities regulations require that non-IFRS measures be clearly defined
and qualified, reconciled with their nearest IFRS measure and given
no more prominence than the closest IFRS measure. If non-IFRS measures are included in
documents incorporated by reference herein, information regarding
these non-IFRS measures are
presented in the sections dealing with these financial measures in
such documents.
Non-IFRS measures are not
audited. These non-IFRS
measures have important limitations as analytical tools and
investors are cautioned not to consider them in isolation or place
undue reliance on ratios or percentages calculated using these
non-IFRS measures.
8
CURRENCY PRESENTATION AND
EXCHANGE RATE INFORMATION
Unless stated otherwise or as the context otherwise requires, all
references to dollar amounts in this Prospectus and any Prospectus
Supplement are references to Canadian dollars. References to “$” or
“C$” are to Canadian dollars and references to “U.S. dollars” or
“U.S.$” are to United States dollars.
Except as otherwise noted in our 2020 AIF and the Company’s
financial statements and related management’s discussion and
analysis of financial condition and results of operations of the
Company that are incorporated by reference into this Prospectus,
the financial information contained in such documents is expressed
in Canadian dollars.
The high, low, average and closing daily exchange rates for the
United States dollar in terms of Canadian dollars for each of the
financial periods of the Company ended December 31, 2020,
June 30, 2018 and June 30, 2019, as quoted by the Bank of
Canada, were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December 31, 2020 |
|
|
Year ended
June 30, 2020 |
|
|
Year ended
June 30, 2019 |
|
|
|
(expressed in
Canadian dollars) |
|
High
|
|
|
1.3349 |
|
|
|
1.4496 |
|
|
|
1.3642 |
|
Low
|
|
|
1.2718 |
|
|
|
1.2970 |
|
|
|
1.2803 |
|
Average
|
|
|
1.3030 |
|
|
|
1.3427 |
|
|
|
1.3237 |
|
Closing
|
|
|
1.2732 |
|
|
|
1.3628 |
|
|
|
1.3087 |
|
On March 26, 2021, the daily exchange rate for the United
States dollar in terms of Canadian dollars, as quoted by the Bank
of Canada, was U.S.$1.00 = $1.2580.
9
OUR BUSINESS
Aurora is a Canadian-headquartered cannabis company focused on
producing, innovating, and selling consistent, high quality
cannabis and cannabis products for both the global medical and
consumer use markets. The Company has differentiated itself
through:
|
• |
|
Purpose-built growing facilities, which we believe are the most
technologically advanced indoor agricultural growing facilities in
the world. These facilities consistently produce high-quality
cannabis at scale, lower the risk of crop failure, and provide low
per-unit production
costs;
|
|
• |
|
Research and innovation in plant genetics, cultivation, consumer
insights and product development;
|
|
• |
|
A broad and growing portfolio of successful brands that align with
the needs of consumers and patients in segments from discount to
ultra-premium;
|
|
• |
|
Global leadership in consumer and medical markets that have
significant and near-term profit potential; and
|
|
• |
|
A transformed cost structure that provides a path to near-term,
sustainable and growing positive earnings before interest, taxes,
depreciation and amortization and cash flow.
|
The Company’s principal strategic business lines are focused on the
production, distribution, and sale of cannabis and
cannabis-derivative products in Canada and internationally. The
Company’s primary market opportunities are:
|
• |
|
Global medical cannabis market: Production, distribution and
sale of pharmaceutical-grade cannabis products in countries around
the world where permitted by government legislation. Currently,
there are approximately 50 countries that have implemented regimes
for some form of access to cannabis for medical purposes. The
Company’s current principal medical markets are Canada and Germany.
Aurora has established a market position in these countries;
|
|
• |
|
Global consumer use cannabis market: Currently, only Canada
and Uruguay have implemented federally regulated consumer use of
cannabis regimes and the Company has primarily focused on the
opportunities in Canada. Aurora has established a top-three market position in the
Canadian consumer market overall. Longer-term, the Company believes
that the increasing success of medical cannabis regimes globally
may lead to increased legalization of adult-use consumer markets; and
|
|
• |
|
Global hemp-derived CBD market: The Company expects consumer
demand for products containing CBD derived from hemp plants to be
an exciting growth opportunity in the coming years. The Company
believes that the most important near-term market opportunity for
hemp-derived CBD is in the U.S. On May 28, 2020, the Company
acquired Reliva, LLC, a U.S. company based in Massachusetts, which
specializes in the distribution and sale of hemp-derived CBD
products and has established a leading brand in the U.S.
market.
|
Recent Developments
Global COVID-19
Pandemic
As at the date of this Prospectus, the production and sale of
medical and consumer cannabis have been recognized as essential
services across Canada and Europe. All of the Company’s facilities
in Canada and internationally continue to be operational and we
continue to work closely with local, national and international
government authorities to ensure that we are following the required
protocols and guidelines related to COVID-19 within each region. Although
there have not been any significant impacts to the Company’s
operations to date, the Company cannot provide assurance that there
will not be disruptions to its operations in the future. Refer to
the “Risk Factors” section in the 2020 Annual
MD&A and the Interim MD&A for further discussion on the
potential impacts of COVID-19.
10
January 2021 Public Offering
On January 26, 2021, the Company completed a bought deal
public offering of units for total gross proceeds of
U.S.$137.9 million. The Company issued a total of 13,200,000
units. Each unit consisted of one Common Share and one-half of one Common Share purchase
warrant. Each whole warrant is exercisable for a period of 36
months and entitles the holder to purchase one Common Share at a
price of U.S.$12.60 per common share.
Sale of Facilities
In January 2021, the Company entered into agreements to sell two of
its production facilities for an aggregate of up to
$24.6 million, subject to certain closing conditions. Upon
closing, the Company will receive approximately 50% of the proceeds
with the remaining 50% receivable upon, and subject to, the
purchaser obtaining certain licenses.
Second Amended and Restated Credit Facility
On December 17, 2020, the Company entered into a second
amended and restated credit facility (the “Second Amended Credit
Facility”) with Bank of Montreal, as administrative agent, lead
arranger and sole bookrunner (“BMO”) and certain lenders
party thereto from time to time (collectively, the
“Lenders”). The Second Amended Credit Facility replaced the
Amended and Restated Credit Facility dated September 4, 2020,
as amended. No changes were made to the commitment amounts under
the facility, and the maturity date for the facility was extended
to December 31, 2022. Seconded Amended Credit Facility
provides for a minimum liquidity covenant rather than the minimum
EBITDA covenants provided for under the prior facility.
Specifically, the milestone targets for each quarter ending
December 31, 2020 through June 30, 2021, the adjusted
EBITDA covenant for the trailing 12-month period ending June 30,
2021, and the maximum senior funded debt to Adjusted EBITDA ratio
covenant have been eliminated. The Company agreed to:
(A) increase the amount of unrestricted cash it will hold at
all times to an amount equal to the lesser of (i) $75 million
and (ii) two hundred and twenty-five percent of the
outstanding principal amount under the term loan less the cash
collateral posted by the Company, (B) introduce additional
cash collateral of $50 million and (C) amend the
amortization schedule to provide for principal payments of
$6.25 million each fiscal quarter until maturity. There are no
changes to the commitment amounts under the facility. The Second
Amended Credit Facility has a first ranking general security
interest in the assets of the Company and can be repaid without
penalty at the Company’s discretion. In addition, the amended
credit facility relieves the Company of the obligation to repay the
credit facility with funds generated from future equity
issuances.
The Second Amended Credit Facility contains customary
representations and warranties, affirmative and negative covenants,
and events of default. In addition, the Second Amended Credit
Facility contains a negative covenant which restricts the Company
from making or acquiring any Investments (as defined in the Second
Amended Credit Facility) that, among other things, do not satisfy
the definition of a Permitted Acquisition, as that term is defined
in the Second Amended Credit Facility.
11
Effect of Reduction of Operations on Financial
Results
In November 2020, the Company formally terminated construction
activity and closed its Aurora Sun facility, and in December 2020
the Company reduced production at its Aurora Sky facility by 75%,
consistent with previous public statements by the Company about
aligning production to current demand. Aurora Sky is currently
testing new processes and methodologies proven successful at other
cultivation sites in Aurora’s network, with an increased focus on
innovation led by deep plant science and genetics
expertise. These decisions are designed to improve Aurora’s
product quality, innovation and agility and improve working capital
cycles to drive positive operating cash flow.
Cybersecurity Incident
In December 2020, the Company was the target of a cybersecurity
incident that involved the theft of company information. The
subsequent investigation identified that certain personally
identifiable information of its employees and consumers was
compromised. It also confirmed that the Company’s patient database
was not compromised, and the Company’s performance and financial
information was not impacted. All impacted individuals have been
notified, as have all required government privacy offices. It is
possible that further analysis will identify additional individuals
affected or additional types of data accessed, which could result
in additional notifications and negative publicity. Globally,
cybersecurity incidents have increased in number and severity and
it is expected that these external trends will continue. In
response to this incident, or any potential future incident, the
Company may incur substantial costs which may include:
|
• |
|
remediation costs, such as liability for stolen information,
repairs to system or data damage, or implementation of new security
measures in response to the evolving security landscape; and
|
|
• |
|
legal expenses, including costs related to litigation, regulatory
actions or penalties.
|
12
THE SELLING
SECURITYHOLDERS
Securities may be sold under this Prospectus by way of secondary
offering by or for the account of certain of our securityholders.
The Prospectus Supplement that we will file in connection with any
offering of Securities by selling securityholders will include the
following information:
|
• |
|
the names of the selling securityholders;
|
|
• |
|
the number or amount of Securities owned, controlled or directed of
the class being distributed by each selling securityholder;
|
|
• |
|
the number or amount of Securities of the class being distributed
for the account of each selling securityholder;
|
|
• |
|
the number or amount of Securities of any class to be owned,
controlled or directed by the selling securityholders after the
distribution and the percentage that number, or amount represents
of the total number of our outstanding Securities;
|
|
• |
|
whether the Securities are owned by the selling securityholders
both of record and beneficially, of record only, or beneficially
only; and
|
|
• |
|
all other information that is required to be included in the
applicable Prospectus Supplement.
|
USE OF PROCEEDS
Information regarding the use of the net proceeds from each
offering of the Securities will be set forth in the Prospectus
Supplement relating to the offering of the Securities. This
information will include the net proceeds to the Company from the
sale of the Securities, the use of those proceeds and the specific
business objectives that the Company expects to accomplish with
such proceeds.
All expenses relating to an offering of Securities and any
compensation paid to underwriters, dealers or agents, as the case
may be, will be paid out of our general funds, unless otherwise
stated in the applicable Prospectus Supplement.
During the fiscal year ended June 30, 2020 and the second
quarter ended December 31, 2020, the Company had negative cash
flow from operating activities. Although the Company anticipates it
will be able to generate positive cash flow from operating
activities in the future, the Company cannot guarantee it will have
positive cash flow from operating activities in any future period.
To the extent that the Company has negative operating cash flow in
any future period, current working capital and certain of the
proceeds from the Offering may be used to fund such negative cash
flow from operating activities. See “Risk Factors – Risks
Related to Future Offerings – Negative Cash Flow from
Operations”.
13
EARNINGS COVERAGE
RATIO
Earnings coverage ratios will be provided as required in the
applicable Prospectus Supplement(s) with respect to the issuance of
Debt Securities pursuant to this Prospectus.
CONSOLIDATED
CAPITALIZATION
As of March 26, 2021, the Company had 197,979,742 Common
Shares issued and outstanding. Except as described below, there
have been no material changes in our share and debt capital, on a
consolidated basis, since December 31, 2020, being the date of
the Interim Financial Statements incorporated by reference in this
Prospectus, other than:
|
• |
|
the issuance of 13,200,000 Common Shares pursuant to the Company’s
January 2021 Public Offering for gross proceeds of
U.S.$137.9 million;
|
|
• |
|
the issuance of 27,083 Common Shares on the exercise of stock
options of the Company (the “Stock Options”) for gross
proceeds of approximately $0.1 million;
|
|
• |
|
the issuance of 18,267 Common Shares on the exercise of 18,267
restricted share units of the Company (“RSUs”);
|
|
• |
|
the issuance of 375,000 Common Shares on the exercise of 375,000
warrants issued from the November 2020 Public Offering for gross
proceeds of U.S.$3.4 million;
|
|
• |
|
The issuance of 116,500 Common Shares on the exercise of 116,500
warrants issued for milestone payments in connection with a
previous acquisition for gross proceeds of $1.3 million;
|
|
• |
|
the issuance of 29,617 Common Shares issued at a deemed price of
$13.38 per share for payment of services;
|
|
• |
|
the issuance of 52,587 Common Share issued at a deemed price of
$14.2620 per share as a milestone payment in connection with the
divestiture of a subsidiary; and
|
|
• |
|
the grant of Stock Options, RSUs, PSUs and DSUs under the Company’s
equity compensation plans,
|
each as described further below under “Prior Sales”.
14
TRADING PRICE AND
VOLUME
Our Common Shares are listed on the TSX and NYSE under the trading
symbol “ACB”. The following tables set forth the reported high and
low closing prices and the aggregate trading volume of our Common
Shares (reflecting the Company’s share consolidation completed on
May 11, 2020) on the TSX and the NYSE for each of the months
(or, if applicable, partial months) indicated during the
12-month period prior to
the date of this Prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
Month
|
|
TSX Price Range |
|
|
Total Volume |
|
|
High |
|
|
Low |
|
March 2020
|
|
|
22.32 |
|
|
|
10.8 |
|
|
|
21,282,576 |
|
April 2020
|
|
|
14.64 |
|
|
|
11.16 |
|
|
|
13,017,487 |
|
May 2020
|
|
|
24.10 |
|
|
|
8.29 |
|
|
|
75,656,069 |
|
June 2020
|
|
|
21.02 |
|
|
|
16.79 |
|
|
|
44,275,334 |
|
July 2020
|
|
|
17.31 |
|
|
|
13.65 |
|
|
|
24,880,382 |
|
August 2020
|
|
|
14.23 |
|
|
|
12.31 |
|
|
|
24,347,074 |
|
September 2020
|
|
|
12.16 |
|
|
|
6.20 |
|
|
|
55,191,623 |
|
October 2020
|
|
|
6.73 |
|
|
|
5.08 |
|
|
|
64,975,508 |
|
November 2020
|
|
|
15.25 |
|
|
|
5.82 |
|
|
|
249,385,247 |
|
December 2020
|
|
|
14.43 |
|
|
|
10.60 |
|
|
|
126,593,162 |
|
January 2021
|
|
|
16.94 |
|
|
|
10.64 |
|
|
|
125,167,037 |
|
February 2021
|
|
|
24.10 |
|
|
|
12.78 |
|
|
|
126,783,137 |
|
March 1 – March 26, 2021
|
|
|
15.28 |
|
|
|
10.80 |
|
|
|
70,378,213 |
|
|
|
|
|
|
NYSE Price Range (in U.S.$) |
|
|
|
|
Month
|
|
High |
|
|
Low |
|
|
Total Volume |
|
March 2020
|
|
|
16.56 |
|
|
|
7.50 |
|
|
|
65,044,377 |
|
April 2020
|
|
|
10.52 |
|
|
|
8.02 |
|
|
|
52,509,794 |
|
May 2020
|
|
|
17.40 |
|
|
|
5.80 |
|
|
|
463,900,797 |
|
June 2020
|
|
|
15.74 |
|
|
|
12.36 |
|
|
|
121,749,317 |
|
July 2020
|
|
|
12.87 |
|
|
|
10.19 |
|
|
|
74,030,133 |
|
August 2020
|
|
|
10.73 |
|
|
|
9.36 |
|
|
|
54,561,560 |
|
September 2020
|
|
|
9.3 |
|
|
|
4.65 |
|
|
|
175,344,201 |
|
October 2020
|
|
|
5.1 |
|
|
|
3.83 |
|
|
|
276,674,319 |
|
November 2020
|
|
|
11.68 |
|
|
|
4.43 |
|
|
|
1,591,071,534 |
|
December 2020
|
|
|
11.24 |
|
|
|
8.31 |
|
|
|
594,307,446 |
|
January 2021
|
|
|
13.32 |
|
|
|
8.30 |
|
|
|
565,596,273 |
|
February 2021
|
|
|
18.98 |
|
|
|
10.10 |
|
|
|
606,550,618 |
|
March 1 – March 26, 2021
|
|
|
12.08 |
|
|
|
8.61 |
|
|
|
232,267,384 |
|
15
PRIOR SALES
The following table sets out details of all Common Shares issued by
the Company since the year ended June 30, 2020. For details of
all Common Shares issued during the year ended June 30, 2020,
see the Company’s 2020 AIF.
|
|
|
|
|
|
|
|
|
|
|
|
|
Date of Issuance
|
|
Type of Security
Issued
|
|
Reason for Issuance
|
|
Number of
Securities
Issued |
|
|
Issue/Exercise Price
per Security |
|
|
|
|
|
|
July 2, 2020
|
|
Common Shares |
|
ATM Program |
|
|
3,768 |
|
|
U.S.$ |
12.4766 |
|
|
|
|
|
|
July 3, 2020
|
|
Common Shares |
|
RSU Release |
|
|
20,046 |
|
|
$ |
16.43 |
|
|
|
|
|
|
August 6, 2020
|
|
Common Shares |
|
Exercise of Stock Options |
|
|
223 |
|
|
$ |
3.60 |
|
|
|
|
|
|
August 7, 2020
|
|
Common Shares |
|
RSU Release |
|
|
973 |
|
|
$ |
14.21 |
|
|
|
|
|
|
August 11, 2020
|
|
Common Shares |
|
Milestone Payment |
|
|
2,171,355 |
|
|
$ |
14.00 |
|
|
|
|
|
|
August 18, 2020
|
|
Common Shares |
|
RSU Release |
|
|
6,913 |
|
|
$ |
13.29 |
|
|
|
|
|
|
August 18, 2020
|
|
Common Shares |
|
Exercise of Stock Options |
|
|
4,861 |
|
|
$ |
3.60 |
|
|
|
|
|
|
August 27, 2020
|
|
Common Shares |
|
RSU Release |
|
|
15,694 |
|
|
$ |
12.65 |
|
|
|
|
|
|
September 14, 2020
|
|
Common Shares |
|
RSU Release |
|
|
1,558 |
|
|
$ |
9.94 |
|
|
|
|
|
|
September 14, 2020
|
|
Common Shares |
|
ATM Program |
|
|
238,400 |
|
|
U.S.$ |
7.6559 |
|
|
|
|
|
|
September 16, 2020
|
|
Common Shares |
|
ATM Program |
|
|
828,909 |
|
|
U.S.$ |
7.2685 |
|
|
|
|
|
|
September 17, 2020
|
|
Common Shares |
|
ATM Program |
|
|
600,000 |
|
|
U.S.$ |
7.1828 |
|
|
|
|
|
|
September 18, 2020
|
|
Common Shares |
|
ATM Program |
|
|
1,407,209 |
|
|
U.S.$ |
7.16 |
|
|
|
|
|
|
September 21, 2020
|
|
Common Shares |
|
ATM Program |
|
|
500,000 |
|
|
U.S.$ |
6.8885 |
|
|
|
|
|
|
September 22, 2020
|
|
Common Shares |
|
ATM Program |
|
|
500,000 |
|
|
U.S.$ |
6.702 |
|
|
|
|
|
|
September 23, 2020
|
|
Common Shares |
|
ATM Program |
|
|
1,200,000 |
|
|
U.S.$ |
6.3241 |
|
|
|
|
|
|
September 25, 2020
|
|
Common Shares |
|
Acquisition |
|
|
830,287 |
|
|
$ |
8.1183 |
|
|
|
|
|
|
September 25, 2020
|
|
Common Shares |
|
ATM Program |
|
|
3,000,000 |
|
|
U.S.$ |
5.5107 |
|
|
|
|
|
|
September 28, 2020
|
|
Common Shares |
|
DSU Release |
|
|
1,285 |
|
|
$ |
8.552 |
|
|
|
|
|
|
September 28, 2020
|
|
Common Shares |
|
RSU Release |
|
|
66 |
|
|
$ |
9.94 |
|
|
|
|
|
|
September 28, 2020
|
|
Common Shares |
|
ATM Program |
|
|
3,028,643 |
|
|
U.S.$ |
5.1551 |
|
|
|
|
|
|
September 29, 2020
|
|
Common Shares |
|
ATM Program |
|
|
1,000,000 |
|
|
U.S.$ |
5.0401 |
|
|
|
|
|
|
September 30, 2020
|
|
Common Shares |
|
ATM Program |
|
|
2,820,729 |
|
|
U.S.$ |
4.8585 |
|
|
|
|
|
|
October 1, 2020
|
|
Common Shares |
|
RSU Release |
|
|
10,814 |
|
|
$ |
6.65 |
|
|
|
|
|
|
October 2, 2020
|
|
Common Shares |
|
DSU Release |
|
|
3,639 |
|
|
$ |
6.668 |
|
|
|
|
|
|
October 2, 2020
|
|
Common Shares |
|
ATM Program |
|
|
795,967 |
|
|
U.S.$ |
4.7635 |
|
|
|
|
|
|
October 5, 2020
|
|
Common Shares |
|
ATM Program |
|
|
750,000 |
|
|
U.S.$ |
4.688 |
|
|
|
|
|
|
October 6, 2020
|
|
Common Shares |
|
ATM Program |
|
|
670,000 |
|
|
U.S.$ |
4.6029 |
|
|
|
|
|
|
October 7, 2020
|
|
Common Shares |
|
ATM Program |
|
|
800,000 |
|
|
U.S.$ |
4.6466 |
|
|
|
|
|
|
October 8, 2020
|
|
Common Shares |
|
ATM Program |
|
|
732,600 |
|
|
U.S.$ |
4.5717 |
|
|
|
|
|
|
October 9, 2020
|
|
Common Shares |
|
ATM Program |
|
|
1,300,000 |
|
|
U.S.$ |
4.5794 |
|
|
|
|
|
|
October 13, 2020
|
|
Common Shares |
|
ATM Program |
|
|
5,650,000 |
|
|
U.S.$ |
4.9391 |
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
Date of Issuance
|
|
Type of Security
Issued
|
|
Reason for Issuance
|
|
Number of
Securities
Issued |
|
|
Issue/Exercise Price
per Security |
|
|
|
|
|
|
October 14, 2020 |
|
Common Shares |
|
ATM Program |
|
|
4,348,487 |
|
|
U.S.$ |
5.2267 |
|
|
|
|
|
|
October 14, 2020 |
|
Common Shares |
|
ATM Program |
|
|
1,589,406 |
|
|
U.S.$ |
4.978 |
|
|
|
|
|
|
October 15, 2020 |
|
Common Shares |
|
ATM Program |
|
|
1,275,000 |
|
|
U.S.$ |
4.8096 |
|
|
|
|
|
|
October 16, 2020 |
|
Common Shares |
|
ATM Program |
|
|
1,330,000 |
|
|
U.S.$ |
4.5942 |
|
|
|
|
|
|
October 19, 2020 |
|
Common Shares |
|
ATM Program |
|
|
2,050,000 |
|
|
U.S.$ |
4.3096 |
|
|
|
|
|
|
October 20, 2020 |
|
Common Shares |
|
RSU Release |
|
|
101 |
|
|
$ |
5.45 |
|
|
|
|
|
|
October 20, 2020 |
|
Common Shares |
|
ATM Program |
|
|
5,940,000 |
|
|
U.S. $ |
4.0539 |
|
|
|
|
|
|
October 23, 2020 |
|
Common Shares |
|
RSU Release |
|
|
304 |
|
|
$ |
6.12 |
|
|
|
|
|
|
November 16, 2020 |
|
Common Shares |
|
November 2020 Public Offering(1) |
|
|
23,000,000 |
|
|
U.S.$ |
7.50 |
|
|
|
|
|
|
November 17, 2020 |
|
Common Shares |
|
RSU Release |
|
|
20,910 |
|
|
C$ |
9.34 |
|
|
|
|
|
|
November 25, 2020 |
|
Common Shares |
|
RSU Release |
|
|
20,156 |
|
|
C$ |
9.43 |
|
|
|
|
|
|
November 30, 2020 |
|
Common Shares |
|
Milestone Payment |
|
|
467,817 |
|
|
C$ |
10.0968 |
|
|
|
|
|
|
December 7, 2020 |
|
Common Shares |
|
RSU Release |
|
|
556 |
|
|
C$ |
14.08 |
|
|
|
|
|
|
December 15, 2020 |
|
Common Shares |
|
RSU Release |
|
|
1,389 |
|
|
C$ |
12.48 |
|
|
|
|
|
|
December 21, 2020 |
|
Common Shares |
|
Service Fee |
|
|
44,095 |
|
|
C$ |
12.4728 |
|
|
|
|
|
|
January 5, 2021 |
|
Common Shares |
|
RSU Release |
|
|
233 |
|
|
C$ |
14.42 |
|
|
|
|
|
|
January 15, 2021 |
|
Common Shares |
|
Service Fee |
|
|
29,617 |
|
|
C$ |
13.38 |
|
|
|
|
|
|
January 19, 2021 |
|
Common Shares |
|
RSU Release |
|
|
281 |
|
|
C$ |
15.64 |
|
|
|
|
|
|
January 26, 2021 |
|
Common Shares |
|
January 2021 Public Offering(2) |
|
|
13,200,000 |
|
|
C$ |
10.45 |
|
|
|
|
|
|
January 28, 2021 |
|
Common Shares |
|
RSU Release |
|
|
1,215 |
|
|
$ |
13.45 |
|
|
|
|
|
|
February 1, 2021 |
|
Common Shares |
|
Milestone Payment |
|
|
52,587 |
|
|
$ |
14.2620 |
|
|
|
|
|
|
February 19, 2021 |
|
Common Shares |
|
RSU Release |
|
|
2,316 |
|
|
$ |
16.94 |
|
|
|
|
|
|
February 19, 2021 |
|
Common Shares |
|
Warrant Exercised |
|
|
375,000 |
|
|
U.S.$ |
9.00 |
|
|
|
|
|
|
February 22, 2021 |
|
Common Shares |
|
Option Exercised |
|
|
2,083 |
|
|
$ |
3.60 |
|
|
|
|
|
|
February 23, 2021 |
|
Common Shares |
|
RSU Release |
|
|
12,139 |
|
|
$ |
15.29 |
|
|
|
|
|
|
February 23, 2021 |
|
Common Shares |
|
Option Exercised |
|
|
25,000 |
|
|
$ |
5.52 |
|
|
|
|
|
|
February 24, 2021 |
|
Common Shares |
|
RSU Release |
|
|
2,083 |
|
|
$ |
15.38 |
|
|
|
|
|
|
February 24, 2021 |
|
Common Shares |
|
Warrant Exercised |
|
|
116,500 |
|
|
$ |
11.1064 |
|
Notes:
(1) |
The November 2020 Public Offering was comprised of
units consisting of one Common Share and one half of one Common
Share purchase warrant.
|
(2) |
The January 2021 Public Offering was comprised of
units consisting of one Common Share and one half of one Common
Share purchase warrant.
|
17
The following table sets out details of all securities convertible
or exercisable into Common Shares that were issued or granted by
the Company following the year ended June 30, 2020. For
details of all securities convertible or exercisable into Common
Shares that were issued or granted during the year ended
June 30, 2020, see the Company’s 2020 AIF.
|
|
|
|
|
|
|
|
|
|
|
Date of Issuance
|
|
Type of Security
Issued |
|
Number of Common Shares
Issuable Upon Exercise or
Conversion |
|
|
Exercise or Conversion Price
Per Common Share |
|
July 27, 2020
|
|
Stock Options |
|
|
2,686 |
|
|
$ |
14.00 |
|
September 10, 2020
|
|
Stock Options |
|
|
131,211 |
|
|
$ |
10.09 |
|
September 10, 2020
|
|
RSUs |
|
|
523,313 |
|
|
|
N/A |
|
September 10, 2020
|
|
DSUs |
|
|
9,107 |
|
|
|
N/A |
|
September 30, 2020
|
|
DSUs |
|
|
1,967 |
|
|
|
N/A |
|
October 9, 2020
|
|
RSUs |
|
|
15,158 |
|
|
|
N/A |
|
November 3, 2020
|
|
RSUs |
|
|
3,800 |
|
|
|
N/A |
|
November 12, 2020
|
|
PSU |
|
|
425,939 |
|
|
|
N/A |
|
November 16, 2020
|
|
Warrants |
|
|
11,500,000 |
|
|
U.S. $ |
9.00 |
|
November 30, 2020
|
|
Warrants |
|
|
233,908 |
|
|
$ |
11.11 |
|
November 30, 2020
|
|
Options |
|
|
20,226 |
|
|
$ |
15.25 |
|
November 30, 2020
|
|
DSUs |
|
|
5,160 |
|
|
|
N/A |
|
December 8, 2020
|
|
PSUs |
|
|
5,076 |
|
|
|
N/A |
|
December 8, 2020
|
|
RSUs |
|
|
6,689 |
|
|
|
N/A |
|
December 8, 2020
|
|
Options |
|
|
8,106 |
|
|
C$ |
13.35 |
|
December 9, 2020
|
|
PSUs |
|
|
2,906 |
|
|
|
N/A |
|
December 9, 2020
|
|
RSUs |
|
|
4,297 |
|
|
|
N/A |
|
December 9, 2020
|
|
Options |
|
|
3,975 |
|
|
$ |
13.59 |
|
December 14, 2020
|
|
RSUs |
|
|
141,547 |
|
|
|
N/A |
|
December 14, 2020
|
|
Options |
|
|
243,963 |
|
|
$ |
12.61 |
|
December 31, 2020
|
|
DSUs |
|
|
1,159 |
|
|
|
N/A |
|
January 19, 2021
|
|
PSUs |
|
|
786 |
|
|
|
N/A |
|
January 19, 2021
|
|
RSUs |
|
|
1,833 |
|
|
|
N/A |
|
January 26, 2021
|
|
Warrants |
|
|
6,600,000 |
|
|
$ |
12.60 |
|
January 26, 2021
|
|
PSUs |
|
|
722 |
|
|
|
N/A |
|
January 26, 2021
|
|
RSUs |
|
|
1,684 |
|
|
|
N/A |
|
January 27, 2021
|
|
PSUs |
|
|
944 |
|
|
|
N/A |
|
January 27, 2021
|
|
RSUs |
|
|
2,202 |
|
|
|
N/A |
|
February 11, 2021
|
|
Options |
|
|
1,198 |
|
|
$ |
23.96 |
|
February 11, 2021
|
|
PSUs |
|
|
373 |
|
|
|
N/A |
|
February 11, 2021
|
|
RSUs |
|
|
373 |
|
|
|
N/A |
|
February 16, 2021
|
|
RSUs |
|
|
46,803 |
|
|
|
N/A |
|
February 16, 2021
|
|
Options |
|
|
69,814 |
|
|
$ |
17.84 |
|
February 28, 2021
|
|
DSUs |
|
|
5,850 |
|
|
|
N/A |
|
February 28, 2021
|
|
Options |
|
|
17,022 |
|
|
$ |
13.46 |
|
March 11, 2021
|
|
DSUs |
|
|
3,623 |
|
|
|
N/A |
|
18
PLAN OF DISTRIBUTION
We may offer and sell Securities directly to one or more
purchasers, through agents, or through underwriters or dealers
designated by us from time to time. We may distribute the
Securities from time to time in one or more transactions at fixed
prices (which may be changed from time to time), at market prices
prevailing at the times of sale, at varying prices determined at
the time of sale, at prices related to prevailing market prices or
at negotiated prices, including sales in transactions that are
considered at-the-market distributions made
through the facilities of a stock exchange or stock market outside
of Canada, including the NYSE. A description of such pricing will
be disclosed in the applicable Prospectus Supplement. No
at-the-market offering as
defined in NI 44-102 will
be made under this Prospectus in Canada or through the facilities
of a stock exchange or stock market in Canada. We may offer
different classes of Securities in the same offering, or we may
offer different classes of Securities in separate offerings.
This Prospectus may also, from time to time, relate to the offering
of our Securities by certain selling securityholders. The selling
securityholders may sell all or a portion of our Securities
beneficially owned by them and offered thereby from time to time
directly or through one or more underwriters, broker-dealers or
agents. Our Securities may be sold by the selling securityholders
in one or more transactions at fixed prices (which may be changed
from time to time), at market prices prevailing at the time of the
sale, at varying prices determined at the time of sale, at prices
related to prevailing market prices or at negotiated prices.
A Prospectus Supplement will describe the terms of each specific
offering of Securities, including: (i) the terms of the
Securities to which the Prospectus Supplement relates, including
the type of Security being offered; (ii) the name or names of
any agents, underwriters or dealers involved in such offering of
Securities; (iii) the name or names of any selling
securityholders; (iv) the purchase price of the Securities
offered thereby and the proceeds to, and the portion of expenses
borne by, the Company from the sale of such Securities;
(v) any agents’ commission, underwriting discounts and other
items constituting compensation payable to agents, underwriters or
dealers; and (vi) any discounts or concessions allowed or
re-allowed or paid to
agents, underwriters or dealers.
If Securities sold pursuant to a Prospectus Supplement are acquired
by underwriters for their own account, they may be resold from time
to time in one or more transactions, including negotiated
transactions, at a fixed public offering price or at varying prices
determined at the time of sale. The obligations of the underwriters
to purchase Securities will be subject to the conditions precedent
agreed upon by the parties and the underwriters will be obligated
to purchase all Securities under that offering if any are
purchased. Any public offering price and any discounts or
concessions allowed or re-allowed or paid to agents,
underwriters or dealers may be changed from time to time.
Underwriters, dealers and agents who participate in the
distribution of the Securities may be entitled under agreements to
be entered into with the Company to indemnification by the Company
against certain liabilities, including liabilities under the U.S.
Securities Act and Canadian securities legislation, or to
contribution with respect to payments which such underwriters,
dealers or agents may be required to make in respect thereof. Such
underwriters, dealers and agents may be customers of, engage in
transactions with, or perform services for, the Company in the
ordinary course of business.
In connection with any offering of Securities, other than an
“at-the-market distribution”,
the underwriters may over-allot or effect transactions which
stabilize or maintain the market price of the Securities offered at
a level above that which might otherwise prevail in the open
market. Such transactions, if commenced, may be discontinued at any
time.
The Securities may also be sold: (i) directly by the Company
or the selling securityholders at such prices and upon such terms
as agreed to; or (ii) through agents designated by the Company
or the selling securityholders from time to time. Any agent
involved in the offering and sale of the Securities in respect of
which this Prospectus is delivered will be named, and any
commissions payable by the Company and/or selling
19
securityholder to such agent will be set forth, in the Prospectus
Supplement. Unless otherwise indicated in the Prospectus
Supplement, any agent is acting on a “best efforts” basis for the
period of its appointment.
We and/or the selling securityholders may agree to pay the
underwriters or agents a commission for various services relating
to the issue and sale of any Securities offered under any
Prospectus Supplement. In addition, underwriters or agents may sell
the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions
from the underwriters or agents and/or commissions from the
purchasers for which they may act as agent. Agents, underwriters or
dealers who participate in the distribution of the Securities may
be entitled under agreements to be entered into with the Company
and/or the selling securityholders to indemnification by the
Company and/or the selling securityholders against certain
liabilities, including liabilities under securities legislation, or
to contribution with respect to payments which such underwriters,
dealers or agents may be required to make in respect thereof.
Each class or series of Warrants, Options, Subscription Receipts,
Debt Securities and Units will be a new issue of Securities with no
established trading market. Unless otherwise specified in the
applicable Prospectus Supplement, Warrants, Options, Subscription
Receipts, Debt Securities or Units will not be listed on any
securities or stock exchange. Unless otherwise specified in the
applicable Prospectus Supplement, there is no market through which
the Warrants, Options, Subscription Receipts, Debt Securities or
Units may be sold and purchasers may not be able to resell
Warrants, Options, Subscription Receipts, Debt Securities or Units
purchased under this Prospectus or any Prospectus Supplement. This
may affect the pricing of the Warrants, Options, Subscription
Receipts, Debt Securities or Units in the secondary market, the
transparency and availability of trading prices, the liquidity of
the Securities, and the extent of issuer regulation. Subject to
applicable laws, certain dealers may make a market in the Warrants,
Options, Subscription Receipts, Debt Securities or Units, as
applicable, but will not be obligated to do so and may discontinue
any market making at any time without notice. No assurance can be
given that any dealer will make a market in the Warrants, Options,
Subscription Receipts or Units or as to the liquidity of the
trading market, if any, for the Warrants, Options, Subscription
Receipts, Debt Securities or Units.
In connection with any offering of Securities, unless otherwise
specified in a Prospectus Supplement, underwriters or agents may
over-allot or effect transactions which stabilize, maintain or
otherwise affect the market price of Securities offered at levels
other than those which might otherwise prevail on the open market.
Such transactions may be commenced, interrupted or discontinued at
any time.
20
DESCRIPTION OF
SECURITIES
The Securities may be offered under this Prospectus in amounts and
at prices to be determined based on market conditions at the time
of the sale and such amounts and prices will be set forth in the
accompanying Prospectus Supplement. The Securities may be issued
alone or in combination and for such consideration determined by
our board of directors.
Common Shares
The holders of Common Shares are entitled to receive notice of any
meeting of the shareholders of the Company and to attend and vote
thereat, except those meetings at which only the holders shares of
another class or of a particular series are entitled to vote. Each
Common Share entitles its holder to one vote. The holders of Common
Shares are entitled to receive on a pro-rata basis such dividends as the
board of directors may declare out of funds legally available
therefor. In the event of the dissolution, liquidation,
winding-up or other
distribution of our assets, such holders are entitled to receive on
a pro-rata basis all of
assets of the Company remaining after payment of all of
liabilities. The Common Shares carry no pre-emptive or conversion rights.
Warrants
This section describes the general terms that will apply to any
Warrants for the purchase of Common Shares. To the extent required
under applicable law, we will not offer Warrants for sale
separately to any member of the public in Canada unless the
offering of such Warrants is in connection with and forms a part of
the consideration for an acquisition or merger transaction, or
unless the applicable Prospectus Supplement containing the specific
terms of the Warrants to be offered separately is first approved,
in accordance with applicable laws, for filing by the securities
commissions or similar regulatory authorities in each of the
jurisdictions where the Warrants will be offered for sale.
Subject to the foregoing, we may issue Warrants independently or
together with other Securities, and Warrants sold with other
Securities may be attached to or separate from the other
Securities. Warrants may be issued directly by us to the purchasers
thereof or under one or more warrant indentures or warrant agency
agreements to be entered into by us and one or more banks or trust
companies acting as warrant agent. Warrants, like other Securities
that may be sold, may be listed on a securities exchange subject to
exchange listing requirements and applicable legal
requirements.
The following description, together with the additional information
the Company may include in any Prospectus Supplements, summarizes
the material terms and provisions of the Warrants that the Company
may offer under the Prospectus, which may consist of Warrants to
purchase Common Shares or other Securities and may be issued in one
or more series. While the terms summarized below will apply
generally to any Warrants that the Company may offer under the
Prospectus, the Company will describe the material terms and
conditions of any series of Warrants that it may offer in more
detail in the applicable Prospectus Supplement filed in respect of
such Warrants. The terms of any Warrants offered under a Prospectus
Supplement may differ from the terms described below. A copy of any
warrant indenture governing the terms of Warrants will be filed on
SEDAR in connection with any offering of Warrants under this
Prospectus.
The material terms and conditions of each issue of Warrants will be
described in the applicable Prospectus Supplement filed in respect
of such Warrants. This description will include, where
applicable:
|
• |
|
the designation and aggregate number of Warrants;
|
|
• |
|
the price at which the Warrants will be offered;
|
|
• |
|
the currency or currencies in which the Warrants will be
offered;
|
21
|
• |
|
the date on which the right to exercise the Warrants will commence
and the date on which the right will expire;
|
|
• |
|
if applicable, the identity of the warrant agent;
|
|
• |
|
whether the Warrants will be listed on any securities exchange;
|
|
• |
|
any minimum or maximum subscription amount;
|
|
• |
|
the number of Common Shares that may be purchased upon exercise of
each Warrant and the price at which and currency or currencies in
which the Common Shares may be purchased upon exercise of each
Warrant;
|
|
• |
|
the designation and terms of any securities with which the Warrants
will be offered, if any, and the number of the Warrants that will
be offered with each security;
|
|
• |
|
the date or dates, if any, on or after which the Warrants and the
related securities will be transferable separately;
|
|
• |
|
whether the Warrants will be subject to redemption and, if so, the
terms of such redemption provisions;
|
|
• |
|
whether the Warrants are to be issued in registered form,
“book-entry only” form, non-certificated inventory system form,
bearer form or in the form of temporary or permanent global
securities and the basis of exchange, transfer and ownership
thereof;
|
|
• |
|
any material risk factors relating to such Warrants and the Common
Shares to be issued upon exercise of the Warrants;
|
|
• |
|
any other rights, privileges, restrictions and conditions attaching
to the Warrants and the Common Shares to be issued upon exercise of
the Warrants;
|
|
• |
|
material Canadian and United States federal income tax consequences
of owning and exercising the Warrants; and
|
|
• |
|
any other material terms or conditions of the Warrants and the
Common Shares to be issued upon exercise of the Warrants.
|
The terms and provisions of any Warrants offered under a Prospectus
Supplement may differ from the terms described above and may not be
subject to or contain any or all of the terms described above.
Prior to the exercise of any Warrants, holders of Warrants will not
have any of the rights of holders of the Common Shares purchasable
upon such exercise or the right to vote such underlying
securities.
Options
We may issue or grant Options in connection with acquisitions,
merger transactions, or to directors, officers employees or
consultants, as applicable.
The material terms and conditions applicable to each Option issue
will be described in the applicable Prospectus Supplement filed in
respect of such Options. This description will include, where
applicable:
|
• |
|
the designation and aggregate number of Options;
|
|
• |
|
the price at which the Options will be offered;
|
|
• |
|
the currency or currencies in which the Options will be
offered;
|
|
• |
|
the date on which the right to exercise the Options will commence
and the date on which the right will expire;
|
22
|
• |
|
the number of Common Shares that may be issued upon exercise of
each Option and the price and currency or currencies in which the
Common Shares may be purchased upon exercise of each Option;
|
|
• |
|
the date or dates, if any, on or after which the Options and the
related securities will be transferable separately;
|
|
• |
|
any resale restrictions and vesting criteria related to the
Options;
|
|
• |
|
any applicable accelerated vesting provisions applicable to the
Options;
|
|
• |
|
any early termination provisions relating to the Options;
|
|
• |
|
any material risk factors relating to such Options and the Common
Shares to be issued upon exercise of the Options;
|
|
• |
|
any other rights, privileges, restrictions and conditions attaching
to the Options and the Common Shares to be issued upon exercise of
the Options;
|
|
• |
|
material Canadian and United States federal income tax consequences
of owning and exercising the Options; and
|
|
• |
|
any other material terms or conditions of the Options and the
Common Shares to be issued upon exercise of the Options.
|
Prior to the exercise of any Options, holders of Options will not
have any of the voting or other rights applicable to holders of
Common Shares.
Subscription Receipts
This section describes the general terms that will apply to any
Subscription Receipts that may be offered by us pursuant to the
Prospectus. Subscription Receipts may be offered separately or
together with Common Shares or Warrants, as the case may be. The
Subscription Receipts will be issued under a subscription receipt
agreement.
In the event we issue Subscription Receipts, we will provide the
original purchasers of Subscription Receipts a contractual right of
rescission exercisable following the issuance of Common Shares to
such purchasers.
The applicable Prospectus Supplement will include details of the
Subscription Receipt agreement covering the Subscription Receipts
being offered. A copy of the subscription receipt agreement
relating to an offering of Subscription Receipts will be filed by
us with the applicable securities regulatory authorities after it
has been entered into by us. The specific terms of the Subscription
Receipts, and the extent to which the general terms described in
this section apply to those Subscription Receipts, will be set
forth in the applicable Prospectus Supplement. This description
will include, where applicable:
|
• |
|
the number of Subscription Receipts;
|
|
• |
|
the price at which the Subscription Receipts will be offered;
|
|
• |
|
the currency at which the Subscription Receipts will be offered and
whether the price is payable in installments;
|
|
• |
|
the procedures for the exchange of the Subscription Receipts into
Common Shares, Warrants or Units;
|
|
• |
|
the number of Common Shares, Warrants or Units that may be issued
upon exercise or deemed conversion of each Subscription
Receipt;
|
|
• |
|
the designation and terms of any other Securities with which the
Subscription Receipts will be offered, if any, and the number of
Subscription Receipts that will be offered with each Security;
|
|
• |
|
conditions to the conversion or exchange of Subscription Receipts
into other Securities and the consequences of such conditions not
being satisfied;
|
23
|
• |
|
terms applicable to the gross or net proceeds from the sale of the
Subscription Receipts plus any interest earned thereon;
|
|
• |
|
the dates or periods during which the Subscription Receipts may be
converted or exchanged;
|
|
• |
|
the circumstances, if any, which will cause the Subscription
Receipts to be deemed to be automatically converted or
exchanged;
|
|
• |
|
provisions applicable to any escrow of the gross or net proceeds
from the sale of the Subscription Receipts plus any interest or
income earned thereon, and for the release of such proceeds from
such escrow;
|
|
• |
|
if applicable, the identity of the subscription receipt agent;
|
|
• |
|
whether the Subscription Receipts will be listed on any securities
exchange;
|
|
• |
|
whether the Subscription Receipts will be issued with any other
Securities and, if so, the amount and terms of these
Securities;
|
|
• |
|
any minimum or maximum subscription amount;
|
|
• |
|
whether the Subscription Receipts are to be issued in registered
form, “book-entry only” form, non-certificated inventory system form,
bearer form or in the form of temporary or permanent global
securities and the basis of exchange, transfer and ownership
thereof;
|
|
• |
|
any material risk factors relating to such Subscription Receipts
and the Securities to be issued upon conversion or exchange of the
Subscription Receipts;
|
|
• |
|
any other rights, privileges, restrictions and conditions attaching
to the Subscription Receipts and the Securities to be issued upon
exchange of the Subscription Receipts;
|
|
• |
|
material Canadian and United States income tax consequences of
owning or converting or exchanging the Subscription Receipts;
and
|
|
• |
|
any other material terms and conditions of the Subscription
Receipts and the Securities to be issued upon the exchange of the
Subscription Receipts.
|
The terms and provisions of any Subscription Receipts offered under
a Prospectus Supplement may differ from the terms described above
and may not be subject to or contain any or all of the terms
described above.
Prior to the exchange of any Subscription Receipts, holders of such
Subscription Receipts will not have any of the rights of holders of
the Securities for which the Subscription Receipts may be
exchanged, including the right to receive payments of dividends or
the right to vote such underlying securities.
Description of Debt Securities
We may issue Debt Securities in one or more series under an
indenture (the “Indenture”), to be entered into among the
Company and a trustee. If the Debt Securities are offered or sold
in the United States or to a U.S. person, the Indenture will be
subject to and governed by the United States Trust Indenture Act of
1939, as amended (the “Trust Indenture Act”). A copy of the
form of the Indenture will be filed with the SEC as an exhibit to
the Registration Statement of which this Prospectus forms a part.
The following description sets forth certain general material terms
and provisions of the Debt Securities. If Debt Securities are
issued, we will describe in the applicable Prospectus Supplement
the particular material terms and provisions of any series of the
Debt Securities and a description of how the general material terms
and provisions described below may apply to that series of the Debt
Securities. Prospective investors should read both the Prospectus
and the Prospectus Supplement for a complete summary of all
material terms relating to a particular series of Debt Securities.
Prospective investors should be aware that information in the
applicable Prospectus Supplement may update and supersede the
following information. Prospective investors also should refer to
the Indenture for a complete
24
description of all terms relating to the Debt Securities. We will
file as exhibits to the Registration Statement, of which this
Prospectus is a part, or will incorporate by reference from a
report on Form 6-K that the
Company furnishes to the SEC, any supplemental indenture describing
the terms and conditions of Debt Securities that we are offering
before the issuance of such Debt Securities. We will also file the
final Indenture for any offering of Debt Securities on SEDAR.
We may issue Debt Securities and incur additional indebtedness
other than through the offering of Debt Securities pursuant to this
Prospectus.
General
The Indenture will not limit the aggregate principal amount of Debt
Securities that we may issue under the Indenture and will not limit
the amount of other indebtedness that we may incur. The Indenture
will provide that we may issue Debt Securities from time to time in
one or more series and may be denominated and payable in U.S.
dollars, Canadian dollars or any foreign currency. Unless otherwise
indicated in the applicable Prospectus Supplement, the Debt
Securities will be unsecured obligations of the Company. The
Indenture will also permit us to increase the principal amount of
any series of the Debt Securities previously issued and to issue
that increased principal amount.
The applicable Prospectus Supplement for any series of Debt
Securities that we offer will describe the specific terms of the
Debt Securities and may include, but is not limited to, any of the
following:
|
• |
|
the title of the Debt Securities;
|
|
• |
|
any limit on the aggregate principal amount of the Debt Securities
and, if no limit is specified, the Company will have the right to
re-open such series for the
issuance of additional Debt Securities from time to time;
|
|
• |
|
whether the payment of principal, interest and premium, if any, on
the Debt Securities will be our senior, senior subordinated or
subordinated obligations;
|
|
• |
|
whether payment of principal, interest and premium, if any, on the
Debt Securities will be secured by certain assets of the Company
and any applicable guarantors;
|
|
• |
|
whether payment of the Debt Securities will be guaranteed by any
other person;
|
|
• |
|
the date or dates, or the method by which such date or dates will
be determined or extended, on which the principal (and premium, if
any) of the Debt Securities of the series is payable;
|
|
• |
|
the rate or rates at which the Securities of the series shall bear
interest, if any, or the method by which such rate or rates shall
be determined, whether such interest shall be payable in cash or
additional Securities of the same series or shall accrue and
increase the aggregate principal amount outstanding of such series,
the date or dates from which such interest shall accrue, or the
method by which such date or dates shall be determined;
|
|
• |
|
the place or places we will pay principal, premium and interest, if
any, and the place or places where Debt Securities can be presented
for registration of transfer, exchange or conversion;
|
|
• |
|
whether and under what circumstances we will be required to pay any
additional amounts for withholding or deduction for taxes with
respect to the Debt Securities, and whether and on what terms we
will have the option to redeem the Debt Securities rather than pay
the additional amounts;
|
|
• |
|
whether we will be obligated to redeem, repay or repurchase the
Debt Securities pursuant to any sinking or other provision, or at
the option of a holder and the terms and conditions of such
redemption, repayment or repurchase;
|
|
• |
|
whether we may redeem the Debt Securities, in whole or in part,
prior to maturity and the terms and conditions of any such
redemption;
|
25
|
• |
|
the denominations in which we will issue any registered Debt
Securities, if other than denominations of $2,000 and any multiple
of $1,000 and, if other than denominations of $5,000, the
denominations in which any unregistered Debt Security shall be
issuable;
|
|
• |
|
whether we will make payments on the Debt Securities in a currency
other than U.S. dollars;
|
|
• |
|
whether payments on the Debt Securities will be payable with
reference to any index, formula or other method;
|
|
• |
|
whether we will issue the Debt Securities as global securities and,
if so, the identity of the depositary for the global
securities;
|
|
• |
|
whether we will issue the Debt Securities as unregistered
securities, registered securities or both;
|
|
• |
|
any changes or additions to, or deletions of, events of default or
covenants whether or not such events of default or covenants are
consistent with the events of default or covenants in the
Indenture;
|
|
• |
|
the applicability of, and any changes or additions to, the
provisions for defeasance described under “Defeasance” below;
|
|
• |
|
whether the holders of any series of Debt Securities have special
rights if specified events occur;
|
|
• |
|
the terms, if any, for any conversion or exchange of the Debt
Securities for any other securities;
|
|
• |
|
provisions as to modification, amendment or variation of any rights
or terms attaching to the Debt Securities; and
|
|
• |
|
any other terms, conditions, rights and preferences (or limitations
on such rights and preferences).
|
Unless stated otherwise in the applicable Prospectus Supplement, no
holder of Debt Securities will have the right to require us to
repurchase the Debt Securities and there will be no increase in the
interest rate if we become involved in a highly leveraged
transaction or if we have a change of control.
We may issue Debt Securities bearing no interest or interest at a
rate below the prevailing market rate at the time of issuance and
may offer and sell the Debt Securities at a discount below their
stated principal amount. We may also sell any of the Debt
Securities for a foreign currency or currency unit, and payments on
the Debt Securities may be payable in a foreign currency or
currency unit. In any of these cases, we will describe certain
Canadian federal and U.S. federal income tax consequences and other
special considerations in the applicable Prospectus Supplement.
We may issue Debt Securities with terms different from those of
Debt Securities previously issued and, without the consent of the
holders thereof, we may reopen a previous issue of a series of Debt
Securities and issue additional Debt Securities of such series
(unless the reopening was restricted when such series was
created).
Guarantees
Our payment obligations under any series of Debt Securities may be
guaranteed by certain of our direct or indirect subsidiaries. In
order to comply with certain registration statement form
requirements under U.S. law, these guarantees may in turn be
guaranteed by the Company. The terms of such guarantees will be set
forth in the applicable Prospectus Supplement.
Ranking and Other Indebtedness
Unless otherwise indicated in an applicable Prospectus Supplement,
and except to the extent prescribed by law, each series of Debt
Securities shall be senior, unsubordinated and unsecured
obligations of the Company and shall rank pari passu and ratably
without preference among themselves and pari passu with all other
senior, unsubordinated and unsecured obligations of the
Company.
26
Our Board of Directors may establish the extent and manner, if any,
to which payment on or in respect of a series of Debt Securities
will be senior, senior subordinated or will be subordinated to the
prior payment of the Company’s other liabilities and obligations,
and whether the payment of principal, premium, if any, and
interest, if any, will be guaranteed by any other person and the
nature and priority of any security.
Debt Securities in Global Form
The Depositary and Book-Entry
Unless otherwise specified in the applicable Prospectus Supplement,
a series of the Debt Securities may be issued in whole or in part
in global form as a “global security” and will be registered in the
name of or issued in bearer form and be deposited with a
depositary, or its nominee, each of which will be identified in the
applicable Prospectus Supplement relating to that series. Unless
and until exchanged, in whole or in part, for the Debt Securities
in definitive registered form, a global security may not be
transferred except as a whole by the depositary for such global
security to a nominee of the depositary, by a nominee of the
depositary to the depositary or another nominee of the depositary
or by the depositary or any such nominee to a successor of the
depositary or a nominee of the successor.
The specific terms of the depositary arrangement with respect to
any portion of a particular series of the Debt Securities to be
represented by a global security will be described in the
applicable Prospectus Supplement relating to such series. The
Company anticipates that the provisions described in this section
will apply to all depositary arrangements.
Upon the issuance of a global security, the depositary therefor or
its nominee will credit, on its book entry and registration system,
the respective principal amounts of the Debt Securities represented
by the global security to the accounts of such persons, designated
as “participants”, having accounts with such depositary or its
nominee. Such accounts shall be designated by the underwriters,
dealers or agents participating in the distribution of the Debt
Securities or by the Company if such Debt Securities are offered
and sold directly by the Company. Ownership of beneficial interests
in a global security will be limited to participants or persons
that may hold beneficial interests through participants. Ownership
of beneficial interests in a global security will be shown on, and
the transfer of that ownership will be effected only through,
records maintained by the depositary therefor or its nominee (with
respect to interests of participants) or by participants or persons
that hold through participants (with respect to interests of
persons other than participants). The laws of some states in the
United States may require that certain purchasers of securities
take physical delivery of such securities in definitive form.
So long as the depositary for a global security or its nominee is
the registered owner of the global security or holder of a global
security in bearer form, such depositary or such nominee, as the
case may be, will be considered the sole owner or holder of the
Debt Securities represented by the global security for all purposes
under the Indenture. Except as provided below, owners of beneficial
interests in a global security will not be entitled to have a
series of the Debt Securities represented by the global security
registered in their names, will not receive or be entitled to
receive physical delivery of such series of the Debt Securities in
definitive form and will not be considered the owners or holders
thereof under the Indenture.
Any payments of principal, premium, if any, and interest, if any,
on global securities registered in the name of a depositary or
securities registrar will be made to the depositary or its nominee,
as the case may be, as the registered owner of the global security
representing such Debt Securities. None of the Company, any trustee
or any paying agent for the Debt Securities represented by the
global securities will have any responsibility or liability for any
aspect of the records relating to or payments made on account of
beneficial ownership interests of the global security or for
maintaining, supervising or reviewing any records relating to such
beneficial ownership interests.
The Company expects that the depositary for a global security or
its nominee, upon receipt of any payment of principal, premium, if
any, or interest, if any, will credit participants’ accounts with
payments in amounts
27
proportionate to their respective beneficial interests in the
principal amount of the global security as shown on the records of
such depositary or its nominee. The Company also expects that
payments by participants to owners of beneficial interests in a
global security held through such participants will be governed by
standing instructions and customary practices, as is now the case
with securities held for the accounts of customers registered in
“street name”, and will be the responsibility of such
participants.
Discontinuance of Depositary’s Services
If a depositary for a global security representing a particular
series of the Debt Securities is at any time unwilling or unable to
continue as depositary or, if at any time the depositary for such
series shall no longer be registered or in good standing under the
Exchange Act, and a successor depositary is not appointed by us
within 90 days, the Company will issue such series of the Debt
Securities in definitive form in exchange for a global security
representing such series of the Debt Securities. If an event of
default under the Indenture has occurred and is continuing, Debt
Securities in definitive form will be printed and delivered upon
written request by the holder to the appropriate trustee. In
addition, the Company may at any time and in the Company’s sole
discretion determine not to have a series of the Debt Securities
represented by a global security and, in such event, will issue a
series of the Debt Securities in definitive form in exchange for
all of the global securities representing that series of Debt
Securities.
Debt Securities in Definitive Form
A series of the Debt Securities may be issued in definitive form,
solely as registered securities, solely as unregistered securities
or as both registered securities and unregistered securities.
Registered securities will be issuable in denominations of $2,000
and integral multiples of $1,000 and unregistered securities will
be issuable in denominations of $5,000 and integral multiples of
$5,000 or, in each case, in such other denominations as may be set
out in the terms of the Debt Securities of any particular series.
Unless otherwise indicated in the applicable Prospectus Supplement,
unregistered securities will have interest coupons attached.
Unless otherwise indicated in the applicable Prospectus Supplement,
payment of principal, premium, if any, and interest, if any, on the
Debt Securities in definitive form will be made at the office or
agency designated by the Company, or at the Company’s option the
Company can pay principal, interest, if any, and premium, if any,
by check mailed to the address of the person entitled at the
address appearing in the security register of the trustee or
electronic funds wire transfer to an account of persons who meet
certain thresholds set out in the Indenture who are entitled to
receive payments by wire transfer. Unless otherwise indicated in
the applicable Prospectus Supplement, payment of interest, if any,
will be made to the persons in whose name the Debt Securities are
registered at the close of business on the day or days specified by
the Company.
At the option of the holder of Debt Securities, registered
securities of any series will be exchangeable for other registered
securities of the same series, of any authorized denomination and
of a like aggregate principal amount. If, but only if, provided in
an applicable Prospectus Supplement, unregistered securities (with
all unmatured coupons, except as provided below, and all matured
coupons in default) of any series may be exchanged for registered
securities of the same series, of any authorized denominations and
of a like aggregate principal amount and tenor. In such event,
unregistered securities surrendered in a permitted exchange for
registered securities between a regular record date or a special
record date and the relevant date for payment of interest shall be
surrendered without the coupon relating to such date for payment of
interest, and interest will not be payable on such date for payment
of interest in respect of the registered security issued in
exchange for such unregistered security, but will be payable only
to the holder of such coupon when due in accordance with the terms
of the Indenture. Unless otherwise specified in an applicable
Prospectus Supplement, unregistered securities will not be issued
in exchange for registered securities.
The applicable Prospectus Supplement may indicate the places to
register a transfer of the Debt Securities in definitive form.
Service charges may be payable by the holder for any registration
of transfer or exchange of the
28
Debt Securities in definitive form, and the Company may, in certain
instances, require a sum sufficient to cover any tax or other
governmental charges payable in connection with these
transactions.
We shall not be required to:
|
• |
|
issue, register the transfer of or exchange any series of the Debt
Securities in definitive form during a period beginning at the
opening of 15 days before any selection of securities of that
series of the Debt Securities to be redeemed and ending on the
relevant date of notice of such redemption, as provided in the
Indenture;
|
|
• |
|
register the transfer of or exchange any registered security in
definitive form, or portion thereof, called for redemption, except
the unredeemed portion of any registered security being redeemed in
part;
|
|
• |
|
exchange any unregistered security called for redemption except to
the extent that such unregistered security may be exchanged for a
registered security of that series and like tenor; provided that
such registered security will be simultaneously surrendered for
redemption; or
|
|
• |
|
issue, register the transfer of or exchange any of the Debt
Securities in definitive form which have been surrendered for
repayment at the option of the holder, except the portion, if any,
of such Debt Securities not to be so repaid.
|
Provision of Financial Information
The Company will file with the trustee within 15 days after the
Company files the same with the SEC, (i) copies of the annual
reports containing audited financial statements and copies of
quarterly reports containing unaudited financial statements and
(ii) copies of the information, documents and other reports
(or copies of such portions of any of the foregoing as the
Commission may from time to time by rules and regulations
prescribe) which the Company may be required to file with or
furnish to the SEC pursuant to Section 13 or
Section 15(d) of the Exchange Act.
In the event that the Company is not required to remain subject to
the reporting requirements of Section 13 or 15(d) of the
Exchange Act, or otherwise report on an annual and quarterly basis
on forms provided for such annual and quarterly reporting pursuant
to rules and regulations promulgated by the SEC, it will
continue to file with the SEC and provide the trustee:
|
• |
|
within 140 days after the end of each fiscal year, annual reports
on Form 20-F,
40-F or Form 10-K, as applicable (or any
successor form), containing audited financial statements and the
other financial information required to be contained therein (or
required in such successor form); and
|
|
• |
|
within 60 days after the end of each of the first three fiscal
quarters of each fiscal year, reports on Form 6-K or Form 10-Q (or any successor form),
containing unaudited financial statements and the other financial
information which, regardless of applicable requirements shall, at
a minimum, contain such information required to be provided in
quarterly reports under the laws of Canada or any province thereof
to security holders of a corporation with securities listed on the
Toronto Stock Exchange, whether or not the Company has any of its
securities so listed.
|
Events of Default
Unless otherwise specified in the applicable Prospectus Supplement
relating to a particular series of Debt Securities, the following
is a summary of events which will, with respect to any series of
the Debt Securities, constitute an event of default under the
Indenture with respect to the Debt Securities of that series:
|
• |
|
the Company fails to pay principal of, or any premium on any Debt
Security of that series when it is due and payable;
|
|
• |
|
the Company fails to pay interest payable on any Debt Security of
that series when it becomes due and payable, and such default
continues for 30 days;
|
29
|
• |
|
the Company fails to make any required sinking fund or analogous
payment when due for that series of Debt Securities;
|
|
• |
|
the Company fails to observe or perform any of its covenants or
agreements in the Indenture that affect or are applicable to the
Debt Securities of that series for 90 days after written notice to
the Company by the trustees or to the Company and the trustees by
holders of at least 25% in aggregate principal amount of the
outstanding Debt Securities of that series;
|
|
• |
|
certain events involving the Company’s bankruptcy, insolvency or
reorganization; and
|
|
• |
|
any other event of default provided for in that series of Debt
Securities.
|
A default under one series of Debt Securities will not necessarily
be a default under another series. A trustee may withhold notice to
the holders of the Debt Securities of any default, except in the
payment of principal or premium, if any, or interest, if any, if in
good faith it considers it in the interests of the holders to do so
and so advises the Company in writing.
If an event of default for any series of Debt Securities occurs and
continues, a trustee or the holders of at least 25% in aggregate
principal amount of the Debt Securities of that series may require
the Company to repay immediately:
|
• |
|
the entire principal and interest of the Debt Securities of the
series; or
|
|
• |
|
if the Debt Securities are discounted securities, that portion of
the principal as is described in the applicable Prospectus
Supplement.
|
If an event of default relates to events involving the Company’s
bankruptcy, insolvency or reorganization, the principal of all Debt
Securities will become immediately due and payable without any
action by the trustee or any holder.
Subject to certain conditions, the holders of a majority of the
aggregate principal amount of the Debt Securities of the affected
series can rescind and annul an accelerated payment requirement. If
Debt Securities are discounted securities, the applicable
Prospectus Supplement will contain provisions relating to the
acceleration of maturity of a portion of the principal amount of
the discounted securities upon the occurrence or continuance of an
event of default.
Other than its duties in case of a default, a trustee is not
obligated to exercise any of the rights or powers that it will have
under the Indenture at the request or direction of any holders,
unless the holders offer the trustee reasonable security or
indemnity. If they provide this reasonable security or indemnity,
the holders of a majority in aggregate principal amount of any
series of Debt Securities may, subject to certain limitations,
direct the time, method and place of conducting any proceeding for
any remedy available to a trustee, or exercising any trust or power
conferred upon a trustee, for any series of Debt Securities.
The Company will be required to furnish to the trustees a statement
annually as to its compliance with all conditions and covenants
under the Indenture and, if the Company is not in compliance, the
Company must specify any defaults. The Company will also be
required to notify the trustees as soon as practicable upon
becoming aware of any event of default.
No holder of a Debt Security of any series will have any right to
institute any proceeding with respect to the Indenture, or for the
appointment of a receiver or a trustee, or for any other remedy,
unless:
|
• |
|
the holder has previously given to the trustees written notice of a
continuing event of default with respect to the Debt Securities of
the affected series;
|
|
• |
|
the holders of at least 25% in principal amount of the outstanding
Debt Securities of the series affected by an event of default have
made a written request, and the holders have offered reasonable
indemnity, to the trustees to institute a proceeding as trustees;
and
|
30
|
• |
|
the trustees have failed to institute a proceeding, and have not
received from the holders of a majority in aggregate principal
amount of the outstanding Debt Securities of the series affected
(or in the case of bankruptcy, insolvency or reorganization, all
series outstanding) by an event of default a direction inconsistent
with the request, within 60 days after receipt of the holders’
notice, request and offer of indemnity.
|
However, such above-mentioned limitations do not apply to a suit
instituted by the holder of a Debt Security for the enforcement of
payment of the principal of or any premium, if any, or interest on
such Debt Security on or after the applicable due date specified in
such Debt Security.
Defeasance
When the Company uses the term “defeasance”, it means discharge
from its obligations with respect to any Debt Securities of or
within a series under the Indenture. Unless otherwise specified in
the applicable Prospectus Supplement, if the Company deposits with
a trustee cash, government securities or a combination thereof
sufficient to pay the principal, interest, if any, premium, if any,
and any other sums due to the stated maturity date or a redemption
date of the Debt Securities of a series, then at the Company’s
option:
|
• |
|
the Company will be discharged from the obligations with respect to
the Debt Securities of that series; or
|
|
• |
|
the Company will no longer be under any obligation to comply with
certain restrictive covenants under the Indenture and certain
events of default will no longer apply to the Company.
|
If this happens, the holders of the Debt Securities of the affected
series will not be entitled to the benefits of the Indenture except
for registration of transfer and exchange of Debt Securities and
the replacement of lost, stolen, destroyed or mutilated Debt
Securities. These holders may look only to the deposited fund for
payment on their Debt Securities.
To exercise the defeasance option, the Company must deliver to the
trustees:
|
• |
|
an opinion of counsel in the United States to the effect that the
holders of the outstanding Debt Securities of the affected series
will not recognize income, gain or loss for U.S. federal income tax
purposes as a result of a defeasance and will be subject to U.S.
federal income tax on the same amounts, in the same manner and at
the same times as would have been the case if the defeasance had
not occurred;
|
|
• |
|
an opinion of counsel in Canada or a ruling from the Canada Revenue
Agency to the effect that the holders of the outstanding Debt
Securities of the affected series will not recognize income, gain
or loss for Canadian federal, provincial or territorial income or
other tax purposes as a result of a defeasance and will be subject
to Canadian federal, provincial or territorial income tax and other
tax on the same amounts, in the same manner and at the same times
as would have been the case had the defeasance not occurred;
and
|
|
• |
|
a certificate of one of the Company’s officers and an opinion of
counsel, each stating that all conditions precedent provided for
relating to defeasance have been complied with.
|
If the Company is to be discharged from its obligations with
respect to the Debt Securities, and not just from the Company’s
covenants, the U.S. opinion must be based upon a ruling from or
published by the United States Internal Revenue Service or a change
in law to that effect.
In addition to the delivery of the opinions described above, the
following conditions must be met before the Company may exercise
its defeasance option:
|
• |
|
no event of default or event that, with the passing of time or the
giving of notice, or both, shall constitute an event of default
shall have occurred and be continuing for the Debt Securities of
the affected series;
|
31
|
• |
|
the Company is not an “insolvent person” within the meaning of
applicable bankruptcy and insolvency legislation; and
|
|
• |
|
other customary conditions precedent are satisfied.
|
Modification and Waiver
Modifications and amendments of the Indenture may be made by the
Company and the trustees pursuant to one or more supplemental
indentures (each, a “Supplemental Indenture”) with the
consent of the holders of at least a majority in aggregate
principal amount of the outstanding Debt Securities of each series
affected by the modification. However, without the consent of each
holder affected, no such modification may:
|
• |
|
change the stated maturity of the principal of, premium, if any, or
any instalment of interest, if any, on any Debt Security;
|
|
• |
|
reduce the principal, premium, if any, or rate of interest, if any,
or change any obligation of the Company to pay any additional
amounts;
|
|
• |
|
reduce the amount of principal of a debt security payable upon
acceleration of its maturity or the amount provable in
bankruptcy;
|
|
• |
|
change the place or currency of any payment;
|
|
• |
|
affect the holder’s right to require the Company to repurchase the
Debt Securities at the holder’s option;
|
|
• |
|
impair the right of the holders to institute a suit to enforce
their rights to payment;
|
|
• |
|
adversely affect any conversion or exchange right related to a
series of Debt Securities;
|
|
• |
|
reduce the percentage of Debt Securities required to modify the
Indenture or to waive compliance with certain provisions of the
Indenture; or
|
|
• |
|
reduce the percentage in principal amount of outstanding Debt
Securities necessary to take certain actions.
|
The holders of at least a majority in principal amount of
outstanding Debt Securities of any series may on behalf of the
holders of all Debt Securities of that series waive, insofar as
only that series is concerned, past defaults under the Indenture
and compliance by the Company with certain restrictive provisions
of the Indenture. However, these holders may not waive a default in
any payment of principal, premium, if any, or interest on any Debt
Security or compliance with a provision that cannot be modified
without the consent of each holder affected.
The Company may modify the Indenture pursuant to a Supplemental
Indenture without the consent of any holders to:
|
• |
|
evidence its successor under the Indenture;
|
|
• |
|
add covenants of the Company or surrender any right or power of the
Company for the benefit of holders;
|
|
• |
|
provide for unregistered securities to become registered securities
under the Indenture and make other such changes to unregistered
securities that in each case do not materially and adversely affect
the interests of holders of outstanding Debt Securities;
|
|
• |
|
establish the forms of the Debt Securities;
|
|
• |
|
appoint a successor trustee under the Indenture;
|
32
|
• |
|
add provisions to permit or facilitate the defeasance and discharge
of the Debt Securities as long as there is no material adverse
effect on the holders;
|
|
• |
|
cure any ambiguity, correct or supplement any defective or
inconsistent provision or make any other provisions in each case
that would not materially and adversely affect the interests of
holders of outstanding Debt Securities, if any; or
|
|
• |
|
change or eliminate any provisions of the Indenture where such
change takes effect when there are no Debt Securities outstanding
which are entitled to the benefit of those provisions under the
Indenture.
|
Governing Law
Unless otherwise provided for in the applicable Prospectus
Supplement, the Indenture and the Debt Securities will be governed
by and construed in accordance with the laws of the State of
New York.
The Trustee
The trustee under the Indenture or its affiliates may provide
banking and other services to the Corporation in the ordinary
course of their business.
The Indenture will contain certain limitations on the rights of the
trustee, as long as it or any of its affiliates remains the
Corporation’s creditor, to obtain payment of claims in certain
cases or to realize on certain property received on any claim as
security or otherwise. The trustee and its affiliates will be
permitted to engage in other transactions with the Corporation. If
the trustee or any affiliate acquires any conflicting interest and
a default occurs with respect to the Debt Securities, the trustee
must eliminate the conflict or resign.
Resignation and Removal of Trustee
A trustee may resign or be removed with respect to one or more
series of the Debt Securities and a successor trustee may be
appointed to act with respect to such series.
Consent to Jurisdiction and Service
If the Debt Securities are offered or sold in the United States or
to a U.S. person, then, unless otherwise provided for in the
applicable Prospectus Supplement for an offering of Debt
Securities, under the Indenture, the Corporation will irrevocably
appoint an authorized agent upon which process may be served in any
suit, action or proceeding arising out of or relating to the
Offered Debt Securities or the Indenture that may be instituted in
any United States federal or New York state court located
in The City of New York, and will submit to such non-exclusive jurisdiction.
Units
We may issue Units comprised of one or more of the other Securities
described in this Prospectus in any combination. Each Unit will be
issued so that the holder of the Unit is also the holder of each of
the Securities included in the Unit. Thus, the holder of a Unit
will have the rights and obligations of a holder of each included
Security. The unit agreement, if any, under which a Unit is issued
may provide that the Securities included in the Unit may not be
held or transferred separately, at any time or at any time before a
specified date.
The material terms and provisions of Units offered by any
Prospectus Supplement, and the extent to which the general terms
and provisions described below may apply thereto, will be described
in the applicable Prospectus Supplement filed in respect of such
Units. This description will include, where applicable:
|
• |
|
the number of Units offered;
|
33
|
• |
|
the price or prices, if any, at which the Units will be issued;
|
|
• |
|
the currency at which the Units will be offered;
|
|
• |
|
the Securities comprising the Units;
|
|
• |
|
whether the Units will be issued with any other Securities and, if
so, the amount and terms of these Securities;
|
|
• |
|
any minimum or maximum subscription amount;
|
|
• |
|
whether the Units and the Securities comprising the Units are to be
issued in registered form, “book-entry only” form, non-certificated inventory system form,
bearer form or in the form of temporary or permanent global
securities and the basis of exchange, transfer and ownership
thereof;
|
|
• |
|
any material risk factors relating to such Units or the Securities
comprising the Units;
|
|
• |
|
any other rights, privileges, restrictions and conditions attaching
to the Units or the Securities comprising the Units; and
|
|
• |
|
any other material terms or conditions of the Units or the
Securities comprising the Units, including whether and under what
circumstances the Securities comprising the Units may be held or
transferred separately.
|
The terms and provisions of any Units offered under a Prospectus
Supplement may differ from the terms described above and may not be
subject to or contain any or all of the terms described above.
34
RISK FACTORS
Before making an investment decision to purchase any Securities,
investors should carefully consider the information described in
this Prospectus and the documents incorporated or deemed
incorporated by reference herein, including the applicable
Prospectus Supplement. There are certain risks inherent in an
investment in the Securities, including the factors described in
the 2020 AIF, in the 2020 MD&A and Interim MD&A and any
other risk factors described herein or in a document incorporated
or deemed incorporated by reference herein, which investors should
carefully consider before investing. Additional risk factors
relating to a specific offering of Securities will be described in
the applicable Prospectus Supplement. Some of the factors described
herein, in the documents incorporated or deemed incorporated by
reference herein, and/or the applicable Prospectus Supplement are
interrelated and, consequently, investors should treat such risk
factors as a whole. If any of the adverse effects set out in the
risk factors described herein, in the 2020 AIF, in the 2020
MD&A and Interim MD&A, in another document incorporated or
deemed incorporated by reference herein or in the applicable
Prospectus Supplement occur, it could have a material adverse
effect on the business, financial condition and results of
operations of the Company. Additional risks and uncertainties of
which the Company currently is unaware or that are unknown or that
it currently deems to be immaterial could have a material adverse
effect on the Company’s business, financial condition and results
of operations. The Company cannot assure you that it will
successfully address any or all of these risks. There is no
assurance that any risk management steps taken will avoid future
loss due to the occurrence of the adverse effects set out in the
risk factors herein, in the 2020 AIF, in the 2020 MD&A and
Interim MD&A, in the other documents incorporated or deemed
incorporated by reference herein or in the applicable Prospectus
Supplement or other unforeseen risks.
Risks Related to our Common Shares
The price of our Common Shares historically has been volatile.
This volatility may affect the price at which you could sell our
Common Shares and the sale of substantial amounts of our Common
Shares could adversely affect the price of our Common
Shares.
The market price for our Common Shares on the TSX has varied
between a high of $26.79 on May 19, 2020 and a low of $4.93 on
October 28, 2020 in the twelve-month period ending on March
26, 2021, and on the NYSE has varied between a high of U.S.$19.68
on May 18, 2020 and a low of U.S.$3.71 on October 28, 2020 in
the same period. This volatility may affect the price at which you
could sell our Common Shares, and the sale of substantial amounts
of our Common Shares could adversely affect the price of our Common
Shares. Our share price is likely to continue to be volatile and
subject to significant price and volume fluctuations in response to
market and other factors, including the other factors discussed in
“Risks Related to our Business;” variations in our quarterly
operating results from our expectations or those of securities
analysts or investors; downward revisions in securities analysts’
estimates; and announcement by us or our competitors of significant
acquisitions, strategic partnerships, joint ventures or capital
commitments.
We may not pay dividends in the future.
We have not paid dividends in the past and do not anticipate paying
dividends in the near future. We expect to retain our earnings to
finance further growth and, when appropriate, retire debt. Any
decision to pay dividends on our Common Shares in the future will
be at the discretion of our board of directors (the “Board”)
and will depend on, among other things, our results of operations,
current and anticipated cash requirements and surplus, financial
condition, any future contractual restrictions and financing
agreement covenants, solvency tests imposed by corporate law and
other factors that the Board may deem relevant. As a result,
investors may not receive any return on an investment in our Common
Shares unless they are able to sell their shares for a price
greater than that which such investors paid for them.
35
Future sales or issuances of equity securities could decrease
the value of our Common Shares, dilute investors’ voting power and
reduce our earnings per share.
We may sell additional equity securities in subsequent offerings
(including through the sale of securities convertible into equity
securities and may issue equity securities in acquisitions). We
cannot predict the size of future issuances of equity securities or
the size and terms of future issuances of debt instruments or other
securities convertible into equity securities or the effect, if
any, that future issuances and sales of our securities will have on
the market price of our Common Shares.
Additional issuances of our securities may involve the issuance of
a significant number of Common Shares at prices less than the
current market price for the Common Shares. Issuances of
substantial numbers of Common Shares, or the perception that such
issuances could occur, may adversely affect prevailing market
prices of our Common Shares. Any transaction involving the issuance
of previously authorized but unissued Common Shares, or securities
convertible into Common Shares, would result in dilution, possibly
substantial, to security holders.
Sales of substantial amounts of our securities by us or our
existing shareholders, or the availability of such securities for
sale, could adversely affect the prevailing market prices for our
securities and dilute investors’ earnings per share. Exercises of
presently outstanding share options or warrants may also result in
dilution to security holders. A decline in the market prices of our
securities could impair our ability to raise additional capital
through the sale of securities should we desire to do so.
As of March 26, 2021, we had outstanding approximately
197,979,742 Common Shares and securities exercisable for and
convertible into approximately 27,894,649 Common Shares (of which
approximately 25,118,930 were exercisable as of that date). The
sale or the availability for sale of a large number of our Common
Shares in the public market could cause the price of our Common
Shares to decline.
The regulated nature of our business may impede or discourage a
takeover, which could reduce the market price of our Common
Shares.
We require and hold various government licenses to operate our
business, which would not necessarily continue to apply to an
acquiror of our business following a change of control. These
licensing requirements could impede a merger, amalgamation,
takeover or other business combination involving us or discourage a
potential acquirer from making a tender offer for our Common
Shares, which, under certain circumstances, could reduce the market
price of our Common Shares.
There is no assurance we will continue to meet the listing
standards of the NYSE and the TSX.
We must meet continuing listing standards to maintain the listing
of our Common Shares on the NYSE and the TSX. If we fail to comply
with listing standards and the NYSE and/or the TSX delists our
Common Shares, we and our shareholders could face significant
material adverse consequences, including:
|
• |
|
a limited availability of market quotations for our Common
Shares;
|
|
• |
|
reduced liquidity for our Common Shares;
|
|
• |
|
a determination that our Common Shares are “penny stock,” which
would require brokers trading in our Common Shares to adhere to
more stringent rules and possibly result in a reduced level of
trading activity in the secondary trading market for our Common
Shares;
|
|
• |
|
a limited amount of news about us and analyst coverage of us;
and
|
|
• |
|
a decreased ability for us to issue additional equity securities or
obtain additional equity or debt financing in the future.
|
36
Risks Related to Future Offerings
There is no existing trading market for the Warrants, Options,
Subscription Receipts, Debt Securities or Units.
There is no existing trading market for the Warrants, Subscription
Receipts, Debt Securities or Units. As a result, there can be no
assurance that a liquid market will develop or be maintained for
those Securities, or that a purchaser will be able to sell any of
those Securities at a particular time (if at all). We may not list
the Warrants, Options, Subscription Receipts, Debt Securities or
Units on any Canadian or U.S. securities exchange.
Future Sales May Affect the Market Price of the Company’s Common
Shares.
In order to finance future operations, we may determine to raise
funds through the issuance of additional Common Shares or the
issuance of debt instruments or other securities convertible into
Common Shares. We cannot predict the size of future issuances of
Common Shares or the issuance of debt instruments or other
securities convertible into Common Shares or the dilutive effect,
if any, that future issuances and sales of our securities will have
on the market price of our Common Shares. These sales may have an
adverse impact on the market price of our Common Shares.
Our management will have substantial discretion concerning the
use of proceeds.
Our management will have substantial discretion concerning the use
of proceeds of an offering under any Prospectus Supplement as well
as the timing of the expenditure of the proceeds thereof. As a
result, investors will be relying on the judgment of management as
to the specific application of the proceeds of any offering of
Securities under any Prospectus Supplement. Management may use the
net proceeds of any offering of Securities under any Prospectus
Supplement in ways that an investor may not consider desirable. The
results and effectiveness of the application of the net proceeds
are uncertain.
Negative Cash Flow from Operations
The Company had negative operating cash flows for the fiscal year
ended June 30, 2020 and the second quarter ended
December 31, 2020. Although the Company anticipates it will be
able to generate positive cash flow from operating activities in
the future, the Company cannot guarantee it will have positive cash
flow from operating activities in any future period. To the extent
that the Company has negative operating cash flow in any future
period, certain of the proceeds from any offering may be used to
fund such negative cash flow from operating activities. See “Use
of Proceeds”.
The Company is a Canadian company and shareholder protections
differ from shareholder protections in the United States and
elsewhere.
We are organized and exist under the laws of British Columbia,
Canada and, accordingly, are governed by the BCBCA. The BCBCA
differs in certain material respects from laws generally applicable
to United States corporations and shareholders, including the
provisions relating to interested directors, mergers and similar
arrangements, takeovers, shareholders’ suits, indemnification of
directors and inspection of corporation records.
The Company is a foreign private issuer within the meaning of
the rules under the Exchange Act, and as such is exempt from
certain provisions applicable to United States domestic public
companies.
Because we are a “foreign private issuer” under the U.S. Exchange
Act, we are exempt from certain provisions of the securities rules
and regulations in the United States that are applicable to U.S.
domestic issuers, including:
|
• |
|
the rules under the U.S. Exchange Act requiring the filing of
quarterly reports on Form 10-Q or current reports on Form
8-K with the SEC;
|
37
|
• |
|
the sections of the U.S. Exchange Act regulating the solicitation
of proxies, consents or authorizations in respect of a security
registered under the U.S. Exchange Act;
|
|
• |
|
the sections of the U.S. Exchange Act requiring insiders to file
public reports of their stock ownership and trading activities and
liability for insiders who profit from trades made in a short
period of time; and
|
|
• |
|
the selective disclosure rules by issuers of material non-public information under Regulation
FD.
|
We are required to file an annual report on Form 40-F with the United States Securities
and Exchange Commission within three months of the end of each
fiscal year. We do not intend to voluntarily file annual reports on
Form 10-K and quarterly
reports on Form 10-Q in
lieu of Form 40-F
requirements. For so long as we choose to only comply with foreign
private issuer requirements, the information we are required to
file with or furnish to the SEC will be less extensive and less
timely compared to that required to be filed with the SEC by U.S.
domestic issuers. As a result, you may not be afforded the same
protections or information which would be made available to you if
you were investing in a U.S. domestic issuer.
38
CERTAIN INCOME TAX
CONSIDERATIONS
The applicable Prospectus Supplement will describe certain Canadian
federal income tax consequences to investors described therein of
acquiring Securities.
The applicable Prospectus Supplement will also describe certain
United States federal income tax consequences of the acquisition,
ownership and disposition of Securities by an initial investor who
is a “U.S. person” (within the meaning of the United States
Internal Revenue Code), if applicable, including, to the extent
applicable, any such consequences relating to Securities payable in
a currency other than the United States dollar, issued at an
original issue discount for United States federal income tax
purposes or other special terms.
AGENT FOR SERVICE OF PROCESS
Miguel Martin, the Chief Executive Officer and a director of the
Company, and Margaret Shan Atkins and Lance Friedmann, directors of
the Company, reside outside of Canada. Each of Miguel Martin,
Margaret Atkins and Lance Friedmann has appointed the Company, at
its head office located at 4818 31 Street East, Edmonton
International Airport, Alberta, Canada, T9E 0V6 as their agent for
service of process in Canada. Purchasers are advised that it may
not be possible for investors to enforce judgments obtained in
Canada against any such person, even though they have each
appointed an agent for service of process.
Investors are advised that it may not be possible for investors to
enforce judgments obtained in Canada against any person who resides
outside of Canada or a company that is incorporated, continued or
otherwise organized under the laws of a foreign jurisdiction, even
if the party has appointed an agent for service of process.
LEGAL MATTERS
Certain legal matters relating to the Securities offered by this
Prospectus will be passed upon for us by (i) McMillan LLP,
Vancouver, B.C., with respect to matters of Canadian law, and
(ii) Jenner & Block LLP with respect to matters of
United States law.
TRANSFER AGENT AND
REGISTRAR
The transfer agent and registrar for the Common Shares of the
Company is Computershare Trust Company of Canada at its principal
office in Vancouver, British Columbia and Toronto, Ontario, and the
United States co-transfer agent for the Common Shares
is Computershare Trust Company, N.A., at its office in Canton,
Massachusetts.
INTEREST OF EXPERTS
The following are the names of each person or company who has
prepared or certified a report, valuation, statement or opinion in
this Prospectus, either directly or in a document incorporated by
reference, and whose profession or business gives authority to the
report, valuation, statement or opinion made by the person or
company:
|
• |
|
KPMG LLP, Chartered Professional Accountants, as the external
auditor of the Company who reported on the Company’s 2020 and 2019
annual financial statements, as filed on SEDAR and incorporated
into this Prospectus by reference.
|
KPMG LLP has confirmed that they are independent of the Company
within the meaning of the relevant rules and related
interpretations prescribed by the relevant professional bodies in
Canada and any applicable legislation or regulations and also that
they are independent accountants with respect to the Company under
all relevant U.S. professional and regulatory standards.
39
ADDITIONAL INFORMATION
We have filed with the SEC a registration statement on Form
F-10 under the U.S.
Securities Act relating to the offering of the Securities. The
Prospectus, which constitutes part of the Registration Statement,
does not contain all of the information set forth in the
Registration Statement or the accompanying exhibits and schedules,
as certain items that are not included in the Prospectus are
included in the Registration Statement in accordance with the rules
and regulations of the SEC. For further information with respect to
us and the Securities offered in the Prospectus, we refer you to
the Registration Statement and the accompanying exhibits and
schedules. Statements contained in the Prospectus regarding the
contents of any contract, agreement or any other document are
summaries of the material terms of these contracts, agreements or
other documents. With respect to each of these contracts,
agreements or other documents filed as an exhibit to the
Registration Statement, reference is made to such exhibit for a
more complete description of the matter involved. Such contracts,
agreements, or other documents are or will also be filed by the
Company on SEDAR at www.sedar.com in accordance with applicable
Canadian securities laws.
We are subject to the informational reporting requirements of the
Exchange Act as the Common Shares are registered under
Section 12(b) of the Exchange Act. Accordingly, we are
required to publicly file reports and other information with the
SEC. Under the MJDS, the Company is permitted to prepare such
reports and other information in accordance with Canadian
disclosure requirements, which are different from United States
disclosure requirements.
As a foreign private issuer, we are exempt from the rules under the
Exchange Act prescribing the furnishing and content of proxy
statements in connection with meetings of its shareholders. In
addition, the officers, directors and principal shareholders of the
Company are exempt from the reporting and short-swing profit
recovery rules contained in Section 16 of the Exchange
Act.
We file annual reports on Form 40-F with the SEC under the MJDS, which
annual reports include:
|
• |
|
the annual information form;
|
|
• |
|
management’s annual discussion and analysis of financial condition
and results of operations;
|
|
• |
|
consolidated audited financial statements, which are prepared in
accordance with IFRS, as issued by the IASB; and
|
|
• |
|
other information specified by the Form 40-F.
|
As a foreign private issuer, we are required to furnish the
following types of information to the SEC under cover of Form
6-K:
|
• |
|
material information that the Company otherwise makes publicly
available in reports that the Company files with securities
regulatory authorities in Canada;
|
|
• |
|
material information that the Company files with, and which is made
public by, the TSX and NYSE; and
|
|
• |
|
material information that the Company distributes to its
shareholders in Canada.
|
Investors may read and download the documents the Company has filed
with the SEC’s Electronic Data Gathering and Retrieval system
(“EDGAR”) at www.sec.gov. Investors may read and download
any public document that the Company has filed with the securities
commissions or similar regulatory authorities in Canada at
www.sedar.com.
40
DOCUMENTS FILED AS PART OF THE
REGISTRATION STATEMENT
The following documents have been or will be filed with the SEC as
part of the Registration Statement of which this Prospectus forms a
part:
|
(i) |
the documents set out under the heading “Documents
Incorporated by Reference”;
|
|
(ii) |
the consents of the Company’s auditor and legal
counsel;
|
|
(iii) |
the powers of attorney from the directors and certain
officers of the Company; and
|
|
(iv) |
the form of Indenture.
|
A copy of the form of any warrant indenture or subscription receipt
agreement, as applicable, will be filed by post-effective amendment
or by incorporation by reference to documents filed or furnished
with or furnished to the SEC under the U.S. Exchange Act.
41
ENFORCEABILITY OF CIVIL
LIABILITIES BY U.S. INVESTORS
The Company is a corporation existing under the BCBCA. Other than
Martin Miguel, Margaret Shan Atkins and Lance Friedman, all of our
directors and officers, and all of the experts named in the
Prospectus, are residents of Canada or otherwise reside outside the
United States, and all or a substantial portion of their assets,
and a majority of our assets, are located outside the United
States. We have appointed an agent for service of process in the
United States, but it may be difficult for holders of the
Securities who reside in the United States to effect service within
the United States upon those directors, officers and experts who
are not residents of the United States. It may also be difficult
for holders of the Securities who reside in the United States to
realize upon judgments of courts of the United States predicated
upon the Company’s civil liability and the civil liability of its
directors, officers and experts under the United States federal
securities laws.
We have been advised by our Canadian legal counsel, McMillan LLP,
that a judgment of a United States court predicated solely upon
civil liability under United States federal securities laws would
probably be enforceable in Canada if the United States court in
which the judgment was obtained has a basis for jurisdiction in the
matter that would be recognized by a Canadian court for the same
purposes. We have also been advised by McMillan LLP, however, that
there is substantial doubt whether an action could be brought in
Canada in the first instance on the basis of liability predicated
solely upon United States federal securities laws.
We have filed with the SEC, concurrently with our Registration
Statement on Form F-10, an
appointment of agent for service of process on Form F-X. Under the Form F-X, we appointed Corporation Service
Company as our agent for service of process in the United States in
connection with any investigation or administrative proceeding
conducted by the SEC, and any civil suit or action brought against
or involving the Company in a United States court arising out of,
related to, or concerning the offering of the Securities under the
Prospectus.
42
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Mar 2023 to Mar 2023
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Mar 2022 to Mar 2023